Modification of brassinosteroid receptor genes for improved yield traits
Editing the rapeseed steroid insensitivity-1 (BRI1) gene through the CRISPR-Cas system has solved the problem of increasing plant yield in the existing technology, achieved the improvement of seed size and oil content, and provided an efficient genetically modified method without genetic modification .
Patent Information
- Application Number
- CN202380035477.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-03-02
- Filing Date
- 2023-03-01
- Publication Date
- 2024-12-03
AI Technical Summary
The prior art has challenges in improving plant yields, especially the difficulty in successfully achieving step changes in yields through stable transformation methods, and single-gene solutions are challenging to complex traits such as yields, and GM methods are not available through hormone-related pathways. Significant effect.
Editing the rapeseed steroid-insensitive-1 (BRI1) gene by introducing the CRISPR-Cas system, producing specific mutations to improve plant yield traits, including seed size and seed oil content, including introduction of CRISPR-Cas effector protein in plant cells. and guided nucleic acids targeting the BRI1 gene, specifically cleavage and edit to generate mutated plants.
Improvements in yield traits in plants, including the increase in seed size and seed oil content, provide a genetically modified edited plant, solving the problem of yield improvement in traditional methods.
Smart Images

Figure SMS_1 
Figure SMS_2 
Figure SMS_3
Abstract
Description
[0001] Statement Regarding Electronic Submission of Sequence Listings
[0002] The sequence listing in XML format, titled 1499-90_ST26.xml, with a size of 298,814 bytes, generated on February 15, 2023 and submitted with this document, is hereby incorporated by reference into this specification for its disclosure content.
[0003] Priority declaration
[0004] This application claims the benefit of U.S. Provisional Application No. 63 / 315,646, filed on March 2, 2022, under 35 USC § 119(e), the entire contents of which are incorporated herein by reference. Field of the Invention
[0005] The present invention relates to compositions and methods for modifying the brassinosteroid insensitive-1 (BRI1) gene in plants, optionally with improved yield traits. The present invention also relates to plants with increased improved yield traits produced using the methods and compositions of the present invention. Background of the Invention
[0006] Intensive breeding of row crops has resulted in progressive increases in plant yield. However, genetic gain from breeding has begun to plateau, and assembling multiple genes of small effect in a breeding program has significantly increased R&D costs. Single-gene solutions are challenging for complex traits such as yield, where background genetics and environment combine to reduce the effects of individual genes. Breeding has been successful by combining many individual genes with small contributing effects, but more resources are needed to find unique combinations with improved effects. To increase yield growth rates, new variations need to be introduced in important genes and pathways that contribute to yield.
[0007] Transgenic approaches involving stable transformation to improve yield have been largely unsuccessful, and no commercially relevant single-gene approach has successfully created a step change in yield. Modification of hormone-related pathways by GM approaches has not been fruitful, as simple over- or under-expression through transgenic technology is inconsistent with the fine-tuned effects required to improve plant yield.
[0008] The present invention addresses these shortcomings in the art by providing new compositions and methods for improving / enhancing yield traits in plants, including soybean, corn, and other plant species. SUMMARY OF THE INVENTION
[0009] One aspect of the present invention provides a plant or plant part thereof comprising at least one mutation in an endogenous brassinosteroid insensitive-1 (BRI1) gene encoding a BRI1 polypeptide (brassinosteroid receptor polypeptide), optionally wherein the at least one mutation is a non-natural mutation.
[0010] A second aspect of the present invention provides a plant cell comprising an editing system, wherein the editing system comprises: (a) a CRISPR-Cas effector protein; and (b) a guide nucleic acid (e.g., gRNA, gDNA, crRNA, crDNA, sgRNA, sgDNA) comprising a spacer sequence complementary to an endogenous target gene encoding a brassinosteroid insensitive-1 (BRI1) polypeptide (brassinosteroid receptor polypeptide).
[0011] A third aspect of the invention provides a plant cell comprising at least one mutation within an endogenous brassinosteroid insensitive-1 (BRI1) gene, wherein the at least one mutation is a substitution, insertion or deletion introduced using an editing system comprising a nucleic acid binding domain that binds to a target site in the endogenous BRI1 gene, optionally wherein the at least one mutation is a non-natural mutation.
[0012] The fourth aspect of the present invention provides a method for producing / cultivating a transgenic-free edited plant, comprising: hybridizing the plant of the present invention with a transgenic-free plant, thereby introducing the at least one mutation into the transgenic-free plant; and selecting offspring plants comprising at least one mutation and without transgenes, thereby producing a transgenic-free edited plant.
[0013] A fifth aspect of the invention provides a method for providing a plurality of plants having one or more improved yield traits (optionally increased seed size (e.g., seed area and / or seed weight) and / or seed oil content), the method comprising planting two or more plants of the invention in a growing area, thereby providing a plurality of plants having one or more improved yield traits compared to a plurality of control plants not comprising at least one mutation.
[0014] A sixth aspect of the present invention provides a method for producing a variation in a region of a brassinosteroid insensitive-1 (BRI1) polypeptide, comprising: introducing an editing system into a plant cell, wherein the editing system targets a region of a brassinosteroid insensitive-1 (BRI1) gene encoding a region of the BRI1 polypeptide, and contacting the region of the BRI1 gene with the editing system, thereby introducing a mutation into the BRI1 gene and producing a variation in the BRI1 polypeptide of the plant cell.
[0015] The seventh aspect provides a method for editing a specific site in the genome of a plant cell, the method comprising: cutting a target site within an endogenous brassinosteroid insensitive-1 (BRI1) gene in a plant cell in a site-specific manner, wherein the endogenous BRI1 gene: (a) comprises a sequence having at least 80% sequence identity to any one of the nucleotide sequences of SEQ ID NOs: 69, 70, 80 or 81, (b) comprises a region having at least 80% sequence identity to any one of the nucleotide sequences of SEQ ID NOs: 73-79 or 83-95, and / or (c) encodes an amino acid sequence having at least 80% sequence identity to any one of SEQ ID NOs: 71, 72 or 82, thereby generating an edit in the endogenous BRI1 gene of the plant cell and generating a plant cell comprising the edit in the endogenous BRI1 gene.
[0016] The eighth aspect provides a method for making a plant, comprising: (a) contacting a population of plant cells comprising an endogenous brassinosteroid insensitive-1 (BRI1) gene with a nuclease linked to a nucleic acid binding domain (e.g., an editing system), wherein the nucleic acid binding domain binds to a sequence that (i) has at least 80% (e.g., 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100%) sequence identity to the nucleotide sequence of any one of SEQ ID NOs: 69, 70, 80, or 81, (ii) encodes an amino acid sequence that has at least 80% sequence identity to any one of SEQ ID NOs: 71, 72, or 82, and / or (iii) comprises a sequence that has at least 80% sequence identity to any one of SEQ ID NOs: 71, 72, or 82. NO: 73-79 or 83-95 has a region of at least 80% identity; (b) selecting plant cells in which the endogenous BRI1 gene has been mutated from the population, thereby producing plant cells comprising a mutation in the endogenous BRI1 gene; and (c) growing the selected plant cells into plants.
[0017] The ninth aspect provides a method for improving one or more yield traits in a plant, comprising (a) contacting a plant cell comprising an endogenous brassinosteroid insensitive-1 (BRI1) gene with a nuclease targeted to the endogenous BRI1 gene, wherein the nuclease is linked to a nucleic acid binding domain (e.g., an editing system) that binds to a target site in the endogenous BRI1 gene, wherein the endogenous BRI1 gene: (i) comprises a sequence having at least 80% sequence identity to a nucleotide sequence of any one of SEQ ID NOs: 69, 70, 80, or 81; (ii) comprises a region having at least 80% identity to a nucleotide sequence of any one of SEQ ID NOs: 73-79 or 83-95; and / or (iii) encodes a region having at least 80% identity to a nucleotide sequence of any one of SEQ ID NOs: 73-79 or 83-95; and / or Any one of NO: 71, 72 or 82 has an amino acid sequence with at least 80% sequence identity to produce a plant cell comprising a mutation in an endogenous BRI1 gene; and (b) growing the plant cell into a plant comprising a mutation in the endogenous BRI1 gene, thereby producing a plant with a mutated endogenous BRI1 gene and one or more improved yield traits.
[0018] The tenth aspect provides a method for producing a plant or part thereof comprising at least one cell having a mutated endogenous brassinosteroid insensitive-1 (BRI1) gene, the method comprising contacting a target site in an endogenous BRI1 gene in the plant or plant part with a nuclease comprising a cleavage domain and a nucleic acid binding domain, wherein the nucleic acid binding domain binds to the target site in the endogenous BRI1 gene, wherein the endogenous BRI1 gene (a) comprises a sequence having at least 80% sequence identity to the nucleotide sequence of any one of SEQ ID NOs: 69, 70, 80 or 81; (b) comprises a region having at least 80% sequence identity to the nucleotide sequence of any one of SEQ ID NOs: 73-79 or 83-95; and / or (c) encodes an amino acid sequence having at least 80% sequence identity to any one of SEQ ID NOs: 71, 72 or 82, thereby producing a plant or part thereof comprising at least one cell having a mutation in an endogenous BRI1 gene.
[0019] The eleventh aspect of the present invention provides a method for producing a plant or part thereof comprising a mutated endogenous brassinosteroid insensitive-1 (BRI1) gene and exhibiting one or more improved yield traits, the method comprising contacting a target site in an endogenous BRI1 gene in a plant or plant part with a nuclease comprising a cleavage domain and a nucleic acid binding domain, wherein the nucleic acid binding domain binds to the target site in the endogenous BRI1 gene, wherein the endogenous BRI1 gene: (a) comprises a sequence having at least 80% sequence identity to the nucleotide sequence of any one of SEQ ID NOs: 69, 70, 80 or 81; (b) comprises a region having at least 80% sequence identity to the nucleotide sequence of any one of SEQ ID NOs: 73-79 or 83-95; and / or (c) encodes an amino acid sequence having at least 80% sequence identity to any one of SEQ ID NOs: 71, 72 or 82, thereby producing a plant or part thereof comprising an endogenous BRI1 gene having a mutation and exhibiting one or more improved yield traits.
[0020] The twelfth aspect provides a guide nucleic acid that binds to a target site in a brassinosteroid insensitive-1 (BRI1) gene, wherein the target site is located in a region of the BRI1 gene that is located (a) at approximately nucleotides 2-213, 42-174, 62-154, 82-134 and / or 92-124 numbered with reference to the nucleotide position of SEQ ID NO: 69 (e.g., SEQ ID NOs: 73-79), and / or (b) at approximately nucleotides 1-267, 40-227, 70-195 and / or 100-168 numbered with reference to the nucleotide position of SEQ ID NO: 80 (e.g., SEQ ID NOs: 83-95).
[0021] In a thirteenth aspect, a system is provided, comprising a guide nucleic acid of the present invention and a CRISPR-Cas effector protein associated with the guide nucleic acid. A system comprising a guide nucleic acid of the present invention and a CRISPR-Cas effector protein associated with the guide nucleic acid.
[0022] A fourteenth aspect provides a guide nucleic acid of the present invention and a CRISPR-Cas effector protein associated with the guide nucleic acid.
[0023] The fifteenth aspect provides a gene editing system comprising a CRISPR-Cas effector protein associated with a guide nucleic acid, wherein the guide nucleic acid comprises a spacer sequence that binds to an endogenous brassinosteroid insensitive-1 (BRI1) gene.
[0024] In the sixteenth aspect, a complex is provided, comprising a guide nucleic acid and a CRISPR-Cas effector protein comprising a cleavage domain, wherein the guide nucleic acid associates with a target site in an endogenous brassinosteroid insensitive-1 (BRI1) gene, wherein the endogenous BRI1 gene: (a) comprises a sequence having at least 80% sequence identity to the nucleotide sequence of any one of SEQ ID NOs: 69, 70, 80 or 81; (b) comprises a region having at least 80% identity to the nucleotide sequence of any one of SEQ ID NOs: 73-79 or 83-95; and / or (c) encodes an amino acid sequence having at least 80% sequence identity to any one of SEQ ID NOs: 71, 72 or 82, wherein the cleavage domain cleaves the target strand in the BRI1 gene.
[0025] In the seventeenth aspect, an expression cassette is provided, the expression cassette comprising (a) a polynucleotide encoding a CRISPR-Cas effector protein comprising a cleavage domain, and (b) a guide nucleic acid that binds to a target site in an endogenous brassinosteroid insensitive-1 (BRI1) gene, wherein the guide nucleic acid comprises a spacer sequence that is complementary to and binds to: (i) a portion of a nucleic acid having at least 80% sequence identity to any one of the nucleotide sequences of SEQ ID NOs: 69, 70, 80 or 81; (ii) a portion of a nucleic acid having at least 80% sequence identity to any one of SEQ ID NOs: 73-79 or 83-95; and / or (iii) a portion of a nucleic acid encoding an amino acid sequence having at least 80% sequence identity to any one of SEQ ID NOs: 71, 72 or 82.
[0026] In an eighteenth aspect, a nucleic acid encoding a hypomorphic, dominant and / or semi-dominant mutation of a brassinosteroid insensitive-1 (BRI1) polypeptide is provided.
[0027] In the nineteenth aspect, a mutated endogenous BRI1 gene is provided, which is produced by contacting a target site in an endogenous BRI1 gene in a plant or plant part with a nuclease comprising a cleavage domain and a nucleic acid binding domain, wherein the nucleic acid binding domain binds to the target site in the endogenous BRI1 gene, wherein the endogenous BRI1 gene: (a) comprises a sequence having at least 80% sequence identity to the nucleotide sequence of any one of SEQ ID NOs: 69, 70, 80 or 81; (b) comprises a region having at least 80% identity to any one of SEQ ID NOs: 73-79 or 83-95; and / or (c) encodes an amino acid sequence having at least 80% sequence identity to any one of SEQ ID NOs: 71, 72 or 82.
[0028] In another aspect, a plant is provided comprising in its genome one or more mutated brassinosteroid insensitive-1 (BRI1) genes produced by the methods of the present invention.
[0029] Another aspect of the present invention provides a corn plant or plant part thereof comprising at least one mutation in at least one endogenous brassinosteroid insensitive-1 (BRI1) gene having a gene identification number (Gene ID) of GRMZM6G437417.
[0030] In another aspect, a soybean plant or plant part thereof is provided, the soybean plant comprising at least one mutation in at least one endogenous brassinosteroid insensitive-1 (BRI1) gene having a gene identification number (gene ID) of Glyma.06g147600 and / or Glyma.04g218300.
[0031] In another aspect, a guide nucleic acid is provided that binds to a target nucleic acid in a brassinosteroid insensitive-1 (BRI1) gene having a gene identification number (gene ID) of Glyma.06g147600 and / or Glyma.04g218300. Another aspect of the invention provides a nucleic acid comprising a mutated brassinosteroid insensitive-1 (BRI1) gene, optionally wherein at least one mutation disrupts an upstream open reading frame (uORF) of an endogenous BRI1 gene (in a cis-regulatory element, e.g., in a promoter region).
[0032] On the other hand, a mutated nucleic acid encoding a brassinosteroid insensitive-1 (BRI1) polypeptide is provided, optionally wherein the mutation is located in the cis-regulatory region of the BRI1 gene, wherein the mutation results in the BRI1 gene having increased expression, optionally wherein the mutated BRI1 gene has at least 90% sequence identity to any one of SEQ ID NOs: 101-117.
[0033] Further provided are plants comprising in their genome one or more brassinosteroid insensitive-1 (BRI1) genes having a mutation produced by the method of the invention, optionally wherein the plant has a phenotype of one or more improved yield traits compared to a plant lacking at least one mutation.
[0034] Also provided are polypeptides, polynucleotides, nucleic acid constructs, expression cassettes and vectors for making the plants of the invention.
[0035] These and other aspects of the invention are set forth in more detail in the description of the invention which follows.
[0036] A brief description of the sequence
[0037] SEQ ID NOs: 1-17 are exemplary Cas12a amino acid sequences that can be used in the present invention.
[0038] SEQ ID NOs: 18-20 are exemplary Cas12a nucleotide sequences that can be used in the present invention.
[0039] SEQ ID NOs: 21-22 are exemplary regulatory sequences encoding promoters and introns.
[0040] SEQ ID NOs: 23-29 are exemplary cytosine deaminase sequences that can be used in the present invention.
[0041] SEQ ID NOs: 30-40 are exemplary adenine deaminase amino acid sequences that can be used in the present invention.
[0042] SEQ ID NO: 41 is an exemplary uracil-DNA glycosylase inhibitor (UGI) sequence that can be used in the present invention.
[0043] Exemplary peptide tags and affinity polypeptides useful in the present invention are provided in SEQ ID NOs: 42-44.
[0044] SEQ ID NOs: 45-55 provide exemplary RNA recruitment motifs and corresponding affinity polypeptides useful in the present invention.
[0045] SEQ ID NOs: 56-57 are exemplary Cas9 polypeptide sequences that can be used in the present invention.
[0046] SEQ ID NOs: 58-68 are exemplary Cas9 polynucleotide sequences that can be used in the present invention.
[0047] SEQ ID NO: 69 and SEQ ID NO: 80 are exemplary BRI1 genomic sequences from soybean.
[0048] SEQ ID NO: 70 and SEQ ID NO: 81 are exemplary BRI1 coding sequences from soybean.
[0049] SEQ ID NOs: 71, 72 and 82 are exemplary BRI1 polypeptide sequences from soybean.
[0050] SEQ ID NOs: 73-79 and SEQ ID NOs: 83-95 are exemplary portions or regions of the soybean BRI1 genomic and coding sequences from SEQ ID NO: 69 and SEQ ID NO: 80, respectively.
[0051] SEQ ID NOs: 96-100 are exemplary spacer sequences that can be used in the nucleic acid guides of the present invention.
[0052] SEQ ID NOs: 101-117 are exemplary edited BRI1 genes.
[0053] Detailed Description
[0054] The present invention will now be described hereinafter with reference to the accompanying drawings and Examples, in which embodiments of the present invention are shown. This description is not intended to be a detailed catalog of all different ways in which the present invention can be implemented or all features that can be added to the present invention. For example, the features illustrated by way of example for one embodiment can be incorporated into other embodiments, and the features illustrated by way of example for a specific embodiment can be deleted from the embodiment. Therefore, the present invention contemplates that in some embodiments of the present invention, any feature or feature combination set forth herein can be excluded or omitted. In addition, according to this disclosure, many changes and additions to the various embodiments proposed herein will be apparent to those skilled in the art, and they do not depart from the present invention. Therefore, the following description is intended to illustrate some specific embodiments of the present invention, rather than exhaustively specifying all its permutations, combinations and variations.
[0055] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the invention belongs. The terms used in the description of the invention herein are for the purpose of describing particular embodiments only and are not intended to limit the invention.
[0056] All publications, patent applications, patents, and other references cited herein are incorporated by reference in their entirety with respect to their teachings relevant to the sentence and / or paragraph in which the reference is presented.
[0057] Unless the context indicates otherwise, the various features of the invention described herein are specifically intended to be used in any combination. In addition, the present invention also contemplates that in some embodiments of the present invention, any feature or combination of features set forth herein may be excluded or omitted. For illustration, if the specification states that a composition comprises components A, B, and C, it is specifically intended that any one or combination of A, B, or C may be omitted and abandoned, either alone or in any combination.
[0058] As used in the description of the invention and the appended claims, the singular forms "a", "an" and "the" are intended to include the plural forms as well, unless the context clearly indicates otherwise. For example, "a uORF" may mean one or more uORFs.
[0059] Also as used herein, "and / or" refers to and includes any and all possible combinations of one or more of the associated listed items, as well as the lack of combinations when construed in the alternative ("or").
[0060] As used herein, the term "about" when referring to a measurable value such as an amount or concentration, is intended to encompass variations of ±10%, ±5%, ±1%, ±0.5%, or even ±0.1% of the specified value as well as the specified value. For example, "about X" where X is a measurable value is intended to include X as well as variations of ±10%, ±5%, ±1%, ±0.5%, or even ±0.1% of X. The ranges of measurable values provided herein may include any other ranges and / or individual values therein.
[0061] As used herein, phrases such as "between X and Y" and "between about X and Y" should be interpreted to include X and Y. As used herein, phrases such as "between about X and Y" mean "between about X and about Y" and phrases such as "from about X to Y" mean "from about X to about Y."
[0062] Recitation of ranges of values herein are merely intended to serve as a shorthand method of referring individually to each separate value falling within the range, unless otherwise indicated herein, and each separate value is incorporated into the specification as if it were individually recited herein. For example, if a range of 10 to 15 is disclosed, 11, 12, 13, and 14 are also disclosed.
[0063] As used herein, the terms “includes,” “comprising,” and “containing” specify the presence of stated features, integers, steps, operations, elements, and / or components, but do not preclude the presence or addition of one or more other features, integers, steps, operations, elements, components, and / or groups thereof.
[0064] As used herein, the transition phrase "consisting essentially of" means that the scope of a claim should be interpreted as including the specific materials or steps recited in the claim, as well as those materials or steps that do not materially affect the basic and novel characteristics of the claimed invention. Therefore, when used in the claims of the present invention, the term "consisting essentially of" is not intended to be interpreted as being equivalent to "comprising".
[0065] As used herein, the terms "increase," "increased," "increase," "enhance," "enhance," "enhance," and "enhance" (and grammatical variations thereof) describe an increase of at least about 5%, 10%, 15%, 20%, 25%, 50%, 75%, 100%, 150%, 200%, 300%, 400%, 500% or more compared to a control. For example, a plant comprising a mutation in a brassinosteroid insensitive-1 (BRI1) gene as described herein can exhibit improved yield traits (e.g., one or more improved yield traits; for example, optionally increased seed size (e.g., seed area and / or seed weight) and / or increased seed oil content and), which is at least about 5% or more increase in yield traits over a control plant that does not comprise the same mutation. A control plant is typically a plant that is the same as the edited plant, but the control plant has not been similarly edited and therefore lacks the mutation. The control plant can be an isogenic plant and / or a wild-type plant. Thus, the control plant can be the same breeding line, variety or cultivar as the subject plant into which the mutation described herein is introgressed, but the control breeding line, variety or cultivar does not contain the mutation. In some embodiments, the comparison between the plants of the invention and the control plants is performed under the same growth conditions, e.g., the same environmental conditions (soil, hydration, light, heat, nutrients, etc.).
[0066] As used herein, the terms "reduce," "lower," "reduced," "reduced," "reduced," "reduced," and "mitigated" (and grammatical variations thereof) describe, for example, a reduction of at least about 5%, 10%, 15%, 20%, 25%, 35%, 50%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.6%, 99.7%, 99.8%, 99.9%, or 100% as compared to a control. In certain embodiments, the reduction can result in no or substantially no (i.e., a negligible amount, e.g., less than about 10% or even 5%) detectable activity or amount.
[0067] As used herein, the terms "expression", "expressed", "expressed" or "expression" and the like with respect to nucleic acid molecules and / or nucleotide sequences (e.g., RNA or DNA) indicate that the nucleic acid molecules and / or nucleotide sequences are transcribed and optionally translated. Thus, the nucleic acid molecules and / or nucleotide sequences can express a polypeptide of interest or, for example, a functional non-translated RNA.
[0068] A "heterologous" or "recombinant" nucleotide sequence is a nucleotide sequence that is not naturally associated with the host cell into which it is introduced, including non-naturally occurring multiple copies of a naturally occurring nucleotide sequence. A "heterologous" nucleotide / polypeptide may originate from a foreign species, or, if from the same species, has been substantially modified from its native form in composition and / or genomic locus by deliberate human intervention.
[0069] A "native" or "wild-type" nucleic acid, nucleotide sequence, polypeptide, or amino acid sequence refers to a naturally occurring or endogenous nucleic acid, nucleotide sequence, polypeptide, or amino acid sequence. In some cases, a "wild-type" nucleic acid is a nucleic acid that has not been edited as described herein, and may be different from an "endogenous" gene (e.g., a mutated endogenous gene) that may be edited as described herein. In some cases, a "wild-type" nucleic acid (e.g., unedited) may be heterologous to an organism (e.g., a transgenic organism) in which the wild-type nucleic acid is found. As an example, a "wild-type endogenous brassinosteroid insensitive-1 (BRI1) gene" is a BRI1 gene that is naturally present or endogenously present in a reference organism (e.g., a plant, such as a soybean plant, a corn plant), and may be modified as described herein, after which such a modified endogenous gene is no longer wild-type.
[0070] As used herein, the term "heterozygous" refers to a genetic state in which different alleles are located at corresponding loci on homologous chromosomes.
[0071] As used herein, the term "homozygous" refers to a genetic state in which identical alleles are located at corresponding loci on homologous chromosomes.
[0072] As used herein, the term "allele" refers to one of two or more different nucleotides or nucleotide sequences occurring at a particular locus.
[0073] A "null allele" is a non-functional allele caused by a gene mutation that results in a complete lack of production of the corresponding protein or the production of a non-functional protein.
[0074] A "recessive mutation" is a genetic mutation that produces a phenotype when homozygous, but the phenotype is not visible when the locus is heterozygous.
[0075] A "dominant mutation" is a gene mutation that produces a mutant phenotype in the presence of a non-mutated copy of the gene. A dominant mutation can be a loss-of-function mutation or a gain-of-function mutation, a hypomorphic allele mutation, a hypermorphic allele mutation, or a weak loss-of-function or weak gain-of-function.
[0076] A "dominant negative mutation" is a mutation that produces an altered gene product (e.g., having an abnormal function relative to the wild type) that adversely affects the function of the wild-type allele or gene product. For example, a "dominant negative mutation" may block the function of the wild-type gene product. A dominant negative mutation may also be referred to as a "reversed allele mutation."
[0077] A "semidominant mutation" is one in which the penetrance of the phenotype in a heterozygous organism is lower than that observed in a homozygous organism.
[0078] A "weak loss-of-function mutation" is a mutation that results in a gene product that has partial or reduced function (partial inactivation) compared to the wild-type gene product.
[0079] A "hypomorphic" allele is a semi-functional allele caused by a genetic mutation that results in the production of a corresponding protein that functions at between 1% and 99% of normal efficiency.
[0080] A "hypergenic allele mutation" is a mutation that results in increased expression of a gene product and / or increased activity of a gene product.
[0081] As used herein, "non-natural mutation" refers to a mutation that is produced by human intervention and is different from a mutation found in the same gene that occurs in nature (eg, naturally occurring).
[0082] A "locus" is a position on a chromosome where a gene or marker or allele is located. In some embodiments, a locus may comprise one or more nucleotides.
[0083] As used herein, the terms "desired allele," "target allele," and / or "allele of interest" are used interchangeably to refer to an allele associated with a desired trait. In some embodiments, a desired allele may be associated with an increase or decrease (relative to a control) in a given trait or a given trait, depending on the nature of the desired phenotype.
[0084] A marker is "associated with" a trait when the trait is associated with the marker and when the presence of the marker is an indication of whether and / or to what extent the desired trait or trait form will appear in a plant / germplasm containing the marker. Similarly, a marker is "associated with" an allele or chromosomal interval when the marker is associated with the allele or chromosomal interval and when the presence of the marker is an indication of whether the allele or chromosomal interval is present in the plant / germplasm containing the marker.
[0085] As used herein, the terms "backcross" and "backcrossed" refer to crossing a progeny plant back to one of its parents one or more times (e.g., 1, 2, 3, 4, 5, 6, 7, 8 times, etc.). In a backcrossing scheme, the "donor" parent refers to the parent plant that has the desired gene or locus to be introgressed. The "recipient" parent (used one or more times) or the "recycling" parent (used two or more times) refers to the parent plant into which the gene or locus is being introgressed. See, e.g., Ragot, M. et al. Marker-assisted Backcrossing: A Practical Example , in Techniques et Utilisations des MarqueursMoleculaires Les Colloques, Vol. 72, pp. 45-56 (1995); and Openshaw et al., Marker- assisted Selection in Backcross Breeding , in Proceedings of the Symposium "Analysis of Molecular Marker Data," pp. 41-43 (1994). The initial cross produced the F1 generation. The term "BC1" refers to the second use of the backcross parents, "BC2" refers to the third use of the backcross parents, and so on.
[0086] As used herein, the term "crossing" or "hybridized" refers to the fusion of gametes through pollination to produce offspring (e.g., cells, seeds, or plants). The term includes sexual crossing (one plant is pollinated by another plant) and selfing (self-pollination, e.g., when pollen and ovules are from the same plant). The term "crossing" refers to the act of fusing gametes through pollination to produce offspring.
[0087] As used herein, the terms "introgression", "introgression" and "introgressed" refer to the natural and artificial transmission of a desired allele or desired allele combination of a genetic locus from one genetic background to another genetic background. For example, the desired allele at a specific locus can be passed to at least one (e.g., one or more) offspring by sexual hybridization between two parents of the same species, wherein at least one parent has the desired allele in its genome. Alternatively, for example, the transmission of the allele can occur by recombination between two donor genomes, such as in fused protoplasts, wherein at least one donor protoplast has the desired allele in its genome. The desired allele can be a selection allele of a marker, QTL, transgenic, etc. The offspring comprising the desired allele can be backcrossed one or more times (e.g., 1, 2, 3, 4 or more times) with a strain having a desired genetic background, selecting the desired allele, with the result that the desired allele becomes fixed in the desired genetic background. For example, a marker associated with increased production under non-water stress conditions can be infiltrated from a donor into a recurrent parent that does not contain the marker and does not exhibit increased production under non-water stress conditions. The resulting offspring can then be backcrossed one or more times and selected until the offspring has a genetic marker associated with increased production under non-water stress conditions in the recurrent parent background.
[0088] A "genetic map" is a description of the genetic linkage relationships between loci on one or more chromosomes within a given species, usually depicted in graphical or tabular form. For each genetic map, the distances between loci are measured by the frequencies of recombination between them. Recombination between loci can be detected using a variety of markers. A genetic map is the product of mapping populations, the types of markers used, and the polymorphic potential of each marker between different populations. The order and genetic distances between loci can vary from one genetic map to another.
[0089] As used herein, the term "genotype" refers to the genetic makeup of an individual (or individual population) at one or more genetic loci, in contrast to observable and / or detectable and / or phenotype traits (phenotypes). Genotype is defined by the alleles of one or more known loci inherited by an individual from its parents. The term genotype can be used to refer to the genetic makeup of an individual at a single locus, a plurality of loci, or more generally, the term genotype can be used to refer to the genetic makeup of all genes in an individual genome. Genotype can be characterized indirectly, for example using a mark, and / or directly characterized by nucleic acid sequencing.
[0090] As used herein, the term "germplasm" refers to an individual (e.g., plant), a population of individuals (e.g., plant strains, varieties, or families), or genetic material therefrom, or a clone derived from a strain, variety, species, or culture. Germplasm can be a part of an organism or cell, or can be separated from an organism or cell. In general, germplasm provides genetic material with a specific genetic makeup that provides a basis for some or all of the genetic properties of an organism or cell culture. As used herein, germplasm includes cells, seeds, or tissues from which new plants can be grown, and plant parts (e.g., leaves, stems, buds, roots, pollen, cells, etc.) that can be cultured into whole plants.
[0091] As used herein, the terms "cultivar" and "variety" refer to a group of similar plants distinguishable from other varieties within the same species by structural or genetic characteristics and / or performance.
[0092] As used herein, the terms "exotic", "exotic strains" and "exotic germplasm" refer to any plant, strain or germplasm that is not superior. Generally speaking, the exotic plant / germplasm is not derived from any known superior plant or germplasm, but is selected to introduce one or more desired genetic elements into a breeding program (e.g., introducing new alleles into a breeding program).
[0093] As used herein, the term "hybrid" in the context of plant breeding refers to a plant that is the offspring of genetically distinct parents produced by crossing plants of different lines or varieties or species, including but not limited to a cross between two inbred lines.
[0094] As used herein, the term "inbred" refers to a substantially homozygous plant or variety. The term can refer to a plant or plant variety that is substantially homozygous throughout the entire genome or substantially homozygous for a portion of the genome of particular interest.
[0095] A "haplotype" is the genotype, i.e., the combination of alleles, of an individual at multiple genetic loci. Typically, the genetic loci that define a haplotype are physically and genetically linked, i.e., on the same chromosome segment. The term "haplotype" can refer to a polymorphism at a specific locus, such as a single marker locus, or to polymorphisms at multiple loci along a chromosome segment.
[0096] As used herein, the term "heterologous" refers to a nucleotide / polypeptide that originates from a foreign species or, if derived from the same species, is significantly modified from its native form in composition and / or genomic locus by deliberate human intervention.
[0097] Plants in which at least one (e.g., one or more, e.g., 1, 2, 3, or 4 or more) endogenous BRI1 gene is modified as described herein (e.g., comprises a modification as described herein) can have improved yield traits compared to plants that do not comprise the modification in at least one BRI1 gene. As used herein, "improved yield trait" refers to any plant trait associated with growth, such as biomass, yield, nitrogen use efficiency (NUE), inflorescence size / weight, fruit yield, fruit quality, fruit size, seed size (e.g., seed area, seed size), seed number, leaf tissue weight, nodule number, nodule quality, nodulation activity, seed head number, tiller number, branch number, flower amount, tuber amount, tuber quality, bulb quality, seed number, total seed mass, leaf emergence rate, tiller / branch emergence rate, seedling emergence rate, root length, number of roots, root mass size and / or weight, or any combination thereof. Thus, in some aspects, "improved yield traits" can include, but are not limited to, increased inflorescence yield, increased fruit yield (e.g., increased fruit number, weight, and / or size), increased fruit quality, increased number, size, and / or weight of roots, increased meristem size, increased seed size (e.g., seed area and / or seed weight), increased biomass, increased leaf size, increased nitrogen use efficiency, increased height, increased number of internodes, and / or increased internode length compared to a control plant or part thereof (e.g., a plant that does not comprise a mutated endogenous BRI1 nucleic acid (e.g., a mutated BRI1 gene). In some aspects, the improved yield trait can be expressed as the number of grains produced per area of land (e.g., bushels per acre of land).
[0098] As used herein, "increased yield" can mean an increase of at least 15% to about 100% (e.g., at least 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75 , 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100%). Increased yield can be assessed according to any of the improved yield traits described herein, including but not limited to higher yield (bu / acre), increased biomass, increased plant height, increased stem diameter, increased leaf area, increased number of flowers, increased number of pods per node, increased number of pods per plant, increased number of seeds, increased number of seeds per pod, increased seed size, and / or increased seed weight (e.g., increase in 100 seed weight). In some embodiments, an increase in yield can be observed in plants comprising a mutation in an endogenous BRI1 gene described herein, compared to a control plant grown under the same conditions but without the mutation in the endogenous BRI1 gene, when the plant is subjected to abiotic stress (e.g., grown under drought, shade, and / or low nitrogen conditions).
[0099] As used herein, "increased seed size" can refer to seeds that have increased area. In some embodiments, the area of the seeds can be increased by up to about 70% (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91 , 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70%). In some embodiments, the weight of the seed can be increased by up to about 50% (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 45, 46, 47, 48, 49, or 50%) compared to seeds from a control plant (e.g., a plant that does not comprise a mutation in an endogenous BRI1 gene as described herein). In some embodiments, the increase in seed size can include an increase in both seed area and seed size.
[0100] As used herein, "control plants" means plants that do not contain one or more BRI1 genes edited to impart enhanced / improved traits (e.g., yield traits) or altered phenotypes as described herein. Control plants are used to identify and select plants edited as described herein and having enhanced traits or altered phenotypes compared to control plants. Suitable control plants can be plants of the parental line used to produce plants containing mutated BRI1 genes, for example, wild-type plants lacking edits in endogenous BRI1 genes as described herein. Suitable control plants can also be plants containing recombinant nucleic acids that impart other traits, such as transgenic plants with enhanced herbicide tolerance. In some cases, suitable control plants can be offspring of heterozygous or hemizygous transgenic plant lines lacking mutated BRI1 genes as described herein, referred to as negative segregants or negative isogenic lines.
[0101] The enhanced traits (e.g., increased yield traits) can include, for example, a reduction in the number of days from planting to maturity, an increased stem size, an increased number of leaves, an increased plant height growth rate in the vegetative stage, an increased ear size, an increased ear dry weight per plant, an increased number of grains per ear, an increased weight per grain, an increased number of grains per plant, reduced empty ears, a prolonged grain filling period, a reduced plant height, an increased number of root shoots, an increased total root length, an increased yield, an increased nitrogen use efficiency, and an increased water use efficiency compared to control plants. The altered phenotype can be, for example, plant height, biomass, canopy area, anthocyanin content, chlorophyll content, water applied, water content, and water use efficiency.
[0102] In some embodiments, plants of the invention may comprise one or more improved yield traits including, but not limited to, higher yield (bushels per acre), increased biomass, increased plant height, increased stem diameter, increased leaf area, increased number of flowers, increased number of pods including increased number of pods per node and / or increased number of pods per plant, increased number of seeds per pod, increased number of seeds, increased seed size, and / or increased seed weight (e.g., an increase in 100 seed weight) compared to control plants lacking at least one mutation.
[0103] As used herein, "properties" are physiology, morphology, biochemistry or physics characteristics of plants or specific plant materials or cells. In some cases, this feature is visible to the human eye and can be measured mechanically, such as the size, weight, shape, form, length, height, growth rate and developmental stage of seeds or plants, or can be measured by biochemical techniques, such as detecting protein, starch, some metabolites or the oil content of seeds or leaves, or by observing metabolism or physiological processes, such as by measuring the tolerance to water shortage or specific salt or sugar concentration, or by measuring the expression level of one or more genes, such as by adopting Northern analysis, RT-PCR, microarray gene expression determination or reporter gene expression system, or by agricultural observations such as high osmotic stress tolerance or yield. However, any technology can be used to measure the amount, comparative level or difference of any selected compound or macromolecule in transgenic plants.
[0104] As used herein, "enhanced traits" refer to characteristics of plants caused by mutations in the BRI1 gene described herein. Such traits include, but are not limited to, enhanced agronomic traits characterized by enhanced plant morphology, physiology, growth and development, yield, nutritional enhancement, disease or pest resistance, or environmental or chemical tolerance. In some embodiments, the enhanced trait / altered phenotype can be, for example, a reduction in the number of days from planting to maturity, an increased stem size, an increased number of leaves, an increased plant height growth rate in the vegetative stage, an increased ear size, an increased ear dry weight per plant, an increased number of grains per ear, an increased weight per grain, an increased number of grains per plant, reduced empty ears, an extended grain filling period, a reduced plant height, an increased number of root branches, an increased total root length, drought tolerance, increased water use efficiency, cold tolerance, increased nitrogen use efficiency, and increased yield compared to control plants. In some embodiments, the trait is an increased yield under non-stress conditions or an increased yield under environmental stress conditions. Stress conditions can include biotic and abiotic stresses, such as drought, shading, fungal diseases, viral diseases, bacterial diseases, insect infestation, nematode infestation, low temperature exposure, heat exposure, osmotic stress, nitrogen nutrient availability, phosphorus nutrient availability and high plant density of reduction. "Yield" can be affected by many characteristics, including but not limited to plant height, plant biomass, pod number, pod position on plant, internode number, incidence of pod fragmentation, grain size, ear size, ear tip fullness, grain abortion, nodulation and nitrogen fixation efficiency, nutrient assimilation efficiency, biotic and abiotic stress resistance, carbon assimilation, plant structure, lodging resistance, seed germination percentage, seedling vigor and young body traits.Yield may also be affected by the following factors: germination efficiency (comprising germination under stress conditions), growth rate (comprising growth rate under stress conditions), flowering time and duration, ear number, ear size, ear weight, seed number of every ear or pod, seed size, seed composition (starch, oil, protein) and the full characteristics of seeds.
[0105] The term "trait modification" as also used herein encompasses altering a naturally occurring trait by producing a detectable characteristic difference in a plant comprising a mutation in an endogenous BRI1 gene as described herein relative to a plant not comprising the mutation (e.g., a wild-type plant or a negative isolate). In some cases, the trait change can be assessed quantitatively. For example, a trait modification can result in an increase or decrease in an observed trait characteristic or phenotype compared to a control plant. It is well known that natural variation may exist in the modified trait. Therefore, the observed trait modification requires a normal distribution and a change in the magnitude of the trait characteristic or phenotype in the plant compared to the control plant.
[0106] The present disclosure relates to plants with improved economically relevant characteristics, more specifically increased yield. More specifically, the present disclosure relates to plants comprising a mutation in a BRI1 gene as described herein, wherein the plant has increased yield compared to a control plant lacking the mutation. In some embodiments, the plants produced as described herein exhibit increased yield or improved yield trait components compared to control plants. In some embodiments, the plants of the present disclosure exhibit improved traits associated with yield, including but not limited to increased nitrogen use efficiency, increased nitrogen stress tolerance, increased water use efficiency, and increased drought tolerance, as defined and discussed below.
[0107] Yield can be defined as the measurable output of a crop of economic value. Yield can be defined in terms of quantity and / or quality. Yield can be directly dependent on several factors, such as the number and size of organs, plant architecture (e.g. number of branches, plant biomass, such as increased root biomass, steeper root angles and / or longer roots, etc.), flowering time and duration, grain filling period. Root structure and development, photosynthetic efficiency, nutrient uptake, stress tolerance, early vigor, delayed senescence and functional stay-green phenotype may be factors that determine yield. Therefore, optimizing the above factors can help to increase crop yield.
[0108] The increase / improvement of the yield correlated traits mentioned herein can also be considered to refer to the increase of the biomass (weight) of one or more parts of plant, which can include above-ground and / or underground (can gather in the crops) plant parts.Particularly, this type of part that can gather in the crops is seed, and the enforcement of the method for the present disclosure causes the plant of the seed yield with increase and the seed yield of particularly increase with respect to the seed yield of suitable control plant.The term "yield" of plant can relate to the vegetative biomass (root and / or bud biomass), reproductive organ and / or propagule (for example seed) of this plant.
[0109] The increased yield of plants of the present disclosure can be measured in a variety of ways, including test weight, number of seeds per plant, seed weight, number of seeds per unit area (e.g., weight of seeds or seeds per acre), bushels per acre, tons per acre, or kilograms per hectare. Increased yield can be achieved by improved utilization of key biochemical compounds (e.g., nitrogen, phosphorus, and carbohydrates), or improved responses to environmental stresses such as cold, heat, drought, salt, shading, high plant density, and pest or pathogen attack.
[0110] "Increased yield" can be manifested as one or more of the following: (i) increased plant biomass (weight) of one or more parts of the plant, in particular the aboveground (harvestable) parts of the plant, increased root biomass (increased root number, increased root thickness, increased root length) or increased biomass of any other harvestable part; or (ii) increased early vigour, defined herein as improved aboveground area of seedlings about three weeks after germination.
[0111] "Early vigor" refers to the growth of plants that are healthy, especially in the early stages of plant growth, and can be caused by the increased plant fitness due to, for example, plants better adapting to their environment (for example, optimizing the use of energy, the absorption of nutrients, and distributing carbon shares between buds and roots). For example, early vigor can be a combination of the ability of seeds to germinate and emerge after planting and the ability of seedlings to grow and develop after emergence. Plants with early vigor also show increased seedling survival and better crop planting, which usually results in highly uniform fields, in which most plants substantially reach different developmental stages at the same time, which usually results in increased yield. Therefore, early vigor can be determined by measuring various factors, such as grain weight, germination percentage, emergence percentage, seedling growth, seedling height, root length, root and bud biomass, canopy size and color, etc.
[0112] In addition, the increased yield can also be manifested as an increased total seed yield, which may be due to an increase in seed biomass (seed weight) due to an increase in seed weight per plant and / or on a single seed basis, such as an increased number of flowers / ears per plant; an increased number of pods; an increased number of nodes; an increased number of flowers ("florets") per ear / plant; an increased seed filling rate; an increased number of filled seeds; an increased seed size (length, width, area, girth and / or weight), which can also affect the composition of the seed; and / or an increased seed volume (which can also affect the composition of the seed) caused by one or more. In one embodiment, the increased yield can be an increased seed yield, such as an increased seed weight; an increased number of filled seeds; and an increased harvest index.
[0113] Increased yield may also result from a modified structure, or may occur as a result of a modified plant structure.
[0114] Increased yield may also be expressed as an increased harvest index, which is expressed as the ratio of the yield of harvestable parts (eg seeds) to the total biomass.
[0115] The present disclosure also extends to harvestable parts of plants, such as, but not limited to, seeds, leaves, fruits, flowers, bolls, pods, siliques, nuts, stems, rhizomes, tubers and bulbs. The present disclosure also relates to products derived from harvestable parts of such plants, such as dry particles, powders, oils, fats and fatty acids, starch or proteins.
[0116] The present disclosure provides methods for increasing "yield" of a plant or "large acre yield" of a plant or plant part, which is defined as the harvestable plant part per unit area, such as seeds or seed weight per acre, pounds per acre, bushels per acre, tones per acre, tons per acre, kilograms per hectare.
[0117] As used herein, "nitrogen use efficiency" refers to the processes that lead to an increase in plant yield, biomass, vigor, and growth rate per unit of nitrogen applied. These processes can include plant uptake, assimilation, accumulation, signal transduction, sensing, retransfer (within the plant), and utilization of nitrogen.
[0118] As used herein, "increased nitrogen use efficiency" refers to the ability of a plant to grow, develop or produce faster or better than normal when subjected to the same amount of available / applied nitrogen as under normal or standard conditions; the ability of a plant to grow, develop or produce normally or to grow, develop or produce faster or better when subjected to less than the optimal amount of available / applied nitrogen or under nitrogen limiting conditions.
[0119] As used herein, "nitrogen limiting conditions" refers to growing conditions or environments that provide less than the optimal amount of nitrogen required for adequate or successful plant metabolism, growth, reproductive success and / or vigor.
[0120] As used herein, "increased nitrogen stress tolerance" refers to the ability of a plant to grow, develop or produce normally, or to grow, develop or produce faster or better, when subjected to less than optimal amounts of available / applied nitrogen or under nitrogen limiting conditions.
[0121] Increased plant nitrogen utilization efficiency can be converted in the field to harvest a similar amount of yield while supplying less nitrogen, or to obtain increased yield by supplying an optimal / sufficient amount of nitrogen. Increased nitrogen utilization efficiency can improve plant nitrogen stress tolerance, and can also improve crop quality and the biochemical composition of seeds, such as protein yield and oil yield. The terms "increased nitrogen utilization efficiency", "enhanced nitrogen utilization efficiency" and "nitrogen stress tolerance" are used interchangeably in this disclosure and refer to plants with increased productivity under nitrogen limiting conditions.
[0122] As used herein, "water use efficiency" refers to the amount of carbon dioxide absorbed by leaves per unit of transpiration water vapor. It constitutes one of the most important traits controlling plant productivity in dry environments. "Drought tolerance" refers to the degree to which plants adapt to dry or drought conditions. The physiological response of plants to water shortage includes leaf wilting, reduced leaf area, leaf shedding, and stimulating root growth by directing nutrients to the underground parts of the plant. Generally, plants are more susceptible to drought during flowering and seed development (reproduction stage) because the resources of the plant are deviated to support root growth. In addition, abscisic acid (ABA), a plant stress hormone, induces leaf stomata (micropores involved in gas exchange) to close, thereby reducing water loss through transpiration and reducing photosynthesis rate. These reactions improve the water use efficiency of plants in the short term. The terms "increased water use efficiency", "enhanced water use efficiency" and "increased drought tolerance" are used interchangeably in this disclosure and refer to plants with improved productivity under water-limited conditions.
[0123] As used herein, "increased water use efficiency" refers to the ability of a plant to grow, develop or produce faster or better than normal when subjected to the same amount of available / applied water as under normal or standard conditions; the ability of a plant to grow, develop or produce normally or to grow, develop or produce faster or better when subjected to reduced amounts of available / applied water (water input) or under water stress or water deficit stress conditions.
[0124] As used herein, "increased drought tolerance" refers to the ability of a plant to grow, develop or produce normally, or to grow, develop or produce faster or better than normal, when subjected to reduced amounts of available / applied water and / or under acute or chronic drought conditions; the ability of a plant to grow, develop or produce normally, when subjected to reduced amounts of available / applied water (water input) or under water stress conditions or under acute or chronic drought conditions.
[0125] As used herein, "drought stress" refers to a dry period (acute or chronic / long term) that results in a lack of water and causes stress to plants and / or damage to plant tissues and / or negatively affects grain / crop yield; a dry period (acute or chronic / long term) that results in a lack of water and / or elevated temperatures and causes stress to plants and / or damage to plant tissues and / or negatively affects grain / crop yield.
[0126] As used herein, "water deficit" refers to conditions or environments that provide less than the optimal amount of water required for adequate / successful growth and development of plants.
[0127] As used herein, "water stress" refers to conditions or environments that provide an inappropriate amount of water (less / insufficient or more / excessive) than required for adequate / successful growth and development of the plant / crop, thereby causing plant stress and / or plant tissue damage and / or negatively affecting grain / crop yield.
[0128] As used herein, "water stress" refers to conditions or circumstances that provide less / insufficient water than required for adequate / successful growth and development of plants / crops, thereby causing plant stress and / or plant tissue damage and / or negatively affecting grain yield.
[0129] As used herein, the terms "nucleic acid", "nucleic acid molecule", "nucleotide sequence" and "polynucleotide" refer to RNA or DNA that is linear or branched, single-stranded or double-stranded, or a hybrid thereof. The term also includes RNA / DNA hybrids. When dsRNA is synthesized, less common bases such as inosine, 5-methylcytosine, 6-methyladenine, hypoxanthine, etc. can also be used for antisense, dsRNA and ribozyme pairing. For example, polynucleotides containing C-5 propyne analogs of uridine and cytidine have been shown to bind RNA with high affinity and are potent antisense inhibitors of gene expression. Other modifications may also be made, such as modifications to the phosphodiester backbone, or the 2'-hydroxyl in the ribose sugar group of the RNA.
[0130] As used herein, the term "nucleotide sequence" refers to a heteropolymer of nucleotides or a sequence of these nucleotides from the 5' end to the 3' end of a nucleic acid molecule, and includes DNA or RNA molecules, including cDNA, DNA fragments or parts, genomic DNA, synthetic (e.g., chemically synthesized) DNA, plasmid DNA, mRNA and antisense RNA, any of which can be single-stranded or double-stranded. The terms "nucleotide sequence", "nucleic acid", "nucleic acid molecule", "nucleic acid construct", "oligonucleotide" and "polynucleotide" are also interchangeably used herein to refer to a heteropolymer of nucleotides. Nucleic acid molecules and / or nucleotide sequences provided herein are presented in this article from left to right in a 5' to 3' direction, and are represented using the standard code representing the nucleotide characters described in the U.S. sequence rules, 37 CFR §§1.821-1.825 and the World Intellectual Property Organization (WIPO) standard ST.25. As used herein, "5' region" can refer to the region of the polynucleotide closest to the 5' end of a polynucleotide. Therefore, for example, the element in the 5' region of a polynucleotide can be located at any position from the first nucleotide located at the 5' end of a polynucleotide to the nucleotide located in the middle of the polynucleotide. As used herein, "3' region" may refer to the region of a polynucleotide closest to the 3' end of a polynucleotide. Thus, for example, an element in the 3' region of a polynucleotide may be located anywhere from the first nucleotide at the 3' end of the polynucleotide to a nucleotide in the middle of the polynucleotide.
[0131] As used herein with respect to nucleic acids, the terms "fragment" or "portion" refer to a portion of a nucleic acid that is reduced in length (e.g., by 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 20, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 260, 270, 280, 290, 300, 310, 320, 330, 340, 350, 400, 450, 500, 500, 510, 520, 530, 540, 550, 560, 570, 580, 590, 610, 620, 630, 640, 650, 660, 670, 680, 690, 711 The nucleic acid fragment may be a nucleic acid having a nucleotide sequence that is identical or nearly identical (e.g., 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% identical) to the corresponding portion of the reference nucleic acid. Where appropriate, such a nucleic acid fragment may be contained within a larger polynucleotide of which it is a component. As an example, the repeat sequence of the guide nucleic acid of the present invention can include a portion of a wild-type CRISPR-Cas repeat sequence (e.g., a wild-type CRISPR-Cas repeat; for example, a repeat from a CRISPR Cas system such as Cas9, Cas12a (Cpf1), Cas12b, Cas12c (C2c3), Cas12d (CasY), Cas12e (CasX), Cas12g, Cas12h, Cas12i, C2c4, C2c5, C2c8, C2c9, C2c10, Cas14a, Cas14b and / or Cas14c, etc.).
[0132] In some embodiments, the nucleic acid fragment can comprise about 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 110, 120, 130, 140, 150, 160, 170, 180, 38, 39, 40, 41, 42, 43, 44, 45, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111 8, 59, 60, 61, 62, 63, 65, 65, 66, 67, 68, 69, 70, 75, 76, 77, 78, 79, 80, 85, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 105, 110, 115, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 145, 150, 155, 160, 165 , 170, 175, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 195, 200, 205, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 225, 230, 235, 240, 245, 250, 255, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, or 270 or more consecutive nucleotides, or any range or value therein (e.g., a fragment or portion of any of SEQ ID NOs: 69, 70, 80, or 81 (e.g., SEQ ID NOs: 73-79 or 83-95)).
[0133] In some embodiments, a "sequence-specific nucleic acid binding domain" can bind to one or more fragments or portions of a nucleotide sequence (eg, DNA, RNA) encoding a BRI1 polypeptide, such as described herein.
[0134] As used herein with respect to polypeptides, the term "fragment" or "portion" may refer to a polypeptide that is reduced in length relative to a reference polypeptide and that comprises, consists essentially of, and / or consists of an amino acid sequence of contiguous amino acids that are identical or nearly identical (e.g., 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% identical) to the corresponding portion of the reference polypeptide. Where appropriate, such polypeptide fragments may be included in a larger polypeptide of which they are a component. In some embodiments, a polypeptide fragment may comprise, consist essentially of, or consist of at least about 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 125, 150, 175, 200, 225, 250, 260, 270, 280, or 290 or more contiguous amino acids of a reference polypeptide.
[0135] In some embodiments, the deletion when included in a plant can result in the plant exhibiting one or more improved yield traits compared to a plant not comprising the deletion.The BRI1 gene can be edited at one or more than one position (and using one or more different editing tools) to provide a BRI1 gene comprising one or more than one mutation.
[0136] In some embodiments, "portion" with respect to a nucleic acid means at least 2, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91 8, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 120, 130, 140, 141, 142, 143, 144, 145, 150, 160, 170, 180, 190, 200, 210, 220, 221, 222, 223, 224, 225, 230, 240, 250, 260, or 270 or more consecutive nucleotides (e.g., consecutive nucleotides from a BRI1 gene) (e.g., SEQ ID NO: 1 A fragment or portion of any one of SEQ ID NOs: 69, 70, 80 or 81 (eg, SEQ ID NOs: 73-79 or 83-95)).
[0137] As used herein with respect to nucleic acids, the term "functional fragment" refers to a nucleic acid encoding a functional fragment of a polypeptide. A "functional fragment" with respect to a polypeptide is a fragment of a polypeptide that retains one or more activities of a native reference polypeptide.
[0138] As used herein, the term "gene" refers to a nucleic acid molecule that can be used to produce mRNA, antisense RNA, miRNA, anti-microRNA antisense oligodeoxynucleotides (AMOs) and the like. A gene may or may not be used to produce a functional protein or gene product. A gene may include coding regions and non-coding regions (e.g., introns, regulatory elements, promoters, enhancers, termination sequences and / or 5' and 3' untranslated regions). A gene can be "isolated", which refers to a nucleic acid that is generally or substantially free of components that are usually associated with nucleic acids in its natural state. These components include other cell materials, culture media from recombinant production and / or various chemicals for chemically synthesizing nucleic acids.
[0139] The term "mutation" refers to a point mutation (e.g., missense or nonsense, or insertion or deletion of a single base pair that results in a frameshift), insertion, deletion, inversion, and / or truncation. When a mutation is a substitution of one residue in an amino acid sequence by another residue, or a deletion or insertion of one or more residues in a sequence, the mutation is typically described by identifying the original residue, then the position of the residue in the sequence, and the identity of the newly substituted residue. Truncation may include truncation at the C-terminus of a polypeptide or at the N-terminus of a polypeptide. Truncation of a polypeptide may be the result of a deletion of the corresponding 5' end or 3' end of the gene encoding the polypeptide. When a deletion or insertion of one or more base pairs is introduced into a gene, a frameshift mutation may occur, optionally resulting in an out-of-frame mutation or an in-frame mutation. A frameshift mutation in a gene may result in a polypeptide that is longer, shorter, or the same length as a wild-type polypeptide, depending on when the first stop codon appears after the mutation region of the gene. As an example, an out-of-frame mutation that produces a premature stop codon may produce a polypeptide that is shorter than a wild-type polypeptide, or in some embodiments, the polypeptide may not be present / detectable. In some embodiments, the mutation may be a DNA inversion, optionally a DNA inversion having a length of about 10 to about 2000 contiguous base pairs.
[0140] As used herein, the terms "complementary" or "complementarity" refer to the natural binding of polynucleotides by base pairing under permissive salt and temperature conditions. For example, the sequence "AGT" (5' to 3') binds to the complementary sequence "TCA" (3' to 5'). Complementarity between two single-stranded molecules may be "partial", in which only some of the nucleotides bind, or complementarity may be complete when there is complete complementarity between the single-stranded molecules. The degree of complementarity between nucleic acid chains has a significant effect on the efficiency and strength of hybridization between nucleic acid chains.
[0141] As used herein, "complementary" can refer to 100% complementarity to a comparison nucleotide sequence, or it can refer to less than 100% complementarity to a comparison nucleotide sequence (e.g., about 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 95%, 96%, 97%, 98%, 99%, etc. complementarity).
[0142] Different nucleic acids or proteins with homology are referred to herein as "homologs". The term homolog includes homologous sequences from the same and from other species and orthologous sequences from the same and other species." Homology " refers to the level of similarity between two or more nucleic acids and / or amino acid sequences in terms of positional identity percentage (i.e., sequence similarity or identity). Homology also refers to the concept of similar functional properties between different nucleic acids or proteins. Therefore, the compositions and methods of the present invention also include homologs to the nucleotide sequences and polypeptide sequences of the present invention. As used herein, "orthologs" refer to homologous nucleotide sequences and / or amino acid sequences in different species produced from a common ancestral gene during species formation. Homologs of the nucleotide sequences of the invention have substantial sequence identity (e.g., at least about 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, or 100%) to the nucleotide sequences of the invention.
[0143] As used herein, "sequence identity" refers to the degree to which two optimally aligned polynucleotide or polypeptide sequences remain unchanged over the entire window of alignment of components (e.g., nucleotides or amino acids). "Identity" can be readily calculated by known methods, including but not limited to those described below: Computational Molecular Biology (Lesk, AM, ed.) Oxford University Press, New York (1988); Biocomputing: Informatics and Genome Projects (Smith, DW, ed.) Academic Press, New York (1993); Computer Analysis of Sequence Data, Part I (Griffin, AM, and Griffin, HG, eds.) Humana Press, New Jersey (1994); Sequence Analysis in Molecular Biology (von Heinje, G., ed.) Academic Press (1987); and Sequence Analysis Primer (Gribskov, M. and Devereux, J., eds.) Stockton Press, New York (1991).
[0144] As used herein, the term "percent sequence identity" or "percent identity" refers to the percentage of identical nucleotides in a linear polynucleotide sequence of a reference ("query") polynucleotide molecule (or its complementary strand) compared to a test ("subject") polynucleotide molecule (or its complementary strand) when the two sequences are optimally aligned. In some embodiments, "percent identity" may refer to the percentage of identical amino acids in an amino acid sequence compared to a reference polypeptide.
[0145] As used herein, the phrases "substantially identical" or "substantial identity" in the context of two nucleic acid molecules, nucleotide sequences, or protein sequences refers to two or more sequences or subsequences having at least about 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, or 100% nucleotide or amino acid residue identity when compared and aligned for maximum correspondence as measured using one of the following sequence comparison algorithms or by visual inspection. In some embodiments of the invention, substantial identity exists over a region of contiguous nucleotides of a nucleotide sequence of the invention that is about 10 nucleotides to about 20 nucleotides, about 10 nucleotides to about 25 nucleotides, about 10 nucleotides to about 30 nucleotides, about 15 nucleotides to about 25 nucleotides, about 30 nucleotides to about 40 nucleotides, about 50 nucleotides to about 60 nucleotides, about 70 nucleotides to about 80 nucleotides, about 90 nucleotides to about 100 nucleotides, about 100 nucleotides to about 200 nucleotides, about 100 nucleotides to about 300 nucleotides, about 100 nucleotides to about 400 nucleotides, about 100 nucleotides to about 500 nucleotides, about 100 nucleotides to about 600 nucleotides, about 100 nucleotides to about 800 nucleotides, about 100 nucleotides to about 900 nucleotides, or more, in length, and any ranges therein, up to the full length of the sequence. In some embodiments, the nucleotide sequences may be substantially identical over at least about 20 consecutive nucleotides (e.g., about 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 50, 60, 70, or 80 nucleotides or more).
[0146] In some embodiments of the invention, substantial identity exists over a region of contiguous amino acid residues of a polypeptide of the invention, the length of the region being about 3 amino acid residues to about 20 amino acid residues, about 5 amino acid residues to about 25 amino acid residues, about 7 amino acid residues to about 30 amino acid residues, about 10 amino acid residues to about 25 amino acid residues, about 15 amino acid residues to about 30 amino acid residues, about 20 amino acid residues to about 40 amino acid residues, about 25 amino acid residues to about 40 amino acid residues, about 25 amino acid residues to about 50 amino acid residues, about 30 amino acid residues to about 50 amino acid residues, about 40 amino acid residues to about 50 amino acid residues, about 40 amino acid residues to about 70 amino acid residues, about 50 amino acid residues to about 70 amino acid residues, about 60 amino acid residues to about 80 amino acid residues, about 70 amino acid residues to about 80 amino acid residues, about 90 amino acid residues to about 100 amino acid residues or more, and any ranges therein, up to the full length of the sequence. In some embodiments, the polypeptide sequence can be at least about 8 consecutive amino acid residues (e.g., about 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73 , 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 130, 140, 150, 175, 200, 225, 250, 300, 350 or more amino acids in length (or more consecutive amino acid residues).In some embodiments, two or more BRI1 polypeptides can be identical or substantially identical (e.g., at least 70% to 99.9% identical; e.g., about 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.9% identical or any range or value therein) over at least 10 amino acids to about 350 amino acids or more.
[0147] For sequence comparison, usually one sequence acts as a reference sequence to which a test sequence is compared. When using a sequence comparison algorithm, the test sequence and the reference sequence are input into a computer, subsequence coordinates are specified if necessary, and sequence algorithm program parameters are specified. Then, the sequence comparison algorithm calculates the sequence identity percentage of the test sequence relative to the reference sequence based on the specified program parameters.
[0148] The optimal comparison for comparing the sequence that the comparison window is compared is well-known to those skilled in the art, and can be by the tool of the search of the similarity method such as the local homology algorithm of Smith and Waterman, the homology comparison algorithm of Needleman and Wunsch, Pearson and Lipman and optionally by the computerized realization of these algorithms such as GAP, BESTFIT, FASTA and TFASTA (as GCG Wisconsin Package (Accelrys Inc., SanDiego, CA) part is provided) to carry out. " Identity score " of the comparison section of test sequence and reference sequence refers to the quantity of the same components shared by two comparison sequences divided by the total number of components in the reference sequence section (for example, the smaller definition part of whole reference sequence or reference sequence). Sequence identity percentage is expressed as identity score multiplied by 100. The comparison of one or more polynucleotide sequences can be with full-length polynucleotide sequence or its part, or with longer polynucleotide sequence to compare. For purposes of the present invention, "percent identity" may also be determined using BLASTX version 2.0 (for translated nucleotide sequences) and BLASTN version 2.0 (for polynucleotide sequences).
[0149] Two nucleotide sequences may also be considered substantially complementary when the two sequences hybridize to each other under stringent conditions. In some embodiments, two nucleotide sequences considered substantially complementary hybridize to each other under highly stringent conditions.
[0150] "Stringent hybridization conditions" and "stringent hybridization wash conditions" in the context of nucleic acid hybridization experiments (such as Southern and Northern hybridizations) are sequence-dependent and are different under different environmental parameters. For an adequate guide to nucleic acid hybridization, see Tijssen et al. Laboratory Techniques in Biochemistry and Molecular Biology- Hybridization with Nucleic Acid Probes part I chapter 2 "Overview of principles of hybridization and the strategy of nucleic acid probe assays" Elsevier, New York (1993). Generally, highly stringent hybridization and washing conditions are selected to exceed the thermal melting point (T) of the specific sequence at a defined ionic strength and pH. m ) is about 5°C lower.
[0151] T m The temperature (under defined ionic strength and pH) at which 50% of the target sequence hybridizes to a perfectly matched probe. Very stringent conditions are selected to equal the T for a specific probe. m . In a Southern or northern blot, an example of stringent hybridization conditions for hybridization of complementary nucleotide sequences with more than 100 complementary residues on the filter is 50% formamide with 1 mg heparin at 42°C, with hybridization performed overnight. An example of highly stringent wash conditions is 0.15 M NaCl, about 15 minutes at 72°C. An example of a stringent wash condition is a 0.2×SSC wash at 65°C for 15 minutes (see Sambrook below for a description of SSC buffer). Typically, a low stringency wash is performed before a high stringency wash to remove background probe signal. For example, an example of a moderate stringency wash for a duplex of more than 100 nucleotides is 1xSSC at 45°C for 15 minutes. For example, an example of a low stringency wash for a duplex of more than 100 nucleotides is 4-6x SSC at 40°C for 15 minutes. For short probes (e.g., about 10 to 50 nucleotides), stringent conditions typically involve a salt concentration of less than about 1.0 M Na ions, typically about 0.01 to 1.0 M Na ion concentration (or other salts) at pH 7.0 to 8.3, and a temperature of typically at least about 30°C. Stringent conditions may also be achieved by adding a destabilizing agent such as formamide. In general, a signal-to-noise ratio of 2x (or higher) of the signal-to-noise ratio observed for an unrelated probe in a particular hybridization assay indicates that specific hybridization has been detected. Nucleotide sequences that do not hybridize to each other under stringent conditions are still substantially identical if the proteins they encode are substantially identical. For example, this may occur when a copy of a nucleotide sequence is created using the maximum codon degeneracy allowed by the genetic code.
[0152] The polynucleotides and / or recombinant nucleic acid constructs (e.g., expression cassettes and / or vectors) of the invention may be codon optimized for expression. In some embodiments, the editing systems of the invention (e.g., comprising / encoding sequence-specific nucleic acid binding domains (e.g., from polynucleotide-guided endonucleases, zinc finger nucleases, transcription activator-like effector nucleases (TALENs), Argonaute proteins, and / or CRISPR-Cas endonucleases (e.g., CRISPR-Cas effector proteins) (e.g., type I CRISPR-Cas effector proteins, type II CRISPR-Cas effector proteins, type III CRISPR-Cas effector proteins, type IV CRISPR-Cas effector proteins, type V CRISPR-Cas effector proteins, or type VI CRISPR-Cas effector proteins) Polynucleotides, nucleic acid constructs, expression cassettes and / or vectors encoding sequence-specific nucleic acid binding domains (e.g., DNA binding domains)), nucleases (e.g., endonucleases (e.g., Fok1), polynucleotide-guided endonucleases, CRISPR-Cas endonucleases (e.g., CRISPR-Cas effector proteins), zinc finger nucleases and / or transcription activator-like effector nucleases (TALENs)), deaminase proteins / domains (e.g., adenine deaminase, cytosine deaminase), polynucleotides encoding reverse transcriptase proteins or domains, polynucleotides encoding 5'-3' exonuclease polypeptides and / or affinity polypeptides, peptide tags, etc.) can be codon-optimized for expression in plants. In some embodiments, a codon-optimized nucleic acid, polynucleotide, expression cassette, and / or vector of the invention is about 70% to about 99.9% (e.g., 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.9%, or 100%) identical or more to a reference nucleic acid, polynucleotide, expression cassette, and / or vector that has not been codon-optimized.
[0153] In any embodiment described herein, polynucleotides or nucleic acid constructs of the present invention can be operably associated with a variety of promoters and / or other regulatory elements to express in plants and / or cells of plants. Therefore, in some embodiments, polynucleotides or nucleic acid constructs of the present invention can further include one or more promoters, introns, enhancers and / or terminators operably connected to one or more nucleotide sequences. In some embodiments, promoters can be operably associated with introns (e.g., Ubil promoter and intron). In some embodiments, promoters associated with introns can be referred to as "promoter regions" (e.g., Ubil promoter and intron).
[0154] As used herein with respect to polynucleotides, "operably connected" or "operably associated" refers to that the elements shown are functionally related to each other, and are generally also physically related. Therefore, as used herein, the term "operably connected" or "operably associated" refers to a nucleotide sequence that is functionally associated on a single nucleic acid molecule. Therefore, a first nucleotide sequence that is operably connected to a second nucleotide sequence refers to a situation when the first nucleotide sequence is in a functional relationship with the second nucleotide sequence. For example, if a promoter affects the transcription or expression of the nucleotide sequence, the promoter is operably associated with the nucleotide sequence. It will be appreciated by those skilled in the art that a control sequence (e.g., a promoter) does not need to be continuous with the nucleotide sequence that is operably connected to, as long as the control sequence works to direct its expression. Therefore, for example, an inserted non-translated but transcribed nucleic acid sequence may be present between a promoter and a nucleotide sequence, and the promoter may still be considered to be "operably connected" to a nucleotide sequence.
[0155] As used herein, the term "linked" with respect to a polypeptide refers to the connection of one polypeptide to another polypeptide. A polypeptide can be linked to another polypeptide (at the N-terminus or C-terminus) directly (e.g., via a peptide bond) or via a linker.
[0156] The term "joint" is recognized in the art and refers to a chemical group or molecule that connects two molecules or parts (e.g., two domains of a fusion protein), such as a nucleic acid binding polypeptide or domain and a peptide tag, and / or a reverse transcriptase and an affinity polypeptide bound to a peptide tag; or a DNA endonuclease polypeptide or domain and a peptide tag and / or a reverse transcriptase and an affinity polypeptide bound to a peptide tag. The joint can consist of a single connecting molecule or can contain more than one connecting molecule. In some embodiments, the joint can be an organic molecule, a group, a polymer, or a chemical part, such as a divalent organic part. In some embodiments, the joint can be an amino acid or it can be a peptide. In some embodiments, the joint is a peptide.
[0157] In some embodiments, the length of peptide linkers useful in the present invention can be from about 2 to about 100 or more amino acids, for example, about 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100 or more amino acids (e.g., about 2 to about 40, about 2 to about 50, about 2 to about 60, about 4 to about 40, about 4 to about 50, about 4 to about 60, about 5 to about 50, about 5 to about 60, about 9 to about 100, about 10 to about 150 40, about 9 to about 50, about 9 to about 60, about 10 to about 40, about 10 to about 50, about 10 to about 60, or about 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25 amino acids to about 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, In some embodiments, the peptide linker can be a GS linker.
[0158] As used herein, the term "connection" or "fusion" with respect to polynucleotides refers to the connection of one polynucleotide to another polynucleotide. In some embodiments, two or more polynucleotide molecules can be connected by a joint, and the joint can be an organic molecule, a group, a polymer or a chemical part, such as a divalent organic part. Polynucleotides can be connected or fused to another polynucleotide (at the 5' end or 3' end) by covalent or non-covalent bonding or combination, including, for example, Watson-Crick base pairing, or by one or more connecting nucleotides. In some embodiments, a polynucleotide motif of a certain structure can be inserted into another polynucleotide sequence (for example, an extension of a hairpin structure in a guide RNA). In some embodiments, the connecting nucleotides can be naturally occurring nucleotides. In some embodiments, the connecting nucleotides can be non-naturally occurring nucleotides.
[0159] "Promoter" is a nucleotide sequence that controls or regulates the transcription of a nucleotide sequence (e.g., a coding sequence) that is operably associated with the promoter. The coding sequence controlled or regulated by the promoter can encode a polypeptide and / or a functional RNA. Generally, "promoter" refers to a nucleotide sequence that contains an RNA polymerase II binding site and directs the initiation of transcription. In general, promoters are found 5' or upstream of the start of the coding region relative to the corresponding coding sequence. The promoter may contain other elements that act as regulatory factors for gene expression; for example, a promoter region. These include the TATA box consensus sequence, and are typically the CAAT box consensus sequence (Breathnach and Chambon, (1981) Annu. Rev. Biochem . 50:349). In plants, the CAAT box can be replaced by the AGGA box (Messing et al., (1983) in Genetic Engineering of Plants , T.Kosuge, C. Meredith and A. Hollaender (eds.), Plenum Press, pp. 211-227).
[0160] Promoters useful in the present invention may include, for example, constitutive, inducible, temporally regulated, developmentally regulated, chemically regulated, tissue-preferred and / or tissue-specific promoters for use in preparing recombinant nucleic acid molecules, such as "synthetic nucleic acid constructs" or "protein-RNA complexes." These different types of promoters are known in the art.
[0161] The selection of promoters may vary depending on the temporal and spatial requirements of expression, and may also vary based on the host cell to be transformed. Many different biological promoters are well known in the art. Based on the existing extensive knowledge in this area, suitable promoters can be selected for a particular host organism of interest. Therefore, for example, a lot is known about promoters upstream of genes highly constitutively expressed in model organisms, and such knowledge can be easily acquired and implemented in other systems where appropriate.
[0162] In some embodiments, promoters that function in plants can be used with the constructs of the present invention. Non-limiting examples of promoters that can be used to drive expression in plants include the promoter of RubisCo small subunit gene 1 (PrbcS1), the promoter of the actin gene (Pactin), the promoter of the nitrate reductase gene (Pnr), and the promoter of the repetitive carbonic anhydrase gene 1 (Pdca1) (see Walker et al. Plant Cell Rep . 23:727-735 (2005); Li et al. Gene 403:132-142 (2007); Li et al. Mol Biol. Rep. 37:1143-1154 (2010)). PrbcS1 and Pactin are constitutive promoters, and Pnr and Pdca1 are inducible promoters. Pnr is induced by nitrate and repressed by ammonium (Li et al. Gene 403:132-142 (2007)), and Pdca1 is induced by salt (Li et al. Mol Biol. Rep . 37:1143-1154 (2010)). In some embodiments, the promoter useful in the present invention is an RNA polymerase II (PolII) promoter. In some embodiments, the U6 promoter or 7SL promoter from corn can be used in the constructs of the present invention. In some embodiments, the U6c promoter and / or the 7SL promoter from corn can be used to drive the expression of the guide nucleic acid. In some embodiments, the U6c promoter, U6i promoter and / or the 7SL promoter from soybean can be used in the constructs of the present invention. In some embodiments, the U6c promoter, U6i promoter and / or the 7SL promoter from soybean can be used to drive the expression of the guide nucleic acid.
[0163] Examples of constitutive promoters that can be used in plants include, but are not limited to, the cestrum virus promoter (cmp) (U.S. Pat. No. 7,166,770), the rice actin 1 promoter (Wang et al. (1992) Mol. Cell. Biol . 12:3399-3406; and U.S. Patent No. 5,641,876), CaMV 35S promoter (Odell et al. (1985) Nature 313:810-812), CaMV 19S promoter (Lawton et al. (1987) Plant Mol. Biol. 9:315-324), nos promoter (Ebert et al. (1987) Proc. Natl. Acad. Sci USA 84:5745-5749), Adh promoter (Walker et al. (1987) Proc. Natl. Acad. Sci. USA 84:6624-6629), sucrose synthase promoter (Yang & Russell (1990) Proc. Natl. Acad. Sci. USA 87:4144-4148) and ubiquitin promoter. Constitutive promoters derived from ubiquitin accumulate in many cell types. The ubiquitin promoter has been isolated from several plant species, such as sunflower (Binet et al., 1991. Plant Science 79: 87-94), corn (Christensen et al., 1989. Plant Molec. Biol. 12: 619-632) and Arabidopsis thaliana (Norris et al. 1993. Plant Molec. Biol. 21:895-906)) was cloned for transgenic plants. The maize ubiquitin promoter (UbiP) has been developed in a transgenic monocot system, and its sequence and construction of a vector for monocot transformation are disclosed in patent publication EP 0 342 926. The ubiquitin promoter is suitable for expression of the nucleotide sequence of the present invention in transgenic plants, especially monocots. In addition, McElroy et al. ( Mol. Gen. Genet The promoter expression cassette described in . 231: 150-160 (1991)) can be readily modified to express the nucleotide sequence of the present invention and is particularly suitable for use in monocotyledonous hosts.
[0164] In some embodiments, tissue-specific / tissue-preferred promoters can be used to express heterologous polynucleotides in plant cells. Tissue-specific or preferred expression patterns include, but are not limited to, green tissue-specific or preferred, root-specific or preferred, stem-specific or preferred, flower-specific or preferred, or pollen-specific or preferred expression patterns. Promoters suitable for expression in green tissues include many genes that regulate the genes involved in photosynthesis, many of which have been cloned from monocots and dicots. In one embodiment, a promoter useful in the present invention is the maize PEPC promoter from the phosphoenol carboxylase gene (Hudspeth & Grula, Plant Molec. Biol . 12:579-589 (1989)). Non-limiting examples of tissue-specific promoters include those associated with genes encoding seed storage proteins (e.g., β-conglycinin, cruciferin, napin, and phaseolin), zein, or oil body proteins (e.g., oleosin), or proteins involved in fatty acid biosynthesis (including acyl carrier protein, stearoyl-ACP desaturase, and fatty acid desaturase (fad2-1)), as well as other nucleic acids expressed during embryo development (e.g., Bce4, see, e.g., Kridl et al. (1991)). Seed Sci. Res . 1:209-219; and EP Patent No. 255378). Tissue-specific or tissue-preferred promoters that can be used to express the nucleotide sequences of the present invention in plants, particularly corn, include, but are not limited to, those promoters that express directly in roots, pith, leaves or pollen. Such promoters are disclosed, for example, in WO93 / 07278, which is incorporated herein by reference in its entirety. Other non-limiting examples of tissue-specific or tissue-preferred promoters that can be used in the present invention are the cotton rubisco promoter disclosed in U.S. Pat. No. 6,040,504; the rice sucrose synthase promoter disclosed in U.S. Pat. No. 5,604,121; the root-specific promoter described by de Framond (FEBS 290:103-106 (1991); EP 0 452 269 to Ciba-Geigy); the stem-specific promoter described in U.S. Pat. No. 5,625,136 (Ciba-Geigy) and driving expression of the maize trpA gene; the cestrum yellow leaf curl virus promoter disclosed in WO01 / 73087; and pollen-specific or -preferred promoters, including but not limited to ProOsLPS10 and ProOsLPS11 from rice (Nguyen et al. Plant Biotechnol. Reports 9(5):297-306 (2015)), ZmSTK2_USP from maize (Wang et al. Genome 60(6):485-495 (2017)), LAT52 and LAT59 from tomato (Twell et al. Development 109(3):705-713 (1990)), Zm13 (U.S. Pat. No. 10,421,972), PLA2-δ promoter from Arabidopsis thaliana (U.S. Pat. No. 7,141,424), and / or ZmC5 promoter from maize (International PCT Publication No. WO 1999 / 042587).
[0165] Other examples of plant tissue-specific / tissue-preferred promoters include, but are not limited to, root hair-specific cis-elements (RHE) ( Kim et al. The Plant Cell 18:2958-2970 (2006)), the root-specific promoter RCc3 (Jeong et al. Plant Physiol . 153:185-197 (2010)) and RB7 (U.S. Patent No. 5459252), lectin promoter (Lindstrom et al. (1990) Der. Genet . 11:160-167; and Vodkin (1983) Prog. Clin. Biol. Res . 138:87-98), corn alcohol dehydrogenase 1 promoter (Dennis et al. (1984) Nucleic Acids Res . 12:3983-4000), S-adenosyl-L-methionine synthetase (SAMS) ( Vander Mijnsbrugge et al. (1996) Plant and Cell Physiology , 37(8):1108-1115), maize light harvesting composite promoter (Bansal et al. (1992) Proc. Natl. Acad. Sci. USA 89:3654-3658), maize heat shock protein promoter (O'Dell et al. (1985) EMBO J . 5:451-458; and Rochester et al. (1986) EMBO J. 5:451-458), pea small subunit RuBP carboxylase promoter (Cashmore, "Nuclear genes encoding the small subunit ofribulose-1,5-bisphosphate carboxylase" pp. 29-39 In: Genetic Engineering of Plants (Hollaender ed., Plenum Press 1983; and Poulsen et al. (1986) Mol. Gen. Genet. 205:193-200), Ti plasmid mannopine synthase promoter (Langridge et al. (1989) Proc. Natl. Acad. Sci. USA 86:3219-3223), the Ti plasmid nopaline synthase promoter (Langridge et al. (1989), supra), the petunia chalcone isomerase promoter (van Tunen et al. (1988) EMBO J . 7:1257-1263), soybean glycine-rich protein 1 promoter (Keller et al. (1989) Genes Dev . 3:1639-1646), truncated CaMV 35S promoter (O'Dell et al. (1985) Nature 313:810-812), potato patatin promoter (Wenzler et al. (1989) Plant Mol. Biol . 13:347-354), root cell promoter (Yamamoto et al. (1990) Nucleic Acids Res . 18:7449), the maize zein promoter (Kriz et al. (1987) Mol. Gen. Genet. 207:90-98; Langridge et al. (1983) Cell 34:1015-1022; Reina et al. (1990) Nucleic Acids Res .18:6425; Reina et al. (1990) Nucleic Acids Res. 18:7449; and Wandelt et al. (1989) Nucleic Acids Res . 17:2354), globin-1 promoter (Belanger et al. (1991) Genetics 129:863-872), α-tubulin cab promoter (Sullivan et al. (1989) Mol. Gen. Genet . 215:431-440), PEPCase promoter (Hudspeth & Grula (1989) Plant Mol. Biol . 12:579-589), R gene complex-associated promoter (Chandler et al. (1989) Plant Cell 1:1175-1183) and the chalcone synthase promoter (Franken et al. (1991) EMBO J . 10:2605-2612).
[0166] A promoter useful for seed-specific expression is the vicilin promoter (Czako et al. (1992) Mol. Gen. Genet . 235:33-40; and seed-specific promoters disclosed in U.S. Pat. No. 5,625,136. Useful for expression in mature leaves are those that are switched at the onset of senescence, such as the SAG promoter from Arabidopsis thaliana (Gan et al. (1995) Science 270:1986-1988).
[0167] In addition, promoters that function in chloroplasts can be used. Non-limiting examples of such promoters include phage T3 gene 9 5'UTR and other promoters disclosed in U.S. Patent No. 7,579,516. Other promoters that can be used in the present invention include, but are not limited to, the S-E9 small subunit RuBP carboxylase promoter and the Kunitz trypsin inhibitor gene promoter (Kti3).
[0168] Other regulatory elements useful in the present invention include, but are not limited to, introns, enhancers, termination sequences, and / or 5' and 3' untranslated regions.
[0169] Introns useful in the present invention can be introns identified and isolated in plants, and then inserted into expression cassettes for plant transformation. As will be appreciated by those skilled in the art, introns can include sequences required for self-excision and are incorporated into nucleic acid constructs / expression cassettes in a manner consistent with the reading frame. Introns can be used as spacers to separate multiple protein coding sequences in a nucleic acid construct, or introns can be used in a protein coding sequence, for example, to stabilize mRNA. If they are used in a protein coding sequence, they will be inserted "in-frame" and include an excision site. Introns can also be associated with promoters to improve or modify expression. As an example, promoter / intron combinations useful in the present invention include, but are not limited to, combinations of corn Ubil promoters and introns (see, for example, SEQ ID NO: 21 and SEQ ID NO: 22).
[0170] Non-limiting examples of introns that can be used in the present invention include introns from the ADHI gene (e.g., Adh1-S introns 1, 2, and 6), the ubiquitin gene (Ubil), the RuBisCO small subunit (rbcS) gene, the RuBisCO large subunit (rbcL) gene, the actin gene (e.g., the actin-1 intron), the pyruvate dehydrogenase kinase gene (pdk), the nitrate reductase gene (nr), the repetitive carbonic anhydrase gene 1 (Tdca1), the psbA gene, the atpA gene, or any combination thereof.
[0171] In some embodiments, the polynucleotides and / or nucleic acid constructs of the present invention may be "expression cassettes" or may be contained within expression cassettes. As used herein, "expression cassettes" refer to recombinant nucleic acid molecules comprising, for example, one or more polynucleotides of the present invention (e.g., polynucleotides encoding sequence-specific nucleic acid binding domains, polynucleotides encoding deaminase proteins or domains, polynucleotides encoding reverse transcriptase proteins or domains, polynucleotides encoding 5'-3' exonuclease polypeptides or domains, guide nucleic acids and / or reverse transcriptase (RT) templates), wherein the polynucleotides are operably associated with one or more control sequences (e.g., promoters, terminators, etc.). Thus, in some embodiments, one or more expression cassettes may be provided, which are designed to express, for example, a nucleic acid construct of the invention (e.g., a polynucleotide encoding a sequence-specific nucleic acid binding domain, a polynucleotide encoding a nuclease polypeptide / domain, a polynucleotide encoding a deaminase protein / domain, a polynucleotide encoding a reverse transcriptase protein / domain, a polynucleotide encoding a 5'-3' exonuclease polypeptide / domain, a polynucleotide encoding a peptide tag, and / or a polynucleotide encoding an affinity polypeptide, etc., or comprising a guide nucleic acid, an extended guide nucleic acid, and / or an RT template, etc.). When the expression cassette of the invention comprises more than one polynucleotide, the polynucleotide may be operably linked to a single promoter that drives expression of all polynucleotides, or the polynucleotide may be operably linked to one or more separate promoters (e.g., three polynucleotides may be driven by one, two, or three promoters in any combination). When two or more separate promoters are used, the promoters may be the same promoter or they may be different promoters. Thus, polynucleotides encoding sequence-specific nucleic acid binding domains, polynucleotides encoding nuclease proteins / domains, polynucleotides encoding CRISPR-Cas effector proteins / domains, polynucleotides encoding deaminase proteins / domains, polynucleotides encoding reverse transcriptase polypeptides / domains (e.g., RNA-dependent DNA polymerases), and / or polynucleotides encoding 5'-3' exonuclease polypeptides / domains, guide nucleic acids, extended guide nucleic acids, and / or RT templates can each be operably linked to a single promoter, or separate promoters in any combination when contained in a single expression cassette.
[0172] The expression cassette comprising the nucleic acid construct of the invention may be chimeric, meaning that at least one (e.g., one or more) of its components is heterologous relative to at least one of its other components (e.g., a promoter from a host organism is operably linked to a polynucleotide of interest expressed in the host organism, wherein the polynucleotide of interest is from an organism different from the host or is not normally associated with the promoter). The expression cassette may also be one that occurs naturally but has been obtained in a recombinant form that can be used for heterologous expression.
[0173] The expression cassette may optionally be included in a transcription and / or translation termination region (i.e., termination region) and / or an enhancer region that works in the selected host cell. Various transcription terminators and enhancers are known in the art and can be used for expression cassettes. The transcription terminator is responsible for the termination of transcription and correct mRNA polyadenylation. Termination region and / or enhancer region may be natural for the transcription initiation region, may be natural for a gene encoding a sequence-specific nucleic acid binding protein, a gene encoding a nuclease, a gene encoding a reverse transcriptase, a gene encoding a deaminase, etc., or may be natural for a host cell, or may be natural for another source (e.g., for a promoter, for a gene encoding a sequence-specific nucleic acid binding protein, a gene encoding a nuclease, a gene encoding a reverse transcriptase, a gene encoding a deaminase, etc., or may be foreign or heterologous for a host cell or any combination thereof).
[0174] The expression cassette of the present invention may also include a polynucleotide encoding a selectable marker, which can be used to select a transformed host cell. As used herein, a "selectable marker" refers to a polynucleotide sequence that, when expressed, gives a different phenotype to the host cell expressing the marker, thereby allowing such transformed cells to be distinguished from cells that do not have the marker. Such a polynucleotide sequence can encode a selectable or screenable marker, depending on whether the marker gives a trait that can be selected by chemical means (e.g., by using a selection agent (e.g., antibiotics, etc.), or whether the marker is just a trait that can be identified by observation or testing, such as by screening (e.g., fluorescence). Many examples of suitable selectable markers are known in the art and can be used in expression cassettes as described herein.
[0175] In addition to the expression cassette, nucleic acid molecules / constructs and polynucleotide sequences described herein can be used in combination with vectors. The term "vector" refers to a composition for transferring, delivering or introducing nucleic acids (or multiple nucleic acids) into cells. The vector comprises a nucleic acid construct (e.g., an expression cassette) containing a nucleotide sequence to be transferred, delivered or introduced. The vector used for host biological transformation is well known in the art. Non-limiting examples of general types of vectors include viral vectors, plasmid vectors, phage vectors, phagemid vectors, cosmid vectors, fosmid vectors, phages, artificial chromosomes, minicircles or Agrobacterium binary vectors in double-stranded or single-stranded linear or circular forms, which may or may not be self-propagating or moving. In some embodiments, viral vectors may include, but are not limited to, retroviruses, slow viruses, adenoviruses, adeno-associated viruses or herpes simplex virus vectors. The vector defined herein can be transformed into a prokaryotic or eukaryotic host by being integrated into the cell genome or being present outside the chromosome (e.g., an autonomously replicating plasmid with a replication origin). In addition, shuttle vectors are included, which means a DNA vector that can be replicated (naturally or by design) in two different host organisms (which can be selected from actinomycetes and related species, bacteria and eukaryotic organisms (e.g., higher plants, mammals, yeast or fungal cells). In some embodiments, the nucleic acid in the vector is under the control of a suitable promoter or other regulatory elements and is operably connected thereto for transcription in a host cell. The vector can be a bifunctional expression vector that works in multiple hosts. In the case of genomic DNA, this can contain its own promoter and / or other regulatory elements, and in the case of cDNA, this can be under the control of a suitable promoter and / or other regulatory elements for expression in a host cell. Therefore, the nucleic acid or polynucleotide of the present invention and / or an expression cassette comprising it can be contained in a vector as described herein and known in the art.
[0176] As used herein, "contacting," "contacted," "contacted," and grammatical variations thereof refer to placing the components of a desired reaction under conditions suitable for carrying out the desired reaction (e.g., transformation, transcriptional control, genome editing, nicking, and / or cleavage). For example, a target nucleic acid can be contacted with a sequence-specific nucleic acid binding protein (e.g., a polynucleotide-guided endonuclease, a CRISPR-Cas endonuclease (e.g., a CRISPR-Cas effector protein), a zinc finger nuclease, a transcription activator-like effector nuclease (TALEN), and / or an Argonaute protein)) and a deaminase or a nucleic acid construct encoding the same under conditions where the sequence-specific nucleic acid binding protein, the reverse transcriptase, and the deaminase are expressed and the sequence-specific nucleic acid binding protein binds to the target nucleic acid, and the reverse transcriptase and / or deaminase can be fused to or recruited to the sequence-specific nucleic acid binding protein (e.g., by a peptide tag fused to the sequence-specific nucleic acid binding protein and an affinity tag fused to the reverse transcriptase and / or deaminase), so that the deaminase and / or reverse transcriptase are located near the target nucleic acid, thereby modifying the target nucleic acid. Other methods of recruiting reverse transcriptase and / or deaminase using other protein-protein interactions may be used, RNA-protein interactions and chemical interactions may also be used for protein-protein and protein-nucleic acid recruitment.
[0177] As used herein, "modified" or "modification" of a target nucleic acid includes editing (e.g., mutation), covalent modification, exchange / replacement of nucleic acid / nucleotide bases, deletion, cutting, nicking, and / or altering the transcriptional control of a target nucleic acid. In some embodiments, the modification may include any type of one or more single base changes (SNPs).
[0178] In the context of a polynucleotide of interest, "introduced," "introduced," "introduced" (and grammatical variations thereof) refers to presenting a nucleotide sequence of interest (e.g., a polynucleotide, RT template, nucleic acid construct, and / or guide nucleic acid) to a plant, a plant part thereof, or a cell thereof in a manner that enables the nucleotide sequence to gain access to the interior of the cell.
[0179] The terms "transformation" or "transfection" are used interchangeably and, as used herein, refer to the introduction of heterologous nucleic acids into cells. The transformation of cells can be stable or transient. Thus, in some embodiments, host cells or host organisms (e.g., plants) can be stably transformed with the polynucleotides / nucleic acid molecules of the present invention. In some embodiments, host cells or host organisms can be transiently transformed with the polynucleotides / nucleic acid molecules of the present invention.
[0180] "Transient transformation" in the context of a polynucleotide means that the polynucleotide is introduced into a cell and does not integrate into the genome of the cell.
[0181] "Stably introduced" or "stably introduced" in the context of introducing a polynucleotide into a cell means that the introduced polynucleotide is stably incorporated into the genome of the cell and thus the cell is stably transformed with the polynucleotide.
[0182] As used herein, "stable transformation" or "stably transformed" refers to the introduction of a nucleic acid molecule into a cell and its integration into the genome of the cell. Thus, the integrated nucleic acid molecule is capable of being inherited by its progeny, more specifically, by multiple successive generations of progeny. As used herein, "genome" includes nuclear and plastid genomes, and thus includes integration of nucleic acids into, for example, chloroplast or mitochondrial genomes. As used herein, stable transformation can also refer to a transgene that is maintained extrachromosomally, for example, as a minichromosome or plasmid.
[0183] Transient transformation can be detected by, for example, enzyme-linked immunosorbent assay (ELISA) or Western blot, which can detect the presence of peptides or polypeptides encoded by one or more transgenics introduced into an organism. Stable transformation of cells can be detected by, for example, Southern blot hybridization assays of the genomic DNA of the cell with nucleic acid sequences that specifically hybridize with the nucleotide sequences of the transgenics introduced into an organism (e.g., a plant). Stable transformation of cells can be detected by, for example, Northern blot hybridization assays of the RNA of the cell with nucleic acid sequences that specifically hybridize with the nucleotide sequences of the transgenics introduced into the host organism. Stable transformation of cells can also be detected by, for example, polymerase chain reaction (PCR) or other amplification reactions well known in the art, using specific primer sequences that hybridize with the target sequences of the transgenics, resulting in amplification of the transgenic sequences, which can be detected according to standard methods. Conversion can also be detected by direct sequencing and / or hybridization protocols well known in the art.
[0184] Thus, in some embodiments, the nucleotide sequences, polynucleotides, nucleic acid constructs and / or expression cassettes of the invention can be transiently expressed and / or they can be stably incorporated into the genome of the host organism. Thus, in some embodiments, the nucleic acid constructs of the invention (e.g., one or more expression cassettes comprising polynucleotides for editing as described herein) can be transiently introduced into a cell along with a guide nucleic acid, and thus, no DNA remains in the cell.
[0185] The nucleic acid construct of the present invention can be introduced into plant cells by any method known to those skilled in the art. Non-limiting examples of transformation methods include nucleic acid delivery mediated by bacteria (e.g., by Agrobacterium), viral-mediated nucleic acid delivery, silicon carbide or nucleic acid whisker-mediated nucleic acid delivery, liposome-mediated nucleic acid delivery, microinjection, microparticle bombardment, calcium phosphate-mediated transformation, cyclodextrin-mediated transformation, electroporation, nanoparticle-mediated transformation, ultrasonic treatment, osmosis, PEG-mediated nucleic acid uptake, and any other electrical, chemical, physical (mechanical) and / or biological mechanism that leads to the introduction of nucleic acid into plant cells, including any combination thereof. Procedures for transforming eukaryotic and prokaryotic organisms are well known in the art and are routine and are described throughout the literature (see, e.g., Jiang et al. 2013. Nat. Biotechnol. 31:233-239; Ran et al. Nature Protocols 8:2281–2308 (2013)). General guidance on various plant transformation methods known in the art includes Miki et al. ("Procedures for Introducing Foreign DNA into Plants" inMethods in Plant Molecular Biology and Biotechnology, Glick, BR and Thompson, JE, Eds. (CRC Press, Inc., BocaRaton, 1993), pages 67-88) and Rakowoczy-Trojanowska ( Cell. Mol. Biol. Lett . 7:849-858 (2002)).
[0186] In some embodiments of the present invention, the transformation of cells can include nuclear transformation. In other embodiments, the transformation of cells can include plastid transformation (for example, chloroplast transformation). In further embodiments, nucleic acid of the present invention can be introduced into cells by conventional breeding techniques. In some embodiments, one or more polynucleotides, expression cassettes and / or vectors can be introduced into plant cells by Agrobacterium transformation.
[0187] Therefore, polynucleotides can be introduced into plants, plant parts, plant cells in any manner well known in the art. The method of the present invention does not rely on a particular method for introducing one or more nucleotide sequences into plants, as long as they can enter the interior of the cell. In the case of introducing more than one polynucleotide, they can be assembled as a part of a single nucleic acid construct, or as a separate nucleic acid construct, and can be located on the same or different nucleic acid constructs. Therefore, polynucleotides can be introduced into interested cells in a single transformation event or in a separate transformation event, or, as part of a breeding scheme, polynucleotides can be incorporated into plants.
[0188] Phytohormones regulate plant growth and development as well as responses to changes in the growth environment (e.g., to drought or other abiotic stresses). Phytohormone signaling can be regulated by synthesizing or breaking down phytohormones at the metabolic level or by controlling phytohormone signaling. Brassinosteroids are a class of polyhydroxylated steroidal phytohormones that are growth-promoting plant hormones. Brassinolide was the first brassinosteroid to be isolated, and since then, more than 70 other brassinosteroid compounds have been isolated from plants. Brassinosteroid phytohormones have been implicated in plant yield and abiotic stress responses (Divi and Krishna 2009 New Biotechnology 26(3-4), 131-136; Gruszka2020 Intl. J. Molecular Sci. 21(1), 354. Brassinosteroid signaling in plants is tightly controlled by multiple layers of transcriptional and post-transcriptional regulation (Li and Jin 2007 Trends Plant Sci. 12(1): 37-41; Gendron and Wang 2007 Curr. Opin.Plant Biol . 10(5), 436-441).
[0189] The present invention relates to modifying a brassinosteroid gene, brassinosteroid insensitive-1 (BRI1), in a plant by editing techniques to provide a plant exhibiting one or more improved yield traits. Mutations that can be used to produce plants having one or more improved yield traits include, for example, substitutions, deletions, and / or insertions. In some aspects, the mutations produced by editing techniques can be point mutations. In some embodiments, the BRI1 polypeptide is included in a cis-regulatory region (e.g., a promoter region comprising one or more upstream open reading frames (uORFs)) in which a mutation is produced, optionally wherein the mutation increases the expression of the BRI1 gene. As described herein, mutations in at least one upstream open reading frame (uORF) within the promoter region or cis-regulatory region of the BRI1 gene result in increased expression of the BRI1 gene by disrupting the inhibition of expression of the BRI1 gene associated with the uORF. Without being limited by any particular theory, an increase in BRI1 gene expression may result in enhanced binding of the BR hormone, thereby resulting in an effective intracellular phosphorylation transmission cascade. This in turn promotes the activity and stability of the plant-specific transcription factors BZR1 (BRASSINAZOLERESISTANT1) and BES1 (BRI1-EMS-SUPPRESSOR1), which directly control the transcription of BR-responsive genes involved in reproductive meristem developmental events in plants.
[0190] In some embodiments, the present invention provides a plant or plant part thereof comprising at least one mutation in an endogenous brassinosteroid insensitive-1 (BRI1) gene encoding a BRI1 polypeptide (brassinosteroid receptor polypeptide), optionally wherein at least one non-natural mutation disrupts one or more upstream open reading frames (uORFs) of the endogenous BRI1 gene (in a cis-regulatory element, such as in a promoter region), optionally wherein at least one mutation is a non-natural mutation.
[0191] In some embodiments, the present invention provides a plant cell comprising at least one mutation within an endogenous brassinosteroid insensitive-1 (BRI1) gene, wherein the mutation is a substitution, insertion, deletion or inversion introduced using an editing system comprising a nucleic acid binding domain that binds to a target site in the endogenous BRI1 gene, optionally wherein the at least one mutation is a non-natural mutation.
[0192] In some embodiments, a plant cell is provided, comprising an editing system, the editing system comprising: (a) a CRISPR-Cas effector protein; and (b) a guide nucleic acid (e.g., gRNA, gDNA, crRNA, crDNA, sgRNA, sgDNA) comprising a spacer sequence complementary to an endogenous target gene encoding a BRI1 protein. The editing system can be used to generate a mutation in an endogenous target gene encoding a BRI1 polypeptide. In some embodiments, the mutation is a non-natural mutation. In some embodiments, the guide nucleic acid of the editing system may comprise a nucleotide sequence (spacer sequence, e.g., one or more spacers) of any one of SEQ ID NO: 96, SEQ ID NO: 97, SEQ ID NO: 98, SEQ ID NO: 99 and / or SEQ ID NO: 100 or any combination thereof.
[0193] The mutation in the BRI1 gene of the plant, plant part thereof or plant cell used in the present invention may be any type of mutation, including base substitution, base deletion and / or base insertion. In some embodiments, the mutation may include base substitution to A, T, G or C. In some embodiments, the mutation can be at least one base pair (e.g., 1 base pair to about 270 base pairs; e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 2, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69 ,70,71,72,73,74,75,76,77,78,79,80,81,82,83,84,85,86,87,88,89,90,91,92,93,94,95,96,97,98,99,100,101,102,103,104,105,106,107,108, In some embodiments, at least one mutation may be a non-natural mutation.
[0194] An endogenous BRI1 gene (e.g., an endogenous target gene) that can be used in the present invention can be any BRI1 gene that encodes a brassinosteroid insensitive-1 (BRI1) polypeptide. In some embodiments, the endogenous BRI1 gene (e.g., an endogenous target gene) can (a) (i) comprise a nucleic acid sequence having at least 80% (e.g., 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100%) sequence identity to any one of SEQ ID NOs: 69, 70, 80, or 81, or (ii) a region having at least 80% sequence identity to any one of SEQ ID NOs: 73-79 or 83-95, and / or (b) encodes a BRI1 polypeptide having at least 80% sequence identity to any one of SEQ ID NOs: 71, 72, or 82.
[0195] Types of editing tools that can be used to generate these and other mutations in the BRI1 gene include any base editor or cutter that is guided to a target site using a spacer that has at least 80% complementarity to a portion of the BRI1 gene described herein.
[0196] In some embodiments, the mutation of the BRI1 gene may be located at the 5' end of the endogenous BRI1 gene encoding the BRI1 polypeptide, optionally wherein the mutation may be 5' of the ATG translation start site of the BRI1 gene. In some embodiments, the mutation at the 5' end of the BRI1 gene may be located in the gene region that is transcribed into mRNA, but may be 5' of the ATG translation start site of the BRI1 polypeptide. As an example, the mutation may be in the cis-regulatory region (e.g., promoter region) of the BRI1 gene, optionally in one or more uORFs located in the cis-regulatory region / promoter region of the BRI1 gene, wherein the mutation destroys one or more uORFs, resulting in a modified BRI1 transcript (mRNA) (e.g., the mRNA comprises one or more destroyed uORFs). In some embodiments, the destruction of the uORFs of the BRI1 gene described herein results in an increased yield of the encoded BRI1 polypeptide. In some embodiments, the disruption of one or more uORFs of the BRI1 gene can be a modification in an ATG located in the uORF (e.g., an insertion, substitution, or deletion of at least one base pair (e.g., 1, 2, or 3 base pairs) of the ATG of the uORF). In some embodiments, one or more uORFs of the BRI1 gene may be disrupted by deletion, insertion, or substitution (optionally a deletion of about 2 to about 270 base pairs). In some embodiments, mutation or editing of the endogenous BRI1 gene can result in a hypomorphic mutation, a dominant mutation, and / or a semi-dominant mutation.
[0197] In some embodiments, the mutation of the BRI1 gene may be located within a portion or region of the endogenous BRI1 gene, which is located at (a) approximately nucleotides 2-213, 42-174, 62-154, 82-134 and / or 92-124 with reference to the nucleotide position numbering of SEQ ID NO: 69 (e.g., SEQ ID NOs: 73-79), and / or (b) approximately nucleotides 1-267, 40-227, 70-195 and / or 100-168 with reference to the nucleotide position numbering of SEQ ID NO: 80 (e.g., SEQ ID NOs: 83-95).
[0198] In some embodiments, the mutated BRI1 gene may have at least 90% identity to any one of SEQ ID NOs: 101-117. In some embodiments, a plant or part thereof may comprise a mutated BRI1 gene having at least 90% sequence identity to any one of SEQ ID NOs: 101-117, optionally wherein the mutated BRI1 gene may be a hypomorphic mutation, a dominant mutation, and / or a semi-dominant mutation.
[0199] In some embodiments, a plant (e.g., a soybean plant) comprising at least one (e.g., one or more) mutations in an endogenous BRI1 exhibits one or more improved yield traits compared to a plant lacking the at least one mutation (e.g., an isogenic plant (e.g., a wild-type, unedited plant or a null isolate). In some embodiments, the one or more improved yield traits may include, but are not limited to, higher yield (bushels per acre), increased biomass, increased plant height, increased stem diameter, increased leaf area, increased number of flowers, increased number of pods per node, increased number of pods per plant, increased number of seeds, increased number of seeds per pod, increased seed size, and / or increased seed weight (e.g., an increase in 100 seed weight) compared to a control plant lacking the at least one mutation. In some embodiments, a plant as described herein can be regenerated from a plant part and / or plant cell of the invention comprising a mutation in a BRI1 gene, wherein the regenerated plant comprises a mutation in an endogenous BRI1 gene and an improved phenotype in one or more yield traits compared to a plant lacking the same mutation in the BRI1 gene.
[0200] In some embodiments, a plant cell is provided, the plant cell comprising at least one (e.g., one or more) mutation within an endogenous brassinosteroid insensitive-1 (BRI1) gene, wherein the mutation is a substitution, insertion, or deletion introduced using an editing system comprising a nucleic acid binding domain that binds to a target site in the endogenous BRI1 gene. In some embodiments, the substitution, insertion, or deletion results in, for example, a mutation in a cis-regulatory region that affects BRI1 gene expression, optionally wherein the mutation is located in one or more uORFs in the promoter region of the BRI1 gene. In some embodiments, at least one mutation may be a non-natural mutation. In some embodiments, at least one mutation is a point mutation. In some embodiments, at least one mutation within the BRI1 gene is an insertion and / or deletion. In some embodiments, at least one mutation may be a hypomorphic mutation, a dominant mutation, and / or a semi-dominant mutation. In some embodiments, at least one mutation results in a mutated BRI1 gene having at least 90% sequence identity to any one of SEQ ID NOs: 101-117.
[0201] In some embodiments, the target site in the BRI1 gene of a plant cell is located within the following region of the BRI1 gene, which is located: (a) about nucleotides 2-213, 42-174, 62-154, 82-134 and / or 92-124, as numbered with reference to the nucleotide position of SEQ ID NO: 69 (e.g., SEQ ID NOs: 73-79), and / or (b) about nucleotides 1-267, 40-227, 70-195 and / or 100-168, as numbered with reference to the nucleotide position of SEQ ID NO: 80 (e.g., SEQ ID NOs: 83-95).
[0202] In some embodiments, the mutation may be performed after cleavage by an editing system comprising a nuclease and a nucleic acid binding domain, the nucleic acid binding domain binding to a target site within a sequence having at least 80% sequence identity to a sequence encoding any one of SEQ ID NOs: 69, 70, 80, or 81, or having at least 80% sequence identity to a sequence encoding any one of SEQ ID NOs: 73-79 or 83-95, and the mutation within the BRI1 gene is performed after cleavage by a nuclease. In some embodiments, at least one mutation may result in a modified ATG site (the site is no longer an ATG) in the uORF of the BRI1 gene. In some embodiments, at least one mutation may be a deletion of a portion of the BRI1 gene or the entire uORF. In some embodiments, at least one mutation may be a non-natural mutation. In some embodiments, at least one mutation may result in a hypomorphic mutation, a dominant mutation, and / or a semi-dominant mutation in an endogenous BRI1 gene. In some embodiments, at least one mutation results in a mutated BRI1 gene having at least 90% sequence identity to any one of SEQ ID NOs: 101-117.
[0203] In some embodiments, the plant cell can be regenerated into a plant comprising at least one mutation (e.g., a non-natural mutation), optionally wherein the plant regenerated from the plant cell exhibits a phenotype of at least one (one or more) improved yield trait compared to a wild-type plant not comprising / lacking the allele (e.g., an isogenic wild-type plant), optionally wherein the one or more improved yield traits include, but are not limited to, higher yield (bushels per acre), increased biomass, increased plant height, increased stem diameter, increased leaf area, increased number of flowers, increased number of pods per node, increased number of pods per plant, increased number of seeds, increased number of seeds per pod, increased seed size, and / or increased seed weight (e.g., an increase in 100 seed weight) compared to a control plant lacking the at least one mutation. In some embodiments, the regenerated plant comprises a mutated BRI1 gene having at least 90% sequence identity to any one of SEQ ID NOs: 101-117.
[0204] In some embodiments, a method for producing / cultivating a transgenic-free edited plant (e.g., a soybean plant) is provided, the method comprising: crossing a plant of the present invention (e.g., a plant comprising one or more mutations (e.g., non-natural mutations) in one or more BRI1 genes and having one or more improved yield traits) with a transgenic-free plant, thereby introducing the mutation into the transgenic-free plant; and selecting offspring plants comprising the mutation and being free of transgenes, thereby producing a transgenic-free edited plant.
[0205] Also provided herein is a method for providing a plurality of plants (e.g., soybean plants) having one or more improved yield traits, the method comprising planting two or more plants of the present invention (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 50, 100, 1000 or more plants comprising one or more mutations (e.g., non-natural mutations) in one or more BRI1 genes and having one or more improved yield traits) in a growing area (e.g., a field (e.g., cultivated land, agricultural field), a growth chamber, a greenhouse, a recreational area, a lawn and / or a roadside, etc.), thereby providing a plurality of plants having one or more improved yield traits compared to a plurality of control plants lacking the mutations.
[0206] The present invention also provides a method for generating a variation in a region of a brassinosteroid insensitive-1 (BRI1) transcript, comprising: introducing an editing system into a plant cell, wherein the editing system targets a region of a brassinosteroid insensitive-1 (BRI1) gene encoding a region of a BRI1 polypeptide, and contacting the region of the BRI1 gene with the editing system, thereby introducing a mutation into the BRI1 gene and generating a variation in the BRI1 transcript of the plant cell. In some embodiments, the BRI1 gene comprises a nucleotide sequence having at least 80% sequence identity to any one of SEQ ID NOs: 69, 70, 80, or 81 and / or encodes an amino acid sequence having at least 80% sequence identity to any one of SEQ ID NOs: 71, 72, or 82, and the mutation is performed after cleavage by the editing system, wherein the editing system comprises a nuclease and a nucleic acid binding domain, wherein the nucleic acid binding domain binds to a target site within a sequence having at least 80% sequence identity to any one of the nucleotide sequences of SEQ ID NOs: 69, 70, 80, or 81.
[0207] In some embodiments, the region of the BRI1 gene targeted for generating a variation in the BRI1 transcript (mRNA) has at least 80% sequence identity to any one of the nucleotide sequences of SEQ ID NOs: 73-79 or 83-95, and / or is located (a) at about nucleotides 2-213, 42-174, 62-154, 82-134, and / or 92-124, numbered with reference to nucleotide positions of SEQ ID NO: 69 (e.g., SEQ ID NOs: 73-79), and / or (b) at about nucleotides 1-267, 40-227, 70-195, and / or 100-168, numbered with reference to nucleotide positions of SEQ ID NO: 80 (e.g., SEQ ID NOs: 83-95). In some embodiments, a region of an endogenous BRI1 gene in a plant cell is contacted with an editing system to produce a plant cell comprising an edited BRI1 gene in its genome, the method further comprising (a) regenerating a plant from the plant cell; (b) selfing the plant to produce a progeny plant (E1); (c) determining one or more improved yield traits of the progeny plant of (b); and (d) selecting a progeny plant that exhibits a phenotype of one or more improved yield traits compared to a control plant. In some embodiments, the method may further comprise (e) selfing the selected progeny plant of (d) to produce a progeny plant (E2); (f) determining one or more improved yield traits of the progeny plant of (e); and (g) selecting a progeny plant that exhibits a phenotype of one or more improved yield traits compared to a control plant, optionally repeating (e) to (g) one or more additional times.
[0208] In some embodiments, a method for editing a specific site in the genome of a plant cell is provided, the method comprising: cleaving a target site within an endogenous brassinosteroid insensitive-1 (BRI1) gene in a plant cell in a site-specific manner, wherein the endogenous BRI1 gene: (a) comprises a sequence having at least 80% sequence identity to any one of the nucleotide sequences of SEQ ID NOs: 69, 70, 80, or 81, (b) comprises a region having at least 80% sequence identity to any one of the nucleotide sequences of SEQ ID NOs: 73-79 or 83-95, and / or (c) encodes an amino acid sequence having at least 80% sequence identity to any one of SEQ ID NOs: 71, 72, or 82, thereby generating an edit in the endogenous BRI1 gene of the plant cell and generating a plant cell comprising the edit in the endogenous BRI1 gene.
[0209] In some embodiments, editing results in mutations, including but not limited to deletions, substitutions, or insertions. In some embodiments, editing results in non-natural mutations. In some embodiments, editing in the endogenous BRI1 gene can result in hypomorphic mutations, dominant mutations, and / or semi-dominant mutations. In some embodiments, editing can be a nucleotide substitution to A, T, G, or C. In some embodiments, editing results in variations in the BRI1 transcript produced by the BRI1 gene, optionally in variations in one or more uORFs of the BRI1 transcript. As an example, the editing can result in a variation in a sequence of a BRI1 gene that is at least 80% identical to any of SEQ ID NOs: 73-79 or 83-95, and / or is located (a) at about nucleotides 2-213, 42-174, 62-154, 82-134, and / or 92-124 numbered with reference to nucleotide positions of SEQ ID NO: 69 (e.g., SEQ ID NOs: 73-79), and / or (b) at about nucleotides 1-267, 40-227, 70-195, and / or 100-168 numbered with reference to nucleotide positions of SEQ ID NO: 80 (e.g., SEQ ID NOs: 83-95), resulting in a BRI1 transcript having one or more modified (optionally deleted) uORF regions. In some embodiments, the editing is located in the ATG site of the BRI1 gene and is located in a BRI1 transcript transcribed from the BRI1 gene. In some embodiments, the editing produces a modified BRI1 gene having at least 90% sequence identity to any one of SEQ ID NOs: 101-117.
[0210] In some embodiments, the editing method can also include regenerating a plant from a plant cell comprising an edit in an endogenous BRI1 gene, thereby producing a plant comprising an edit in its endogenous BRI1 gene and having a phenotype of one or more improved yield traits compared to a control plant lacking the edit, optionally wherein the regenerated plant comprises a mutated BRI1 gene having at least 90% sequence identity to any one of SEQ ID NOs: 101-117.
[0211] In some embodiments, a method of making a plant is provided, the method comprising (a) contacting a population of plant cells comprising an endogenous brassinosteroid insensitive-1 (BRI1) gene with a nuclease linked to a nucleic acid binding domain (e.g., an editing system) that binds a sequence that: (i) has at least 80% (e.g., 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100%) sequence identity to the nucleotide sequence of any one of SEQ ID NOs: 69, 70, 80, or 81, (ii) encodes an amino acid sequence having at least 80% sequence identity to any one of SEQ ID NOs: 71, 72, or 82, and / or (iii) comprises a sequence identical to any one of SEQ ID NOs: NO: 73-79 or 83-95 has a region of at least 80% identity; (b) selecting plant cells in which the endogenous BRI1 gene has been mutated from the population, thereby producing plant cells comprising a mutation in the endogenous BRI1 gene; and (c) growing the selected plant cells into plants.
[0212] In some embodiments, a method for improving one or more yield traits in a plant is provided, the method comprising (a) contacting a plant cell comprising an endogenous brassinosteroid insensitive-1 (BRI1) gene with a nuclease targeted to the endogenous BRI1 gene, wherein the nuclease is linked to a nucleic acid binding domain (e.g., an editing system) that binds to a target site in the endogenous BRI1 gene, wherein the endogenous BRI1 gene: (i) comprises a sequence having at least 80% sequence identity to a nucleotide sequence of any one of SEQ ID NOs: 69, 70, 80, or 81; (ii) comprises a region having at least 80% identity to a nucleotide sequence of any one of SEQ ID NOs: 73-79 or 83-95; and / or (iii) encodes a region having at least 80% identity to a nucleotide sequence of any one of SEQ ID NOs: 73-79 or 83-95; Any one of NO: 71, 72 or 82 has an amino acid sequence with at least 80% sequence identity to produce a plant cell comprising a mutation in an endogenous BRI1 gene; and (b) growing the plant cell into a plant comprising a mutation in the endogenous BRI1 gene, thereby producing a plant with a mutated endogenous BRI1 gene and one or more improved yield traits.
[0213] In some embodiments, a method for producing a plant or part thereof comprising a cell having at least one endogenous BRI1 gene having a mutation is provided, the method comprising contacting a target site in an endogenous BRI1 gene in a plant or plant part with a nuclease comprising a cleavage domain and a nucleic acid binding domain, wherein the nucleic acid binding domain binds to the target site in the endogenous BRI1 gene, wherein the endogenous BRI1 gene (a) comprises a sequence having at least 80% sequence identity to the nucleotide sequence of any one of SEQ ID NOs: 69, 70, 80, or 81; (b) comprises a region having at least 80% sequence identity to the nucleotide sequence of any one of SEQ ID NOs: 73-79 or 83-95; and / or (c) encodes an amino acid sequence having at least 80% sequence identity to any one of SEQ ID NOs: 71, 72, or 82, thereby producing a plant or part thereof comprising at least one cell having a mutation in an endogenous BRI1 gene.
[0214] Also provided herein is a method for producing a plant or part thereof comprising a mutated endogenous brassinosteroid insensitive-1 (BRI1) gene and exhibiting one or more improved yield traits, the method comprising contacting a target site in an endogenous BRI1 gene in a plant or plant part with a nuclease comprising a cleavage domain and a nucleic acid binding domain, wherein the nucleic acid binding domain binds to the target site in the endogenous BRI1 gene, wherein the endogenous BRI1 gene: (a) comprises a sequence having at least 80% sequence identity to a nucleotide sequence of any one of SEQ ID NOs: 69, 70, 80, or 81; (b) comprises a region having at least 80% sequence identity to a nucleotide sequence of any one of SEQ ID NOs: 73-79 or 83-95; and / or (c) encodes a nucleotide sequence having at least 80% sequence identity to a nucleotide sequence of any one of SEQ ID NOs: NO: 71, 72 or 82 has an amino acid sequence with at least 80% sequence identity, thereby producing a plant or part thereof comprising an endogenous BRI1 gene with a mutation and exhibiting one or more improved yield traits, optionally wherein the one or more improved yield traits include but are not limited to higher yield (bushels / acre), increased biomass, increased plant height, increased stem diameter, increased leaf area, increased number of flowers, increased number of pods per node, increased number of pods per plant, increased number of seeds, increased number of seeds per pod, increased seed size and / or increased seed weight (e.g., an increase in 100 seed weights) compared to a control plant lacking the at least one mutation.
[0215] In some embodiments, the nuclease can cut the endogenous BRI1 gene, thereby introducing mutations into the endogenous BRI1 gene. The nuclease that can be used in the present invention can be any nuclease that can be used to edit / modify the target nucleic acid. Such nucleases include, but are not limited to, zinc finger nucleases, transcription activator-like effector nucleases (TALENs), endonucleases (e.g., Fok1), and / or CRISPR-Cas effector proteins. Similarly, any nucleic acid binding domain that can be used in the present invention can be any DNA binding domain or RNA binding domain that can be used to edit / modify the target nucleic acid. Such nucleic acid binding domains include, but are not limited to, zinc fingers, transcription activator-like DNA binding domains (TALs), argonautes, and / or CRISPR-Cas effector DNA binding domains.
[0216] In some embodiments, the nucleic acid binding domain (e.g., DNA binding domain) is included in the nucleic acid binding polypeptide. As used herein, "nucleic acid binding protein" or "nucleic acid binding polypeptide" refers to a polypeptide that binds and / or can bind to nucleic acids in a site- and / or sequence-specific manner. In some embodiments, the nucleic acid binding polypeptide can be a sequence-specific nucleic acid binding polypeptide (e.g., sequence-specific DNA binding domain), such as but not limited to sequence-specific binding polypeptides and / or domains from, for example, polynucleotide-guided endonucleases, CRISPR-Cas effector proteins (e.g., CRISPR-Cas endonucleases), zinc finger nucleases, transcription activator-like effector nucleases (TALENs) and / or Argonaute proteins. In some embodiments, the nucleic acid binding polypeptide comprises a cleavage polypeptide (e.g., a nuclease polypeptide and / or domain), such as but not limited to endonucleases (e.g., Fok1), polynucleotide-guided endonucleases, CRISPR-Cas endonucleases, zinc finger nucleases and / or transcription activator-like effector nucleases (TALENs). In some embodiments, the nucleic acid binding polypeptide is associated with and / or is capable of associating (e.g., forming a complex) with one or more nucleic acid molecules (e.g., forming a complex with a guide nucleic acid described herein), and the one or more nucleic acid molecules can guide or direct the nucleic acid binding polypeptide to a specific target nucleotide sequence (e.g., a genomic locus) that is complementary to one or more nucleic acid molecules (or a portion or region thereof), thereby causing the nucleic acid binding polypeptide to bind to the nucleotide sequence at the specific target site. In some embodiments, the nucleic acid binding polypeptide is a CRISPR-Cas effector protein described herein. In some embodiments, for simplicity, CRISPR-Cas effector proteins are specifically referred to, but nucleic acid binding polypeptides described herein may also be used. In some embodiments, the polynucleotides and / or nucleic acid constructs of the present invention may be "expression cassettes" or may be contained in expression cassettes.
[0217] In some embodiments, a method for editing an endogenous BRI1 gene in a plant or a plant part is provided, the method comprising contacting a target site in an endogenous BRI1 gene in a plant or a plant part with a cytosine base editing system comprising a cytosine deaminase and a nucleic acid binding domain that binds to the target site in the endogenous BRI1 gene, wherein the endogenous BRI1 gene: (a) comprises a sequence having at least 80% sequence identity to the nucleotide sequence of any one of SEQ ID NOs: 69, 70, 80, or 81; (b) comprises a region having at least 80% sequence identity to the nucleotide sequence of any one of SEQ ID NOs: 73-79 or 83-95; and / or (c) encodes an amino acid sequence having at least 80% sequence identity to any one of SEQ ID NOs: 71, 72, or 82, thereby editing the endogenous BRI1 gene in the plant or a part thereof and producing a plant or a part thereof comprising at least one cell having a mutation in the endogenous BRI1 gene.
[0218] In some embodiments, a method for editing an endogenous BRI1 gene in a plant or a plant part is provided, the method comprising contacting a target site in a BRI1 gene in a plant or a plant part with an adenosine base editing system comprising an adenosine deaminase and a nucleic acid binding domain that binds to the target site in the BRI1 gene, wherein the BRI1 gene (a) comprises a sequence having at least 80% sequence identity to the nucleotide sequence of any one of SEQ ID NOs: 69, 70, 80, or 81; (b) comprises a region having at least 80% sequence identity to the nucleotide sequence of any one of SEQ ID NOs: 73-79 or 83-95; and / or (c) encodes an amino acid sequence having at least 80% sequence identity to any one of SEQ ID NOs: 71, 72, or 82, thereby editing the endogenous BRI1 gene in the plant or a part thereof and producing a plant or a part thereof comprising at least one cell having a mutation in the endogenous BRI1 gene.
[0219] In some embodiments, a method for generating a mutation in an endogenous brassinosteroid insensitive-1 (BRI1) gene in a plant comprises: (a) targeting a gene editing system to a portion of a BRI1 gene comprising a nucleotide sequence having at least 90% sequence identity to any one of SEQ ID NOs: 73-79 or 83-95; and (b) selecting plants comprising modifications located in a region of one or more BRI1 genes having at least 90% identity to a nucleotide sequence of any one of SEQ ID NOs: 73-79 or 83-95.
[0220] In some embodiments, a method for generating a mutation in a brassinosteroid insensitive-1 (BRI1) gene in a plant is provided, comprising: (a) targeting a gene editing system to a portion of the BRI1 gene located at approximately nucleotides 2-213, 42-174, 62-154, 82-134 and / or 92-124 numbered with reference to the nucleotide position of SEQ ID NO: 69 (e.g., SEQ ID NOs: 73-79), and / or (b) approximately nucleotides 1-267, 40-227, 70-195 and / or 100-168 numbered with reference to the nucleotide position of SEQ ID NO: 80 (e.g., SEQ ID NOs: 83-95).
[0221] In some embodiments, a method for detecting a mutant BRI1 gene in a plant (a mutation in an endogenous BRI1 gene) is provided, the method comprising detecting a BR1 gene having at least one mutation in the genome of the plant, the mutation being located within a region having at least 80% sequence identity to any one of the nucleotide sequences of SEQ ID NOs: 73-79 or 83-95. In some embodiments, the mutant BRI1 gene detected may comprise a nucleic acid sequence having at least 90% sequence identity to any one of SEQ ID NOs: 101-117.
[0222] In some embodiments, the mutation provided by the methods of the present invention may be a non-natural mutation. In some embodiments, the mutation may be a substitution, insertion and / or deletion, wherein the insertion or deletion is optionally an in-frame insertion or in-frame deletion. In some embodiments, the mutation in the endogenous BRI1 gene may result in a hypomorphic mutation, a dominant mutation and / or a semi-dominant mutation. In some embodiments, the mutation can be a deletion of about 1 base pair to about 270 consecutive base pairs, optionally wherein the deletion disrupts at least one upstream open reading frame (uORF) of the endogenous BRI1 gene (in a cis-regulatory element, such as in a promoter region), optionally wherein the at least one uORF is located at about nucleotides 2-213, 42-174, 62-154, 82-134, and / or 92-124 numbered with reference to nucleotide positions of SEQ ID NO: 69 (e.g., SEQ ID NOs: 73-79), and / or (b) about nucleotides 1-267, 40-227, 70-195, and / or 100-168 numbered with reference to nucleotide positions of SEQ ID NO: 80 (e.g., SEQ ID NOs: 83-95). In some embodiments, the mutation results in a modified BRI1 transcript. In some embodiments, the mutation results in a mutated BRI1 gene having at least 90% sequence identity to any one of SEQ ID NOs: 101-117, optionally, the mutation may be a hypomorphic mutation, a dominant mutation, and / or a semi-dominant mutation.
[0223] In some embodiments, a method of detecting a mutant BRI1 gene is provided, the method comprising detecting in a plant genome an endogenous BRI1 gene encoding a BRI1 polypeptide comprising a mutation in a cis-regulatory region (optionally located in a uORF located at about nucleotides 2-213, 42-174, 62-154, 82-134, and / or 92-124 numbered with reference to nucleotide positions of SEQ ID NO: 69 (e.g., SEQ ID NOs: 74-79), and / or (b) at about nucleotides 1-267, 40-227, 70-195, and / or 100-168 numbered with reference to nucleotide positions of SEQ ID NO: 80 (e.g., SEQ ID NOs: 83-95)). In some embodiments, a method of detecting a mutant BRI1 gene is provided, the method comprising detecting in a plant genome a mutant BRI1 transcript, wherein the mutation is located in one or more uORFs of the transcript. In some embodiments, the mutated BRI1 gene detected can have at least 90% sequence identity to any one of SEQ ID NOs: 101-117.
[0224] In some embodiments, the present invention provides a method for producing a plant comprising a mutation in an endogenous brassinosteroid insensitive-1 (BRI1) gene and at least one polynucleotide of interest, the method comprising crossing a plant of the present invention (a first plant) comprising at least one mutation in an endogenous BRI1 gene with a second plant comprising at least one polynucleotide of interest to produce offspring plants; and selecting offspring plants comprising at least one mutation in the BRI1 gene and at least one polynucleotide of interest, thereby producing a plant comprising a mutation in the endogenous BRI1 gene and at least one polynucleotide of interest.
[0225] The present invention also provides a method of producing a plant comprising a mutation in an endogenous BRI1 gene and at least one polynucleotide of interest, the method comprising introducing at least one polynucleotide of interest into a plant of the present invention comprising at least one mutation in the BRI1 gene, thereby producing a plant comprising at least one mutation in the BRI1 gene and at least one polynucleotide of interest. In some embodiments, the plant is a corn plant. In some embodiments, the plant is a soybean plant.
[0226] In some embodiments, a method for producing a plant comprising a mutation in an endogenous BRI1 gene and exhibiting a phenotype of improved yield traits, improved plant structure and / or improved defense traits is also provided, the method comprising crossing a first plant with a second plant, wherein the first plant is a plant of the present invention comprising at least one mutation in the BRI1 gene, and the second plant exhibits a phenotype of improved yield traits, improved plant structure and / or improved defense traits; and selecting offspring plants comprising a mutation in the BRI1 gene and a phenotype of improved yield traits, improved plant structure and / or improved defense traits, thereby producing a plant comprising a mutation in the endogenous BRI1 gene and exhibiting a phenotype of improved yield traits, improved plant structure and / or improved defense traits compared to a control plant.
[0227] Also provided is a method for controlling weeds in a container (e.g., a flower pot or seed tray, etc.), a growth chamber, a greenhouse, a field, a recreational area, a lawn, or a roadside, the method comprising applying a herbicide to one or more (plural) plants of the present invention growing in a container, a growth chamber, a greenhouse, a field, a recreational area, a lawn, or a roadside, thereby controlling the weeds in the container, growth chamber, greenhouse, field, recreational area, lawn, or roadside in which the one or more plants are growing.
[0228] In some embodiments, a method of reducing insect predation on a plant is provided, the method comprising optionally applying an insecticide to one or more plants of the present invention, wherein the one or more plants are grown in a container, a growth chamber, a greenhouse, a field, a recreational area, a lawn, or a roadside, thereby reducing insect predation on the one or more plants.
[0229] In some embodiments, a method of reducing fungal diseases on plants is provided, the method comprising applying a fungicide to one or more plants of the present invention, wherein the one or more plants are grown in a container, a growth chamber, a greenhouse, a field, a recreational area, a lawn, or a roadside, thereby reducing fungal diseases on the one or more plants.
[0230] The polynucleotide of interest may be any polynucleotide that can confer a desired phenotype or otherwise modify the phenotype or genotype of a plant. In some embodiments, the polynucleotide of interest may be a polynucleotide that confers herbicide tolerance, insect resistance, nematode resistance, disease resistance, increased yield, increased nutrient use efficiency, or abiotic stress resistance.
[0231] Therefore, plants or plant cultivars to be treated preferentially according to the invention include all plants which, by genetic modification, have received genetic material which imparts particularly advantageous useful properties ("traits") to these plants. Examples of such properties are better plant growth, vigor, stress tolerance, standability, resistance to lodging, nutrient uptake, plant nutrition and / or yield, in particular improved growth, increased tolerance to high or low temperatures, increased tolerance to drought or moisture levels or soil salinity, enhanced flowering performance, easier harvesting, accelerated maturation, higher yield, higher quality and / or higher nutritional value of the harvested product, better storage life and / or processability of the harvested product.
[0232] Further examples of such properties are increased resistance against animal and microbial pests (e.g. against insects, arachnids, nematodes, mites, slugs and snails, for example against toxins formed in plants). Among the DNA sequences encoding proteins which confer tolerance properties against such animal and microbial pests, in particular insects, mention will be made in particular of the Bacillus thuringiensis ( Bacillus thuringiensis ) are widely described in the literature and are well known to those skilled in the art. Mention will also be made of the genetic material of Bt proteins obtained from bacteria such as Photorhabdus luminescens ( Photorhabdus ) (WO97 / 17432 and WO98 / 08932). In particular, reference will be made to Bt Cry or VIP proteins, including Cry1A, CryIAb, CryIAc, CryIIA, CryIIIA, CryIIIB2, Cry9cCry2Ab, Cry3Bb and CryIF proteins or toxic fragments thereof, and hybrids or combinations thereof, in particular CrylF protein or a hybrid derived from CrylF protein (e.g. a hybrid CrylA-CrylF protein or a toxic fragment thereof), a CrylA-type protein or a toxic fragment thereof, preferably CrylAc protein or a hybrid derived from CrylAc protein (e.g. a hybrid CrylAb-CrylAc protein) or CrylAb or Bt2 protein or a toxic fragment thereof, Cry2Ae, Cry2Af or Cry2Ag protein or a toxic fragment thereof, CrylA.105 protein or a toxic fragment thereof, VIP3Aa19 protein, VIP3Aa20 protein, VIP3A protein produced in COT202 or COT203 cotton events, as described in Estruch et al. (1996), Proc Natl Acad Sci US A. 28; 93(11):5389-94, the VIP3Aa protein or its toxic fragment described in WO2001 / 47952, the Cry protein from the genus Heterobacterium ( Xenorhabdus ) (as described in WO98 / 50427), Serratia ( Serratia ) (particularly from Serratia entomophaga (S. entomophila )) or an insecticidal protein of a Photorhabdus species strain, such as the Tc-protein from Photorhabdus, as described in WO98 / 08932. Also included herein are any variants or mutants of any of these proteins that differ from any of the above sequences in some amino acids (1-10, preferably 1-5), in particular the sequences of their toxic fragments, or fused to a transit peptide, such as a plastid transit peptide or another protein or peptide.
[0233] Another and particularly emphasized example of such properties is the conferring of tolerance to one or more herbicides such as imidazolinone, sulfonylurea, glyphosate or glufosinate. Among the DNA sequences encoding proteins that confer tolerance properties to certain herbicides on transformed plant cells and plants (i.e., polynucleotides of interest), particular mention will be made of the bar or PAT gene described in WO 2009 / 152359 or the Streptomyces coelicolor ( Streptomyces coelicolor ) gene that confers tolerance to glufosinate herbicides, a gene encoding a suitable EPSPS (5-enolpyruvylshikimate-3-phosphate-synthase) that confers tolerance to herbicides that target EPSPS (especially herbicides such as glyphosate and its salts), a gene encoding a glyphosate-n-acetyltransferase, or a gene encoding a glyphosate oxidoreductase. Other suitable herbicide tolerance traits include at least one ALS (acetolactate synthase) inhibitor (e.g., WO 2007 / 024782), a mutant Arabidopsis ALS / AHAS gene (e.g., U.S. Pat. No. 6,855,533), a gene encoding a 2,4-D-monooxygenase that confers tolerance to 2,4-D (2,4-dichlorophenoxyacetic acid), and a gene encoding a dicamba monooxygenase that confers tolerance to dicamba (3,6-dichloro-2-methoxybenzoic acid).
[0234] Further examples of such traits are increased resistance to phytopathogenic fungi, bacteria and / or viruses due to, for example, systemic acquired resistance (SAR), systemins, phytoalexins, elicitors and resistance genes and correspondingly expressed proteins and toxins.
[0235] Particularly useful transgenic events in transgenic plants or plant cultivars that can be treated according to the invention include event 531 / PV-GHBK04 (cotton, insect control, described in WO2002 / 040677), event 1143-14A (cotton, insect control, not deposited, described in WO2006 / 128569); event 1143-51B (cotton, insect control, not deposited, described in WO2006 / 128570); event 1445 (cotton, herbicide tolerance, not deposited, described in US-A2002-120964 or WO2002 / 034946); event 17053 (rice, herbicide tolerance, deposited as PTA-9843, described in WO2010 / 117737); event 17314 (rice, herbicide tolerance, deposited as PTA-9844, described in WO20 10 / 117735); Event 281-24-236 (cotton, insect control-herbicide tolerance, deposited as PTA-6233, described in WO2005 / 103266 or US-A2005-216969); Event 3006-210-23 (cotton, insect control-herbicide tolerance, deposited as PTA-6233, described in US-A2007-143876 or WO20 05 / 103266); Event 3272 (corn, quality traits, deposited as PTA-9972, described in WO2006 / 098952 or US-A2006-230473); Event 33391 (wheat, herbicide tolerance, deposited as PTA-2347, described in WO2002 / 027004), Event 40416 (corn, insect control-herbicide tolerance, deposited as ATCC PTA-11508, described in WO11 / 075593); event 43A47 (corn, insect control - herbicide tolerance, deposited as ATCC PTA-11509, described in WO2011 / 075595); event 5307 (corn, insect control, deposited as ATCC PTA-9561, described in WO2010 / 077816); event ASR-368 (evergreen grass, herbicide tolerance, deposited as ATCC PTA-4816, described in US-A2006-162007 or WO2004 / 053062); event B16 (corn, herbicide tolerance, not deposited, described in US-A2003-126634); event BPS-CV127-9 (soybean, herbicide tolerance, deposited as NCIMB No. 41603, described in WO2010 / 080829); event BLR1 (rapeseed, restoration of male sterility, deposited as NCIMB 41193, described in WO2005 / 074671), event CE43-67B (cotton, insect control, deposited as DSMACC2724,described in US-A2009-217423 or WO2006 / 128573); Event CE44-69D (cotton, insect control, not deposited, described in US-A2010-0024077); Event CE44-69D (cotton, insect control, not deposited, described in WO2006 / 128571); Event CE46-02A (cotton, insect control, not deposited, described in WO2006 / 128572); Event COT102 (cotton, insect control, not deposited, described in US-A2006-13017 5 or WO2004 / 039986); event COT202 (cotton, insect control, not deposited, described in US-A2007-067868 or WO2005 / 054479); event COT203 (cotton, insect control, not deposited, described in WO2005 / 054480); event DAS21606-3 / 1606 (soybean, herbicide tolerance, deposited as PTA-11028, described in WO2012 / 033794), event DAS40278 (corn, herbicide tolerance, deposited as ATCC PTA-10244, described in WO2011 / 022469); event DAS-44406-6 / pDAB8264.44.06.1 (soybean, herbicide tolerant, deposited as PTA-11336, described in WO2012 / 075426), event DAS-14536-7 / pDAB8291.45.36.2 (soybean, herbicide tolerant, deposited as PTA-11335, described in WO2012 / 075429), event DAS-59122-7 (corn, insect control - herbicide tolerant, deposited as ATCC PTA11384, described in US-A2006-070139); event DAS-59132 (corn, insect control - herbicide tolerance, not deposited, described in WO2009 / 100188); event DAS68416 (soybean, herbicide tolerance, deposited as ATCC PTA-10442, described in WO2011 / 066384 or WO2011 / 066360); event DP-098140-6 (corn, herbicide tolerance, deposited as ATCC PTA-8296, described in US-A2009-137395 or WO08 / 112019); event DP-305423-1 (soybean, quality traits, not deposited, described in US-A2008-312082 or WO2008 / 054747); event DP-32138-1 (corn, hybrid system, deposited as ATCC PTA-9158, described in US-A2009-0210970 or WO2009 / 103049); event DP-356043-5 (soybean, herbicide tolerance, deposited as ATCC PTA-8287,described in US-A2010-0184079 or WO2008 / 002872); event EE-I (eggplant, insect control, not deposited, described in WO07 / 091277); event Fil17 (corn, herbicide tolerance, deposited as ATCC209031, described in US-A2006-059581 or WO98 / 044140); event FG72 (soybean, herbicide tolerance, deposited as PTA-11041, described in WO 2011 / 063413), event GA21 (corn, herbicide tolerance, deposited as ATCC 209033, described in US-A 2005-086719 or WO 98 / 044140); event GG25 (corn, herbicide tolerance, deposited as ATCC 209032, described in US-A 2005-188434 or WO 98 / 044140); event GHB119 (cotton, insect control-herbicide tolerance, deposited as ATCC PTA-8398, described in WO 2008 / 151780); event GHB614 (cotton, herbicide tolerance, deposited as ATCC PTA-6878, described in US-A2010-050282 or WO2007 / 017186); event GJ11 (corn, herbicide tolerance, deposited as ATCC209030, described in US-A2005-188434 or WO98 / 044140); event GMRZ13 (sugar beet, virus resistance, deposited as NCIMB-41601, described in WO2010 / 076212); event H7-1 (sugar beet, herbicide tolerance, deposited as NCIMB41158 or NCIMB41159, described in US-A2004-172669 or WO2004 / 074492); event JOPLIN1 (wheat, disease resistance, not deposited, described in US-A2008-064032); event LL27 (soybean, herbicide tolerance, deposited as NCIMB41658, described in WO2006 / 108674 or US-A2008-320616); event LL55 (soybean, herbicide tolerance, deposited as NCIMB41660, described in WO2006 / 108675 or US-A2008-196127); event LLcotton25 (cotton, herbicide tolerance, deposited as ATCC PTA-3343, described in WO2003 / 013224 or USA2003-097687); event LLRICE06 (rice, herbicide tolerant, deposited as ATCC203353, described in US6,468,747 or WO2000 / 026345); event LLRice62 (rice, herbicide tolerant, deposited as ATCC203352, described in WO2000 / 026345),Event LLRICE601 (rice, herbicide tolerance, deposited as ATCC PTA-2600, described in US-A2008-2289060 or WO2000 / 026356); Event LY038 (maize, quality traits, deposited as ATCC PTA-5623, described in US-A2007-028322 or WO2005 / 061720); event MIR162 (corn, insect control, deposited as PTA-8166, described in US-A2009-300784 or WO2007 / 142840); event MIR604 (corn, insect control, not deposited, described in US-A2008-167456 or WO2005 / 103301); event MON15985 (cotton, insect control, deposited as ATCC PTA-2516, described in US-A2004-250317 or WO2002 / 100163); event MON810 (corn, insect control, not deposited, described in US-A2002-102582); event MON863 (corn, insect control, deposited as ATCC PTA-2605, described in WO2004 / 011601 or US-A2006-095986); event MON87427 (maize, pollination control, deposited as ATCC PTA-7899, described in WO2011 / 062904); event MON87460 (maize, stress tolerance, deposited as ATCC PTA-8910, described in WO2009 / 111263 or US-A2011-0138504); event MON87701 (soybean, insect control, deposited as ATCC PTA-8194, described in US-A2009-130071 or WO2009 / 064652); event MON87705 (soybean, quality trait - herbicide tolerance, deposited as ATCC PTA-9241, described in US-A2010-0080887 or WO2010 / 037016); event MON87708 (soybean, herbicide tolerance, deposited as ATCC PTA-9670, described in WO2011 / 034704); event MON87712 (soybean, yield, deposited as PTA-10296, described in WO2012 / 051199), event MON87754 (soybean, quality traits, deposited as ATCC PTA-9385, described in WO2010 / 024976); event MON87769 (soybean, quality traits, deposited as ATCC PTA-8911, described in US-A2011-0067141 or WO2009 / 102873); event MON88017 (maize, insect control-herbicide tolerance, deposited as ATCC PTA-5582,described in US-A2008-028482 or WO2005 / 059103); event MON88913 (cotton, herbicide tolerance, deposited as ATCC PTA-4854, described in WO2004 / 072235 or US-A2006-059590); event MON88302 (canola, herbicide tolerance, deposited as PTA-10955, described in WO2011 / 153186), event MON88701 (cotton, herbicide tolerance, deposited as PTA-11754, described in WO2012 / 134808), event MON89034 (corn, insect control, deposited as ATCC PTA-7455, described in WO07 / 140256 or US-A2008-260932); event MON89788 (soybean, herbicide tolerant, deposited as ATCC PTA-6708, described in US-A2006-282915 or WO2006 / 130436); event MS11 (canola, pollination control-herbicide tolerant, deposited as ATCC PTA-850 or PTA-2485, described in WO2001 / 031042); event MS8 (canola, pollination control-herbicide tolerant, deposited as ATCC PTA-730, described in WO2001 / 041558 or US-A2003-188347); event NK603 (maize, herbicide tolerant, deposited as ATCC PTA-2478, described in US-A2007-292854); event PE-7 (rice, insect control, not deposited, described in WO2008 / 114282); event RF3 (canola, pollination control-herbicide tolerance, deposited as ATCC PTA-730, described in WO2001 / 041558 or US-A2003-188347); event RT73 (canola, herbicide tolerance, not deposited, described in WO2002 / 036831 or US-A2008-070260); event SYHT0H2 / SYN-000H2-5 (soybean, herbicide tolerance, deposited as PTA-11226, described in WO2012 / 082548), event T227-1 (sugar beet, herbicide tolerance, not deposited, described in WO2002 / 44407 or US-A2009-265817); event T25 (corn, herbicide tolerance, not deposited, described in US-A2001-029014 or WO2001 / 051654); event T304-40 (cotton, insect control-herbicide tolerance, deposited as ATCC PTA-8171, described in US-A2010-077501 or WO2008 / 122406); event T342-142 (cotton, insect control, not deposited, described in US-A2001-077501 or WO2008 / 122406); event T343-143 (cotton, insect control, not deposited, described in US-A2001-077501 or WO2008 / 122406); event T344-144 (cotton, insect control, not deposited, described in US-A2001-029014 or WO2001 / 051654); event T344-14 ...29014 or WO2001 / 051654); event T344-144 (cotton, insect control, not deposited, described in US-A2001-029described in WO2006 / 128568); event TC1507 (corn, insect control-herbicide tolerance, not deposited, described in US-A2005-039226 or WO2004 / 099447); event VIP1034 (corn, insect control-herbicide tolerance, deposited as ATCC PTA-3925, described in WO2003 / 052073), event 32316 (corn, insect control-herbicide tolerance, deposited as PTA-11507, described in WO2011 / 084632), event 4114 (corn, insect control-herbicide tolerance, deposited as PTA-11506, described in WO2011 / 084621), event EE-GM3 / FG72 (soybean, herbicide tolerance, ATCC accession number PTA-11041) optionally with event EE-GM1 stacked / LL27 or event EE-GM2 / LL55 (WO2011 / 063413A2), event DAS-68416-4 (soybean, herbicide tolerance, ATCC accession number PTA-10442, WO2011 / 066360A1), event DAS-68416-4 (soybean, herbicide tolerance, ATCC accession number PTA-10442, WO2011 / 066384A1), event DP-040416-8 (corn, insecticide tolerance control, ATCC Accession No. PTA-11508, WO2011 / 075593A1), event DP-043A47-3 (corn, insect control, ATCC Accession No. PTA-11509, WO2011 / 075595A1), event DP-004114-3 (corn, insect control, ATCC Accession No. PTA-11506, WO2011 / 084621A1), event DP-032316-8 (corn, insect control, ATCC Accession No. PTA-11507, WO2011 / 084621A1), event DP-032316-8 (corn, insect control, ATCC Accession No. PTA-11508, WO2011 / 075593A1), event DP-043A47-3 (corn, insect control, ATCC Accession No. PTA-11509, WO2011 / 075595A1), event DP-004114-3 (corn, insect control, ATCC Accession No. PTA-11506, WO2011 / 084621A1), event DP-032316-8 (corn, insect control, ATCC Accession No. A-11507, WO2011 / 084632A1), event MON-88302-9 (canola, herbicide tolerance, ATCC accession number PTA-10955, WO2011 / 153186A1), event DAS-21606-3 (soybean, herbicide tolerance, ATCC accession number PTA-11028, WO2012 / 033794A2), event MON-87712-4 (soybean, quality traits, ATCC accession number PTA-10296, WO2012 / 051199A2), event DAS-44406-6 (soybean, stacked herbicide tolerance, ATCC accession number PTA-11336, WO2012 / 075426A1), event DAS-14536-7 (soybean, stacked herbicide tolerance, ATCC accession number PTA-11335, WO2012 / 075429A1), event SYN-000H2-5 (soybean, herbicide tolerance,ATCC accession number PTA-11226, WO2012 / 082548A2), event DP-061061-7 (canola, herbicide tolerance, no available deposit number, WO2012071039A1), event DP-073496-4 (canola, herbicide tolerance, no deposit number, US2012131692), event 8264.44.06.1 (soybean, stacked herbicide tolerance, accession number PTA-11336, WO2012075426A2), event 8291.45.36.2 (soybean, stacked herbicide tolerance, accession number PTA-11335, WO2012075429A2), event SYHT0H 2 (soybean, ATCC Accession No. PTA-11226, WO2012 / 082548A2), event MON88701 (cotton, ATCC Accession No. PTA-11754, WO2012 / 134808A1), event KK179-2 (alfalfa, ATCC Accession No. PTA-11833, WO2013 / 003558A1), event pDAB8264.42.32.1 (soybean, stacked herbicide tolerance, ATCC Accession No. PTA-11993, WO2013 / 010094A1), event MZDT09Y (corn, ATCC Accession No. PTA-13025, WO2013 / 012775A1). ,
[0236] Genes / events (e.g., polynucleotides of interest) that confer desired traits may also be present in transgenic plants in combination with one another. Examples of transgenic plants include, but are not limited to, crops such as cereals (wheat, rice, triticale, barley, rye, oats), corn, soybeans, potatoes, beets, sugar cane, tomatoes, peas and other types of vegetables, cotton, tobacco, rapeseed, and fruit plants (including fruit apples, pears, citrus fruits, and grapes), with particular emphasis on corn, soybeans, wheat, rice, potatoes, cotton, sugar cane, tobacco, and rapeseed. Specially emphasized properties are the increased resistance of plants to insects, arachnids, nematodes, slugs, and snails, and the increased resistance of plants to one or more herbicides.
[0237] Commercially available examples of such plants, plant parts or plant seeds which may preferably be treated according to the invention include commercial products, such as plant seeds, sold or distributed under the trade names GENUITY®, DROUGHTGARD®, SMARTSTAX®, RIB COMPLETE®, ROUNDUP READY®, VTDOUBLE PRO®, VT TRIPLE PRO®, BOLLGARD II®, ROUNDUP READY 2 YIELD®, YIELDGARD®, ROUNDUP READY® 2 XTEND™, INTACTA RR2 PRO®, VISTIVE GOLD® and / or XTENDFLEX™.
[0238] BRI1 genes useful in the present invention include any BRI1 gene in which the mutations described herein can confer an improvement in one or more yield traits in a plant or part thereof comprising the mutation. In some embodiments, the endogenous BRI1 gene (a) comprises a sequence having at least 80% sequence identity to the nucleotide sequence of any one of SEQ ID NOs: 69, 70, 80, or 81; (b) comprises a region having at least 80% sequence identity to any one of SEQ ID NOs: 73-79 or 83-95; (c) encodes an amino acid sequence having at least 80% sequence identity to any one of SEQ ID NOs: 71, 72, or 82. The mutation in the endogenous BRI1 gene in the plant can be a base substitution, a base deletion, and / or a base insertion, optionally a non-natural mutation. In some embodiments, a mutation in an endogenous BRI1 gene in a plant may result in a plant having a phenotype of one or more improved yield traits compared to a control plant without the edit / mutation, optionally wherein the improved yield trait may include, but is not limited to, higher yield (bushels per acre), increased biomass, increased plant height, increased stem diameter, increased leaf area, increased number of flowers, increased number of pods per node, increased number of pods per plant, increased number of seeds, increased number of seeds per pod, increased seed size, and / or increased seed weight (e.g., an increase in 100 seed weight).In some embodiments, the mutation in the endogenous BRI1 gene can be at least 1 nucleotide to about 270 nucleotides (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 2, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 1, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 120, 130, 140, 141, 142, 143, 144, 145 5, 150, 160, 170, 180, 190, 200, 210, 220, 221, 222, 223, 224, 225, 230, 240, 250, 260 or 270, and any range or value therein), optionally wherein the mutation may result in substitution, deletion and / or insertion in the uORF region of the gene and transcript. In some embodiments, the at least one mutation may be a point mutation, optionally a base substitution to A, T, G or C. In some embodiments, the mutation may be generated in the following positions in the BRI1 gene: (a) about nucleotides 2-213, 42-174, 62-154, 82-134 and / or 92-124 numbered with reference to the nucleotide positions of SEQ ID NO: 69 (e.g., SEQ ID NOs: 73-79), and / or (b) about nucleotides 1-267, 40-227, 70-195 and / or 100-168 numbered with reference to the nucleotide positions of SEQ ID NO: 80 (e.g., SEQ ID NOs: 83-95). In some embodiments, the mutation in the BRI1 gene may be a deletion of one base pair to about 250 base pairs, wherein at least the ATG site in the uORF is deleted. In some embodiments, the mutation in the BRI1 gene (mutated BRI1 gene) may have at least 90% sequence identity with any one of SEQ ID NOs: 101-117.
[0239] In some embodiments, mutations in the endogenous BRI1 gene can be made following cleavage by an editing system comprising a nuclease and a nucleic acid binding domain that binds to a target site within a target nucleic acid (e.g., a BRI1 gene), the target nucleic acid comprising a sequence having at least 80% sequence identity to any one of the nucleotide sequences of SEQ ID NOs: 69, 70, 80, or 81, and / or encoding an amino acid sequence having at least 80% sequence identity to any one of SEQ ID NOs: 71, 72, or 82, optionally wherein the target site is located in a region of the BRI1 gene comprising a sequence having at least 90% identity to any one of SEQ ID NOs: 73-79 or 83-95.
[0240] Further provided is a guide nucleic acid (e.g., gRNA, gDNA, crRNA, crDNA) that binds to a target site in a brassinosteroid insensitive-1 (BRI1) gene, wherein the target site is located in the following region of the BRI1 gene, the region being located: (a) about nucleotides 2-213, 42-174, 62-154, 82-134, and / or 92-124 numbered with reference to nucleotide positions of SEQ ID NO: 69 (e.g., SEQ ID NOs: 73-79), and / or (b) about nucleotides 1-267, 40-227, 70-195, and / or 100-168 numbered with reference to nucleotide positions of SEQ ID NO: 80 (e.g., SEQ ID NOs: 83-95). In some embodiments, the guide nucleic acid comprises a spacer region, the spacer region comprising any one of the nucleotide sequences of SEQ ID NOs: 96-100.
[0241] In some embodiments, a soybean plant or plant part thereof is provided, comprising at least one mutation in at least one endogenous brassinosteroid insensitive-1 (BRI1) gene having a gene identification number (Gene ID) of Glyma.06g147600 (SEQ ID NO: 69) and / or Glyma.04g218300 (SEQ ID NO: 80), optionally wherein the mutation is a non-natural mutation. In some embodiments, a soybean plant or plant part thereof is provided, comprising a mutated BRI1 gene having at least 90% sequence identity to any one of SEQ ID NOs: 101-117.
[0242] In some embodiments, a guide nucleic acid is provided that binds to a target nucleic acid in a brassinosteroid insensitive-1 (BRI1) gene having a gene identification number (gene ID) of Glyma.06g147600 (SEQ ID NO: 69) and / or Glyma.04g218300 (SEQ ID NO: 80).
[0243] In some embodiments, a system is provided, comprising a guide nucleic acid comprising a spacer (e.g., one or more spacers) having a nucleotide sequence of any one of SEQ ID NOs: 96-100, and a CRISPR-Cas effector protein associated with the guide nucleic acid. In some embodiments, the system may also include a tracr nucleic acid associated with the guide nucleic acid and the CRISPR-Cas effector protein, optionally wherein the tracr nucleic acid and the guide nucleic acid are covalently linked. As used herein, "CRISPR-Cas effector protein associated with a guide nucleic acid" refers to a complex formed between a CRISPR-Cas effector protein and a guide nucleic acid to guide the CRISPR-Cas effector protein to a target site in a gene.
[0244] The present invention also provides a gene editing system, comprising a CRISPR-Cas effector protein associated with a guide nucleic acid, and the guide nucleic acid comprises a spacer sequence that binds to a brassinosteroid insensitive-1 (BRI1) gene, optionally wherein the BRI1 gene (a) comprises a sequence having at least 80% sequence identity to a nucleotide sequence of any one of SEQ ID NOs: 69, 70, 80, or 81; (b) comprises a region having at least 80% sequence identity to a nucleotide sequence of any one of SEQ ID NOs: 73-79 or 83-95; and / or (c) encodes an amino acid sequence having at least 80% sequence identity to any one of SEQ ID NOs: 71, 72, or 82. In some embodiments, the spacer sequence of the guide nucleic acid may comprise a nucleotide sequence of any one of SEQ ID NOs: 96-100. In some embodiments, the gene editing system may further comprise a tracr nucleic acid associated with the guide nucleic acid and the CRISPR-Cas effector protein, optionally wherein the tracr nucleic acid and the guide nucleic acid are covalently linked.
[0245] The present invention also provides a complex comprising a CRISPR-Cas effector protein containing a cleavage domain and a guide nucleic acid, wherein the guide nucleic acid binds to a target site in an endogenous brassinosteroid insensitive-1 (BRI1) gene, wherein the endogenous BRI1 gene: (a) comprises a sequence having at least 80% sequence identity to the nucleotide sequence of any one of SEQ ID NOs: 69, 70, 80 or 81; (b) comprises a region having at least 80% sequence identity to the nucleotide sequence of any one of SEQ ID NOs: 73-79 or 83-95; and / or (c) encodes an amino acid sequence having at least 80% sequence identity to any one of SEQ ID NOs: 71, 72 or 82, wherein the cleavage domain cleaves the target chain in the BRI1 gene.
[0246] In some embodiments, one or more expression cassettes are provided, comprising (a) a polynucleotide encoding a CRISPR-Cas effector protein comprising a cleavage domain, and (b) a guide nucleic acid that binds to a target site in an endogenous brassinosteroid insensitive-1 (BRI1) gene, wherein the guide nucleic acid comprises a spacer sequence that is complementary to and binds to: (i) a portion of a nucleic acid having at least 80% sequence identity to any one of the nucleotide sequences of SEQ ID NOs: 69, 70, 80, or 81; (ii) a portion of a nucleic acid having at least 80% sequence identity to any one of SEQ ID NOs: 73-79 or 83-95; and / or (iii) a portion of a nucleic acid encoding an amino acid sequence having at least 80% sequence identity to any one of SEQ ID NOs: 71, 72, or 82.
[0247] In some embodiments, a modified brassinosteroid insensitive-1 (BRI1) gene or transcript is provided, comprising a mutation in a cis-regulatory region (e.g., a promoter region, such as one or more uORFa) located at: (a) about nucleotides 2-213, 42-174, 62-154, 82-134 and / or 92-124 numbered with reference to nucleotide positions of SEQ ID NO: 69 (e.g., SEQ ID NOs: 73-79), and / or (b) about nucleotides 1-267, 40-227, 70-195 and / or 100-168 numbered with reference to nucleotide positions of SEQ ID NO: 80 (e.g., SEQ ID NOs: 83-95), optionally wherein when present in a plant or plant part, the mutated BRI1 gene / transcript results in a plant phenotype comprising one or more improved yield traits compared to a plant or plant part lacking the mutation. In some embodiments, a mutated BRI1 transcript can be produced from a mutated BRI1 gene having at least 90% sequence identity to any one of SEQ ID NOs: 101-117.
[0248] The nucleic acid constructs of the present invention (e.g., constructs comprising a sequence-specific nucleic acid binding domain (e.g., a sequence-specific DNA binding domain), a CRISPR-Cas effector domain, a deaminase domain, a reverse transcriptase (RT), an RT template and / or a guide nucleic acid, etc.) and expression cassettes / vectors comprising the same can be used as the editing system of the present invention for modifying a target nucleic acid (e.g., an endogenous BRI1 gene) and / or its expression.
[0249] Any plant comprising an endogenous BRI1 gene that is capable of conferring at least one improved yield trait when modified as described herein can be modified (e.g., mutated, such as base editing, cleavage, incision, etc.) as described herein (e.g., using the polypeptides, polynucleotides, RNPs, nucleic acid constructs, expression cassettes and / or vectors of the invention) to improve one or more yield traits in the plant. A plant exhibiting an improved yield trait can exhibit from about 5% to about 100% (e.g., about 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 109, 95, 9 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89 , 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100% or more, or any range or value therein; for example, an improvement of about 5% to about 10%, about 5% to about 15%, about 5% to about 20%, about 10% to about 50%, about 10% to about 80%, about 10% to about 90%, about 10% to about 100%, about 20% to about 50%, about 20% to about 80%, about 20% to about 90%, about 20% to about 100%, about 30% to about 50%, about 30% to about 80%, about 30% to about 90%, about 30% to about 100%, about 50% to about 100%, about 75% to about 100% or more, and any range or value therein).
[0250] The editing system that can be used for the present invention can be any site-specific (sequence-specific) genome editing system that is now known or developed later, which can introduce mutations in a target-specific manner. For example, the editing system (e.g., a site-specific or sequence-specific editing system) can include, but is not limited to, a CRISPR-Cas editing system, a meganuclease editing system, a zinc finger nuclease (ZFN) editing system, a transcription activator-like effector nuclease (TALEN) editing system, a base editing system, and / or a lead editing system, each of which can include one or more polypeptides and / or one or more polynucleotides, which, when expressed as a system in a cell, can modify (mutate) a target nucleic acid in a sequence-specific manner. In some embodiments, the editing system (e.g., a site-specific or sequence-specific editing system) can include one or more polynucleotides and / or one or more polypeptides, including but not limited to a nucleic acid binding domain (DNA binding domain), a nuclease, and / or other polypeptides, and / or polynucleotides.
[0251] In some embodiments, the editing system may include one or more sequence-specific nucleic acid binding domains (e.g., DNA binding domains), which may be derived from, for example, polynucleotide-guided endonucleases, CRISPR-Cas endonucleases (e.g., CRISPR-Cas effector proteins), zinc finger nucleases, transcription activator-like effector nucleases (TALENs), and / or Argonaute proteins. In some embodiments, the editing system may include one or more cleavage domains (e.g., nucleases), including but not limited to endonucleases (e.g., Fok1), polynucleotide-guided endonucleases, CRISPR-Cas endonucleases (e.g., CRISPR-Cas effector proteins), zinc finger nucleases, and / or transcription activator-like effector nucleases (TALENs). In some embodiments, the editing system may include one or more polypeptides, including but not limited to deaminases (e.g., cytosine deaminases, adenine deaminases), reverse transcriptases, Dna2 polypeptides, and / or 5' flap endonucleases (FENs). In some embodiments, the editing system may comprise one or more polynucleotides including, but not limited to, a CRISPR array (CRISPR guide) nucleic acid, an extended guide nucleic acid, and / or a reverse transcriptase template.
[0252] In some embodiments, methods for modifying or editing a brassinosteroid insensitive-1 (BRI1) gene may include contacting a target nucleic acid (e.g., a nucleic acid encoding a BRI1 polypeptide) with a base editing fusion protein (e.g., a sequence-specific DNA binding protein (e.g., a CRISPR-Cas effector protein or domain)) fused to a deaminase domain (e.g., an adenine deaminase and / or a cytosine deaminase) and a guide nucleic acid, wherein the guide nucleic acid is capable of guiding / targeting the base editing fusion protein to the target nucleic acid, thereby editing a locus within the target nucleic acid. In some embodiments, the base editing fusion protein and the guide nucleic acid may be contained in one or more expression cassettes. In some embodiments, the target nucleic acid may be contacted with a base editing fusion protein and an expression cassette comprising a guide nucleic acid. In some embodiments, the sequence-specific nucleic acid binding fusion protein and the guide may be provided as a ribonucleoprotein (RNP). In some embodiments, a cell may be contacted with more than one base editing fusion protein and / or one or more guide nucleic acids that can target one or more target nucleic acids in a cell.
[0253] In some embodiments, methods of modifying or editing a brassinosteroid insensitive-1 (BRI1) gene may include contacting a target nucleic acid (e.g., a nucleic acid encoding a BRI1 polypeptide) with a sequence-specific nucleic acid binding fusion protein (e.g., a sequence-specific DNA binding protein (e.g., a CRISPR-Cas effector protein or domain)) fused to a peptide tag, a deaminase fusion protein comprising a deaminase domain (e.g., an adenine deaminase and / or a cytosine deaminase) fused to an affinity polypeptide capable of binding to the peptide tag, and a guide nucleic acid, wherein the guide nucleic acid is capable of guiding / targeting the sequence-specific nucleic acid binding fusion protein to the target nucleic acid, and the sequence-specific nucleic acid binding fusion protein is capable of recruiting the deaminase fusion protein to the target nucleic acid through a peptide tag-affinity polypeptide interaction, thereby editing a locus within the target nucleic acid. In some embodiments, the sequence-specific nucleic acid binding fusion protein may be fused to an affinity polypeptide that binds to a peptide tag, and the deaminase may be fused to the peptide tag, thereby recruiting the deaminase to the sequence-specific nucleic acid binding fusion protein and the target nucleic acid. In some embodiments, the sequence-specific binding fusion protein, the deaminase fusion protein, and the guide nucleic acid can be contained in one or more expression cassettes. In some embodiments, the target nucleic acid can be contacted with the sequence-specific binding fusion protein, the deaminase fusion protein, and the expression cassette containing the guide nucleic acid. In some embodiments, the sequence-specific nucleic acid binding fusion protein, the deaminase fusion protein, and the guide can be provided as a ribonucleoprotein (RNP).
[0254] In some embodiments, methods such as lead editing can be used to generate mutations in the endogenous BRI1 gene. In lead editing, RNA-dependent DNA polymerase (reverse transcriptase, RT) and reverse transcriptase template (RT template) are used in combination with sequence-specific nucleic acid binding domains that confer the ability to recognize and bind to targets in a sequence-specific manner and can also cause nicks of chains containing PAMs within the target. The nucleic acid binding domain can be a CRISPR-Cas effector protein, and in this case, the CRISPR array or guide RNA can be an extended guide that includes an extension containing a primer binding site (PSB) and an editor (template) to be incorporated into the genome. Similar to base editing, lead editing can utilize various methods for recruiting proteins for editing target sites, including non-covalent and covalent interactions between proteins and nucleic acids used in the selected genome editing process.
[0255] As used herein, a "CRISPR-Cas effector protein" is a protein or polypeptide or a domain thereof that cuts or cleaves nucleic acids, binds nucleic acids (e.g., target nucleic acids and / or guide nucleic acids), and / or identifies, recognizes, or binds to guide nucleic acids as defined herein. In some embodiments, the CRISPR-Cas effector protein may be an enzyme (e.g., a nuclease, an endonuclease, a nickase, etc.) or a portion thereof and / or may function as an enzyme. In some embodiments, the CRISPR-Cas effector protein refers to a CRISPR-Cas nuclease polypeptide or a domain thereof that comprises nuclease activity or wherein the nuclease activity has been reduced or eliminated, and / or comprises nickase activity or wherein the nickase has been reduced or eliminated, and / or comprises single-stranded DNA cleavage activity (ssDNAse activity) or wherein the ssDNAse activity has been reduced or eliminated, and / or comprises self-processing RNAse activity or wherein the self-processing RNAse activity has been reduced or eliminated. The CRISPR-Cas effector protein may bind to a target nucleic acid.
[0256] In some embodiments, the sequence-specific nucleic acid binding domain may be a CRISPR-Cas effector protein. In some embodiments, the CRISPR-Cas effector protein may be from a type I CRISPR-Cas system, a type II CRISPR-Cas system, a type III CRISPR-Cas system, a type IV CRISPR-Cas system, a type V CRISPR-Cas system, or a type VI CRISPR-Cas system. In some embodiments, the CRISPR-Cas effector protein of the present invention may be from a type II CRISPR-Cas system or a type V CRISPR-Cas system. In some embodiments, the CRISPR-Cas effector protein may be a type II CRISPR-Cas effector protein, such as a Cas9 effector protein. In some embodiments, the CRISPR-Cas effector protein may be a type V CRISPR-Cas effector protein, such as a Cas12 effector protein.
[0257] In some embodiments, the CRISPR-Cas effector protein may include, but is not limited to, Cas9, C2c1, C2c3, Cas12a (also known as Cpf1), Cas12b, Cas12c, Cas12d, Cas12e, Cas13a, Cas13b, Cas13c, Cas13d, Cas1, Cas1B, Cas2, Cas3, Cas3', Cas3", Cas4, Cas5, Cas6, Cas7, Cas8, Cas9 (also known as Csn1 and Csx12), Cas10, Csyl, Csy2, Csy3, Csel, Cse2, Cscl, Csc2, Csa5, Csn2, Csm2, Csm3, Csm4, Csm5, Csm6, Cmrl , Cmr3, Cmr4, Cmr5, Cmr6, Csbl, Csb2, Csb3, Csxl7, Csxl4, CsxlO, Csxl6, CsaX, Csx3, Csxl, Csxl5, Csfl, Csf2, Csf3, Csf4 (dinG) and / or Csf5 nuclease, optionally wherein the CRISPR-Cas effector protein can be Cas9, Cas12a (Cpf1), Cas12b, Cas12c (C2c3), Cas12d (CasY), Cas12e (CasX), Cas12g, Cas12h, Cas12i, C2c4, C2c5, C2c8, C2c9, C2c10, Cas14a, Cas14b and / or Cas14c effector protein.
[0258] In some embodiments, the CRISPR-Cas effector protein useful in the present invention may include a mutation in its nuclease active site (e.g., RuvC, HNH, e.g., RuvC site of a Cas12a nuclease domain; e.g., RuvC site and / or HNH site of a Cas9 nuclease domain). CRISPR-Cas effector proteins that have a mutation in their nuclease active site and therefore no longer contain nuclease activity are often referred to as "dead", such as dCas. In some embodiments, a CRISPR-Cas effector protein domain or polypeptide having a mutation in its nuclease active site may have impaired activity or reduced activity compared to the same CRISPR-Cas effector protein (e.g., nickase, e.g., Cas9 nickase, Cas12a nickase) without a mutation.
[0259] The CRISPR Cas9 effector protein or CRISPR Cas9 effector domain useful in the present invention can be any known or later identified Cas9 nuclease. In some embodiments, the CRISPR Cas9 polypeptide can be from, for example, several species of Streptococcus ( Streptococcus spp.) (e.g., Streptococcus pyogenes ( S. pyogenes )、Streptococcus thermophilus( S. thermophilus )), several species of Lactobacillus ( Lactobacillus spp.), several species of Bifidobacterium ( Bifidobacterium spp . ), several species of the genus Candlerella ( Kandleria spp.), several species of Leuconostoc ( Leuconostoc spp.), several species of Oenococcus ( Oenococcus spp.), several species of Pediococcus ( Pediococcus spp.), several species of Weissella ( Weissella spp.) and / or several species of Moraxella osloensis ( Olsenella spp.) Exemplary Cas9 sequences include, but are not limited to, the amino acid sequences of SEQ ID NOs: 56 and 57 or the nucleotide sequences of SEQ ID NOs: 58-68.
[0260] In some embodiments, the CRISPR-Cas effector protein may be derived from Streptococcus pyogenes ( Streptococcus pyogenes ) and recognizes Cas9 polypeptides of the PAM sequence motifs NGG, NAG, NGA (Mali et al., Science 2013; 339(6121): 823-826). In some embodiments, the CRISPR-Cas effector protein can be derived from Streptococcus thermophilus ( Streptococcusthermophiles ) and recognizes a Cas9 polypeptide having a PAM sequence motif NGGNG and / or NNAGAAW (W=A or T) (see, e.g., Horvath et al., Science, 2010; 327(5962): 167-170 and Deveau et al., J Bacteriol 2008; 190(4): 1390-1400). In some embodiments, the CRISPR-Cas effector protein may be derived from Streptococcus mutans ( Streptococcusmutans ) and recognizes a Cas9 polypeptide having a PAM sequence motif NGG and / or NAAR (R=A or G) (see, e.g., Deveau et al., J BACTERIOL 2008; 190(4): 1390-1400). In some embodiments, the CRISPR-Cas effector protein may be derived from Streptococcus aureus ( Streptococcusaureus ) and recognizes a Cas9 polypeptide having a PAM sequence motif NN GRR (R = A or G). In some embodiments, the CRISPR-Cas effector protein may be derived from Streptococcus aureus ( S. aureus ) Cas9 protein, which recognizes the PAM sequence motif N GRRT (R = A or G). In some embodiments, the CRISPR-Cas effector protein can be a Cas9 polypeptide derived from Streptococcus aureus, which recognizes the PAM sequence motif N GRRV (R = A or G). In some embodiments, the CRISPR-Cas effector protein can be a Cas9 polypeptide derived from Neisseria meningitidis ( Neisseria meningitidis ) and recognizes a Cas9 polypeptide of the PAM sequence motif N GATT or N GCTT (R = A or G, V = A, G or C) (see, e.g., Hou et al., PNAS 2013, 1-6). In the above embodiments, N can be any nucleotide residue, such as any one of A, G, C or T. In some embodiments, the CRISPR-Cas effector protein can be derived from Leptotrichia saburoi ( Leptotrichia shahii ) of the Cas13a protein, which recognizes a single 3' A, U or C protospacer flanking sequence (PFS) (or RNA PAM (rPAM)) sequence motif, which may be located within the target nucleic acid.
[0261] In some embodiments, the CRISPR-Cas effector protein can be derived from Cas12a, which is a V-type clustered regularly interspaced short palindromic repeat (CRISPR)-Cas nuclease, see, e.g., SEQ ID NO: 1-17 amino acid sequence, SEQ ID NO: 18-20 nucleic acid sequence. Cas12a differs from the more well-known type II CRISPR Cas9 nuclease in several aspects. For example, Cas9 recognizes a G-rich protospacer adjacent motif (PAM) located 3' (3'-NGG) of its guide RNA (gRNA, sgRNA, crRNA, crDNA, CRISPR array) binding site (protospacer, target nucleic acid, target DNA), while Cas12a recognizes a T-rich PAM (5'-TTN, 5'-TTTN) located 5' of the target nucleic acid. In fact, the directions in which Cas9 and Cas12a bind to their guide RNAs are very nearly opposite with respect to their N and C termini. In addition, the Cas12a enzyme uses a single guide RNA (gRNA, CRISPR array, crRNA), rather than the dual guide RNA (sgRNA (e.g., crRNA and tracrRNA)) found in the natural Cas9 system, and Cas12a processes its own gRNA. In addition, the Cas12a nuclease activity produces staggered DNA double-strand breaks, rather than the flat ends produced by the Cas9 nuclease activity, and Cas12a relies on a single RuvC domain to cut two DNA chains, while Cas9 uses the HNH domain and the RuvC domain for cutting.
[0262] CRISPR Cas12a effector protein / domain that can be used in the present invention can be any known or later identified Cas12a polypeptide (formerly known as Cpf1) (see, e.g., U.S. Pat. No. 9,790,490, the disclosure of which about Cpf1 (Cas12a) sequence is incorporated herein by reference). The term "Cas12a", "Cas12a polypeptide" or "Cas12a domain" refers to an RNA-guided nuclease comprising a Cas12a polypeptide or a fragment thereof, which comprises a guide nucleic acid binding domain of Cas12a and / or an active, inactive or partially active DNA cleavage domain of Cas12a. In some embodiments, Cas12a that can be used in the present invention may comprise a mutation in a nuclease active site (e.g., a RuvC site of a Cas12a domain). A Cas12a domain or Cas12a polypeptide that has a mutation in its nuclease active site and therefore no longer comprises nuclease activity is generally referred to as a dead Cas12a (e.g., dCas12a). In some embodiments, a Cas12a domain or Cas12a polypeptide having a mutation in its nuclease active site may have impaired activity, for example, may have nickase activity.
[0263] Any deaminase domain / polypeptide that can be used for base editing can be used in the present invention. In some embodiments, the deaminase domain can be a cytosine deaminase domain or an adenine deaminase domain. The cytosine deaminase (or cytidine deaminase) that can be used in the present invention can be any known or later identified cytosine deaminase from any organism (see, e.g., U.S. Pat. No. 10,167,457 and Thuronyi et al. Nat. Biotechnol . 37:1070–1079 (2019), each of which is incorporated herein by reference for its disclosure on cytosine deaminases). Cytosine deaminases can catalyze the hydrolytic deamination of cytidine or deoxycytidine to uridine or deoxyuridine, respectively. Therefore, in some embodiments, the deaminase or deaminase domain useful in the present invention can be a cytidine deaminase domain that catalyzes the hydrolytic deamination of cytosine to uracil. In some embodiments, the cytosine deaminase can be a variant of a naturally occurring cytosine deaminase, including but not limited to primates (e.g., humans, monkeys, chimpanzees, gorillas), dogs, cows, rats, or mice. Thus, in some embodiments, a cytosine deaminase useful in the present invention can be about 70% to about 100% identical to a wild-type cytosine deaminase (e.g., about 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to a naturally occurring cytosine deaminase, and any range or value therein).
[0264] In some embodiments, the cytosine deaminase useful in the present invention can be an apolipoprotein B mRNA-editing complex (APOBEC) family deaminase. In some embodiments, the cytosine deaminase can be an APOBEC 1 deaminase, an APOBEC 2 deaminase, an APOBEC 3A deaminase, an APOBEC 3B deaminase, an APOBEC 3C deaminase, an APOBEC 3D deaminase, an APOBEC 3F deaminase, an APOBEC 3G deaminase, an APOBEC 3H deaminase, an APOBEC 4 deaminase, a human activation-induced deaminase (hAID), rAPOBEC1, FERNY and / or CDA1, optionally pmCDA1, atCDA1 (e.g., At2g19570), and their evolved forms (e.g., SEQ ID NO: 27, SEQ ID NO: 28 or SEQ ID NO: 29). In some embodiments, the cytosine deaminase may be an APOBEC1 deaminase having an amino acid sequence of SEQ ID NO: 23. In some embodiments, the cytosine deaminase may be an APOBEC3A deaminase having an amino acid sequence of SEQ ID NO: 24. In some embodiments, the cytosine deaminase may be a CDA1 deaminase, optionally a CDA1 having an amino acid sequence of SEQ ID NO: 25. In some embodiments, the cytosine deaminase may be a FERNY deaminase, optionally a FERNY having an amino acid sequence of SEQ ID NO: 26. In some embodiments, a cytosine deaminase useful in the present invention can be about 70% to about 100% identical (e.g., 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, or 100% identical) to the amino acid sequence of a naturally occurring cytosine deaminase (e.g., an evolved deaminase).In some embodiments, a cytosine deaminase useful in the invention may be about 70% to about 99.5% identical (e.g., about 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 99.5% identical) to the amino acid sequence of SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, or SEQ ID NO: 26 (e.g., about 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 99.5% identical) to the amino acid sequence of SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, or SEQ ID NO: NO:29 is at least 80%, at least 85%, at least 90%, at least 92%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% identical). In some embodiments, the polynucleotide encoding the cytosine deaminase can be codon-optimized for expression in plants, and the codon-optimized polypeptide can be about 70% to 99.5% identical to the reference polynucleotide.
[0265] In some embodiments, the nucleic acid construct of the present invention may further encode a uracil glycosylase inhibitor (UGI) (e.g., a uracil-DNA glycosylase inhibitor) polypeptide / domain. Therefore, in some embodiments, a nucleic acid construct encoding a CRISPR-Cas effector protein and a cytosine deaminase domain (e.g., encoding a fusion protein comprising a CRISPR-Cas effector protein domain fused to a cytosine deaminase domain, and / or a CRISPR-Cas effector protein domain fused to a peptide tag or an affinity polypeptide capable of binding to a peptide tag and / or a deaminase protein domain fused to a peptide tag or an affinity polypeptide capable of binding to a peptide tag) may further encode a uracil-DNA glycosylase inhibitor (UGI), optionally wherein UGI may be codon optimized for expression in plants. In some embodiments, the present invention provides a fusion protein comprising a CRISPR-Cas effector polypeptide, a deaminase domain and UGI and / or one or more polynucleotides encoding them, optionally wherein one or more polynucleotides may be codon optimized for expression in plants. In some embodiments, the present invention provides fusion proteins, wherein the CRISPR-Cas effector polypeptide, the deaminase domain and the UGI can be fused with any combination of peptide tags and affinity polypeptides described herein, thereby recruiting the deaminase domain and the UGI to the CRISPR-Cas effector polypeptide and the target nucleic acid. In some embodiments, the guide nucleic acid can be linked to a recruitment RNA motif, and one or more of the deaminase domain and / or the UGI can be fused with an affinity polypeptide capable of interacting with the recruitment RNA motif, thereby recruiting the deaminase domain and the UGI to the target nucleic acid.
[0266] "Uracil glycosylase inhibitors" useful in the present invention may be any protein capable of inhibiting uracil-DNA glycosylase base excision repair enzymes. In some embodiments, the UGI domain comprises a wild-type UGI or a fragment thereof. In some embodiments, the UGI domain useful in the present invention may be about 70% to about 100% identical to the amino acid sequence of a naturally occurring UGI domain (e.g., 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5% or 100% identical and any range or value therein). In some embodiments, the UGI domain may comprise the amino acid sequence of SEQ ID NO:41, or a polypeptide having about 70% to about 99.5% identity to the amino acid sequence of SEQ ID NO:41 (e.g., at least 80%, at least 85%, at least 90%, at least 92%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% identical to the amino acid sequence of SEQ ID NO:41). For example, in some embodiments, the UGI domain can comprise a fragment of the amino acid sequence of SEQ ID NO:41 that is 100% identical to a portion of consecutive nucleotides (e.g., 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80 consecutive nucleotides; e.g., about 10, 15, 20, 25, 30, 35, 40, 45 to about 50, 55, 60, 65, 70, 75, 80 consecutive nucleotides) of the amino acid sequence of SEQ ID NO:41. In some embodiments, the UGI domain can be a variant of a known UGI (e.g., SEQ ID NO: 41) having about 70% to about 99.5% sequence identity (e.g., 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5% sequence identity, and any ranges or values therein) to the known UGI. In some embodiments, the polynucleotide encoding the UGI can be codon-optimized for expression in a plant (e.g., a plant), and the codon-optimized polypeptide can be about 70% to about 99.5% identical to the reference polynucleotide.
[0267] Adenine deaminase (or adenosine deaminase) useful in the present invention can be any known or later identified adenine deaminase from any organism (see, e.g., U.S. Pat. No. 10,113,163, the disclosure of which is incorporated herein by reference for its adenine deaminase). Adenine deaminase can catalyze the hydrolytic deamination of adenine or adenosine. In some embodiments, adenine deaminase can catalyze the hydrolytic deamination of adenosine or deoxyadenosine to inosine or deoxyinosine, respectively. In some embodiments, adenosine deaminase can catalyze the hydrolytic deamination of adenine or adenosine in DNA. In some embodiments, adenine deaminase encoded by a nucleic acid construct of the present invention can produce an A→G conversion in the sense strand (e.g., "+"; template) of a target nucleic acid or a T→C conversion in the antisense strand (e.g., "-", complementary) of a target nucleic acid.
[0268] In some embodiments, adenosine deaminase can be a variant of a naturally occurring adenine deaminase. Thus, in some embodiments, adenosine deaminase can be about 70% to 100% identical to wild-type adenine deaminase (e.g., about 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to a naturally occurring adenine deaminase, and any range or value therein). In some embodiments, one or more deaminases do not exist in nature and can be referred to as engineered, mutated or evolved adenosine deaminase. Thus, for example, an engineered, mutated or evolved adenine deaminase polypeptide or adenine deaminase domain can be about 70% to 99.9% identical to a naturally occurring adenine deaminase polypeptide / domain (e.g., about 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, or 99.9% identical to a naturally occurring adenine deaminase polypeptide or adenine deaminase domain, and any ranges or values therein). In some embodiments, the adenosine deaminase can be from a bacterium (e.g., Escherichia coli ( Escherichia coli ), Staphylococcus aureus ( Staphylococcus aureus )、Haemophilus influenzae( Haemophilus influenzae )、Caulobacter crescentus( Caulobacter crescentus In some embodiments, the polynucleotide encoding the adenine deaminase polypeptide / domain may be codon optimized for expression in plants.
[0269] In some embodiments, the adenine deaminase domain can be a wild-type tRNA-specific adenosine deaminase domain, such as a tRNA-specific adenosine deaminase (TadA) and / or a mutant / evolved adenosine deaminase domain, such as a mutant / evolved tRNA-specific adenosine deaminase domain (TadA*). In some embodiments, the TadA domain can be from Escherichia coli ( E. coli In some embodiments, TadA can be modified, such as truncated, to delete one or more N-terminal and / or C-terminal amino acids relative to full-length TadA (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 6, 17, 18, 19, or 20 N-terminal and / or C-terminal amino acid residues may be deleted relative to full-length TadA. In some embodiments, the TadA polypeptide or TadA domain does not include an N-terminal methionine. In some embodiments, wild-type E. coli TadA comprises the amino acid sequence of SEQ ID NO: 30. In some embodiments, the mutant / evolved E. coli TadA* comprises the amino acid sequence of SEQ ID NOs: 31-40 (e.g., SEQ ID NOs: 31, 32, 33, 34, 35, 36, 37, 38, 39, or 40). In some embodiments, the polynucleotide encoding TadA / TadA* can be codon-optimized for expression in plants.
[0270] Cytosine deaminase catalyzes the deamination of cytosine and produces thymidine (via a uracil intermediate), resulting in a C to T transition or a G to A transition in the complementary strand in the genome. Thus, in some embodiments, the cytosine deaminase encoded by the polynucleotides of the invention produces a C→T transition in the sense strand (e.g., "+"; template) of a target nucleic acid or a G→A transition in the antisense strand (e.g., "-", complementary) of a target nucleic acid.
[0271] In some embodiments, an adenine deaminase encoded by a nucleic acid construct of the invention produces an A→G transition in the sense strand (eg, "+"; template) of a target nucleic acid or a T→C transition in the antisense strand (eg, "-", complementary) of a target nucleic acid.
[0272] The nucleic acid construct encoding the base editor comprising a sequence-specific nucleic acid binding protein and a cytosine deaminase polypeptide of the present invention, and the nucleic acid construct / expression cassette / vector encoding the same, can be used in combination with a guide nucleic acid to modify the target nucleic acid, including but not limited to generating C→T or G→A mutations in the target nucleic acid (including but not limited to plasmid sequences); generating C→T or G→A mutations in the coding sequence to change the amino acid identity; generating C→T or G→A mutations in the coding sequence to generate a stop codon; generating C→T or G→A mutations in the coding sequence to destroy the start codon; generating point mutations in genomic DNA to destroy function; and / or generating point mutations in genomic DNA to destroy splice junctions.
[0273] The nucleic acid construct encoding the base editor comprising a sequence-specific nucleic acid binding protein and an adenine deaminase polypeptide of the present invention, and the expression cassette and / or vector encoding the same, can be used in combination with a guide nucleic acid for modifying a target nucleic acid, including but not limited to generating an A→G or T→C mutation in a target nucleic acid (including but not limited to a plasmid sequence); generating an A→G or T→C mutation in a coding sequence to change the amino acid identity; generating an A→G or T→C mutation in a coding sequence to generate a stop codon; generating an A→G or T→C mutation in a coding sequence to destroy a start codon; generating a point mutation in genomic DNA to destroy function; and / or generating a point mutation in genomic DNA to destroy a splice junction.
[0274] The nucleic acid constructs of the present invention comprising a CRISPR-Cas effector protein or a fusion protein thereof can be used in combination with a guide RNA (gRNA, CRISPR array, CRISPR RNA, crRNA) designed to function with the encoded CRISPR-Cas effector protein or domain to modify the target nucleic acid. The guide nucleic acid useful in the present invention comprises at least one spacer sequence and at least one repeat sequence. The guide nucleic acid is capable of forming a complex with the CRISPR-Cas nuclease domain encoded and expressed by the nucleic acid construct of the present invention, and the spacer sequence is capable of hybridizing with the target nucleic acid, thereby guiding the complex (e.g., CRISPR-Cas effector fusion protein (e.g., CRISPR-Cas effector domain fused to a deaminase domain and / or CRISPR-Cas effector domain fused to a peptide tag or affinity polypeptide to recruit a deaminase domain and optionally a UGI) to the target nucleic acid, wherein the target nucleic acid can be modified (e.g., cut or edited) or regulated (e.g., regulated transcription) by the deaminase domain.
[0275] As an example, a nucleic acid construct encoding a Cas9 domain (e.g., a fusion protein) connected to a cytosine deaminase domain can be used in combination with a Cas9 guide nucleic acid to modify a target nucleic acid, wherein the cytosine deaminase domain of the fusion protein deaminates cytosine bases in the target nucleic acid, thereby editing the target nucleic acid. In another example, a nucleic acid construct encoding a Cas9 domain (e.g., a fusion protein) connected to an adenine deaminase domain can be used in combination with a Cas9 guide nucleic acid to modify a target nucleic acid, wherein the adenine deaminase domain of the fusion protein deaminates adenosine bases in the target nucleic acid, thereby editing the target nucleic acid.
[0276] Similarly, encoding a Cas12a domain (or other selected CRISPR-Cas nucleases, such as C2c1, C2c3, Cas12b, Cas12c, Cas12d, Cas12e, Cas13a, Cas13b, Cas13c, Cas13d, Cas1, Cas1B, Cas2, Cas3, Cas3', Cas3", Cas4, Cas5, Cas6, Cas7, Cas8, Cas9 (also known as Csn1 and Csx12), Cas10, Csyl, Csy2, Csy3, Csel, Cse2, Cscl, Csc2, Csa5, Cs In some embodiments, the present invention relates to a CRISPR-Cas9 nuclease or a Cas12a guide nucleic acid. In some embodiments, the Csp12a guide nucleic acid is a Cas12a guide nucleic acid. In some embodiments, the Csp12a guide nucleic acid is a Cas12a guide nucleic acid. In some embodiments, the Csp12a guide nucleic acid is a Cas12a guide nucleic acid. In some embodiments, the Csp12a guide nucleic acid is a Cas12a guide nucleic acid. In some embodiments, the Csp12a guide nucleic acid is a Cas12a guide nucleic acid.
[0277] As used herein, “guide nucleic acid,” “guide RNA,” “gRNA,” “CRISPR RNA / DNA,” “crRNA,” or “crDNA” refers to a sequence comprising at least one spacer sequence complementary to (and hybridizing with) a target DNA (e.g., a protospacer) and at least one repeat sequence (e.g., a repeat sequence of a type V Cas12a CRISPR-Cas system, or a fragment or portion thereof; a repeat sequence of a type II Cas9 CRISPR-Cas system, or a fragment thereof; a type V C2c1 CRISPR Repeat sequences of the Cas system, or fragments thereof; for example, C2c3, Cas12a (also known as Cpf1), Cas12b, Cas12c, Cas12d, Cas12e, Cas13a, Cas13b, Cas13c, Cas13d, Cas1, Cas1B, Cas2, Cas3, Cas3', Cas3", Cas4, Cas5, Cas6, Cas7, Cas8, Cas9 (also known as Csn1 and Csx12), Cas10, Csyl, Csy2, Csy3, Csel, Cse2, Cscl, Csc2, Csa5, Csn2, Csm2, Csm3, C The gRNA of the present invention can be designed based on a type I, type II, type III, type IV, type V or type VI CRISPR-Cas system.
[0278] In some embodiments, the Cas12a gRNA can comprise a repeat sequence (full length or a portion thereof ("handle"); e.g., a pseudoknot-like structure) and a spacer sequence from 5' to 3'.
[0279] In some embodiments, the guide nucleic acid can include more than one repeat-spacer (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10 or more repeat-spacers) (e.g., repeat-spacer-repeat, e.g., repeat-spacer-repeat-spacer-repeat-spacer-repeat-spacer-repeat-spacer, etc.). The guide nucleic acids of the present invention are synthetic, artificial, and do not exist in nature. The gRNA can be very long and can be used as an aptamer (e.g., in the MS2 recruitment strategy) or other RNA structures hanging off the spacer.
[0280] As used herein, "repetitive sequence" refers to, for example, any repetitive sequence of a wild-type CRISPR Cas locus (e.g., Cas9 locus, Cas12a locus, C2c1 locus, etc.) or a repetitive sequence of a synthetic crRNA that works with a CRISPR-Cas effector protein encoded by a nucleic acid construct of the present invention. The repetitive sequence that can be used in the present invention can be any known or later identified repetitive sequence of a CRISPR-Cas locus (e.g., type I, type II, type III, type IV, type V, or type VI), or it can be a synthetic repetitive sequence designed to work in a type I, II, III, IV, V, or VI CRISPR-Cas system. The repetitive sequence may include a hairpin structure and / or a stem-loop structure. In some embodiments, the repetitive sequence may form a pseudoknot-like structure (i.e., "handle") at its 5' end. Thus, in some embodiments, the repetitive sequence can be identical or substantially identical to a repetitive sequence from a wild-type type I, CRISPR-Cas locus, type II CRISPR-Cas locus, type III CRISPR-Cas locus, type IV CRISPR-Cas locus, type V CRISPR-Cas locus, and / or type VI CRISPR-Cas locus. Repetitive sequences from a wild-type CRISPR-Cas locus can be determined by established algorithms, such as using CRISPRfinder provided by CRISPRdb (see Grissa et al. Nucleic Acids Res. 35 (Web Server issue): W52-7). In some embodiments, the repeat sequence or a portion thereof is linked at its 3' end to the 5' end of the spacer sequence, thereby forming a repeat sequence-spacer sequence sequence (e.g., guide nucleic acid, guide RNA / DNA, crRNA, crDNA).
[0281] In some embodiments, the repetitive sequence comprises, consists essentially of, or consists of at least 10 nucleotides, depending on the particular repetitive sequence and whether the guide nucleic acid comprising the repetitive sequence is processed or unprocessed (e.g., about 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50 to 100 or more nucleotides, or any range or value therein). In some embodiments, the repetitive sequence comprises, consists essentially of, or consists of about 10 to about 20, about 10 to about 30, about 10 to about 45, about 10 to about 50, about 15 to about 30, about 15 to about 40, about 15 to about 45, about 15 to about 50, about 20 to about 30, about 20 to about 40, about 20 to about 50, about 30 to about 40, about 40 to about 80, about 50 to about 100, or more nucleotides.
[0282] The repeat sequence linked to the 5' end of the spacer sequence can include a portion of the repeat sequence (e.g., 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 or more consecutive nucleotides of the wild-type repeat sequence). In some embodiments, the portion of the repeat sequence linked to the 5' end of the spacer sequence can be about 5 to about 10 contiguous nucleotides in length (e.g., about 5, 6, 7, 8, 9, 10 nucleotides) and have at least 90% sequence identity (e.g., at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more (e.g., 99.1, 99.2, 99.3, 99.4, 99.5, 99.6, 99.7, 99.8, 99.9 or 100%) to the same region (e.g., 5' end) of a wild-type CRISPR Cas repeat nucleotide sequence. In some embodiments, a portion of the repeat sequence can include a pseudoknot-like structure (e.g., a "handle") at its 5' end.
[0283] As used herein, a "spacer sequence" is a nucleotide sequence (e.g., a pre-spacer sequence) that is complementary to a target nucleic acid (e.g., a target DNA) (e.g., a portion of consecutive nucleotides that (a) has at least 80% sequence identity with any one of SEQ ID NOs: 69, 70, 80, or 81, or SEQ ID NOs: 73-79, or 83-95; and / or (b) encodes an amino acid sequence that has at least 80% sequence identity with any one of SEQ ID NOs: 71, 72, or 82). In some embodiments, the spacer sequence (e.g., one or more spacers) may include, but is not limited to, the nucleotide sequence of any one of SEQ ID NOs: 96-100. The spacer sequence can be fully complementary or substantially complementary to the target nucleic acid (e.g., at least about 70% complementary (e.g., about 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more (e.g., 99.1, 99.2, 99.3, 99.4, 99.5, 99.6, 99.7, 99.8, 99.9 or 100%)). Thus, in some embodiments, the spacer sequence can have one, two, three, four or five mismatches compared to the target nucleic acid, which can be continuous or discontinuous. In some embodiments, the spacer sequence can have 70% complementarity with the target nucleic acid. In other embodiments, the spacer nucleotide sequence can have In some embodiments, the spacer sequence is complementary to the target nucleic acid (forespacer). In some embodiments, the spacer sequence is complementary to the target nucleic acid (forespacer). In some embodiments, the spacer sequence is complementary to the target nucleic acid (forespacer). The spacer sequence can have a length of about 15 nucleotides to about 30 nucleotides (for example, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30 nucleotides or any range or value therein). Therefore, in some embodiments, the spacer sequence can have complete complementarity or basic complementarity in the region of the target nucleic acid (for example, forespacer) of at least about 15 nucleotides to about 30 nucleotides in length. In some embodiments, the length of the spacer is about 20 nucleotides. In some embodiments, the length of the spacer is about 21, 22 or 23 nucleotides.
[0284] In some embodiments, the 5' region of the spacer sequence of the guide nucleic acid can be identical to the target DNA, while the 3' region of the spacer region can be substantially complementary to the target DNA (e.g., for type V CRISPR-Cas), or the 3' region of the spacer sequence of the guide nucleic acid can be identical to the target DNA, while the 5' region of the spacer region can be substantially complementary to the target DNA (e.g., for type II CRISPR-Cas), and thus, the overall complementarity of the spacer sequence to the target DNA may be less than 100%. Thus, for example, in a guide of a type V CRISPR-Cas system, the first 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 nucleotides in the 5' region (i.e., the seed region) of, for example, a 20-nucleotide spacer sequence can be 100% complementary to the target DNA, while the remaining nucleotides in the 3' region of the spacer sequence are substantially complementary to the target DNA (e.g., at least about 70% complementary). In some embodiments, the first 1 to 8 nucleotides (e.g., the first 1, 2, 3, 4, 5, 6, 7, 8 nucleotides, and any range therein) of the 5' end of the spacer sequence can be 100% complementary to the target DNA, while the remaining nucleotides in the 3' region of the spacer sequence are substantially complementary to the target DNA (e.g., at least about 50% complementary (e.g., 50%, 55%, 60%, 65%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more)).
[0285] As another example, in a guide for a type II CRISPR-Cas system, the first 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 nucleotides in the 3' region (i.e., the seed region) of, for example, a 20-nucleotide spacer sequence can be 100% complementary to the target DNA, while the remaining nucleotides in the 5' region of the spacer sequence are substantially complementary to the target DNA (e.g., at least about 70% complementary). In some embodiments, the first 1 to 10 nucleotides (e.g., the first 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 nucleotides, and any ranges therein) of the 3' end of the spacer sequence can be 100% complementary to the target DNA, while the remaining nucleotides of the 5' region of the spacer sequence are substantially complementary to the target DNA (e.g., at least about 50% complementary (e.g., at least about 50%, 55%, 60%, 65%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more or any range or value therein)).
[0286] In some embodiments, the seed region of the spacer can be about 8 to about 10 nucleotides in length, about 5 to about 6 nucleotides in length, or about 6 nucleotides in length.
[0287] As used herein, "target nucleic acid", "target DNA", "target nucleotide sequence", "target region" or "target region in a genome" refers to a region in a plant genome that is completely complementary (100% complementary) or substantially complementary (e.g., at least 70% complementary (e.g., 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more)) to a spacer sequence in a guide nucleic acid of the invention. The target region that can be used for a CRISPR-Cas system can be positioned immediately 3' (e.g., a type V CRISPR-Cas system) or immediately 5' (e.g., a type II CRISPR-Cas system) to a PAM sequence in the genome of an organism (e.g., a plant genome). The target region can be selected from any region of at least 15 consecutive nucleotides (e.g., 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 nucleotides, etc.) located immediately adjacent to the PAM sequence.
[0288] "Pre-spacer" refers to a target double-stranded DNA, and in particular refers to a portion of a target DNA (e.g., or a target region in a genome) that is completely or substantially complementary (and hybridizes) to a CRISPR repeat-spacer sequence (e.g., a guide nucleic acid, a CRISPR array, a crRNA).
[0289] In the case of type V CRISPR-Cas (e.g., Cas12a) systems and type II CRISPR-Cas (Cas9) systems, the protospacer sequence is flanked by (e.g., immediately adjacent to) a protospacer adjacent motif (PAM). For type IV CRISPR-Cas systems, the PAM is located at the 5' end of the non-target strand and the 3' end of the target strand (see below, as an example).
[0290]
[0291] In the case of type II CRISPR-Cas (e.g., Cas9) systems, the PAM is positioned immediately 3' to the target region. The PAM for type I CRISPR-Cas systems is located 5' to the target strand. There are no known PAMs for type III CRISPR-Cas systems. The nomenclature for all classes, types, and subtypes of CRISPR systems is described by Makarova et al. ( Nature Reviews Microbiology 13:722–736 (2015)). R. Barrangou ( Genome Biol . 16:247 (2015)) describes the guide structure and PAM.
[0292] Typical Cas12a PAMs are T-rich. In some embodiments, typical Cas12a PAM sequences can be 5'-TTN, 5'-TTTN, or 5'-TTTV. In some embodiments, typical Cas9 (e.g., Streptococcus pyogenes) PAMs can be 5'-NGG-3'. In some embodiments, atypical PAMs can be used, but the efficiency may be lower.
[0293] Those skilled in the art can determine additional PAM sequences by established experimental and computational methods. Thus, for example, experimental methods include targeting sequences that flank all possible nucleotide sequences and identifying sequence members that do not undergo targeting, such as by transformation of target plasmid DNA (Esvelt et al. 2013. Nat. Methods 10:1116-1121; Jiang et al. 2013. Nat. Biotechnol. 31:233-239). In some aspects, the computational method can include performing a BLAST search on the natural spacer to identify the original target DNA sequence in the phage or plasmid, and aligning these sequences to determine conserved sequences adjacent to the target sequence (Briner and Barrangou. 2014. Appl. Environ. Microbiol. 80:994-1001; Mojica et al. 2009. Microbiology 155:733-740).
[0294] In some embodiments, the present invention provides expression cassettes and / or vectors comprising nucleic acid constructs of the present invention (e.g., one or more components of the editing system of the present invention). In some embodiments, expression cassettes and / or vectors comprising nucleic acid constructs of the present invention and / or one or more guide nucleic acids may be provided. In some embodiments, nucleic acid constructs of the present invention encoding base editors (e.g., constructs (e.g., fusion proteins) comprising CRISPR-Cas effector proteins and deaminase domains) or components for base editing (e.g., CRISPR-Cas effector proteins fused to peptide tags or affinity polypeptides, deaminase domains fused to peptide tags or affinity polypeptides, and / or UGI fused to peptide tags or affinity polypeptides) may be included on the same expression cassette or vector or on an expression cassette or vector separate from an expression cassette or vector comprising one or more guide nucleic acids. When the nucleic acid construct encoding a base editor or a component for base editing is contained on an expression cassette or vector different from the expression cassette or vector comprising the guide nucleic acid, the target nucleic acid can be contacted with (e.g., provided together with) the expression cassette or vector encoding the base editor or the component for base editing and the guide nucleic acid in any order, for example, provided before, simultaneously with, or after the expression cassette comprising the guide nucleic acid (e.g., contacted with the target nucleic acid).
[0295] The fusion protein of the present invention may comprise a sequence-specific nucleic acid binding domain (sequence-specific DNA binding domain), a CRISPR-Cas polypeptide and / or a deaminase domain fused to a peptide tag as known in the art or an affinity polypeptide that interacts with a peptide tag, for recruiting deaminase to a target nucleic acid. The recruitment method may also include a guide nucleic acid connected to an RNA recruitment motif and a deaminase fused to an affinity polypeptide that can interact with an RNA recruitment motif, thereby recruiting the deaminase to the target nucleic acid. Alternatively, chemical interactions may be used to recruit polypeptides (e.g., deaminase) to a target nucleic acid.
[0296] Peptide tags (e.g., epitopes) that can be used in the present invention may include, but are not limited to, GCN4 peptide tags (e.g., Sun-Tag), c-Myc affinity tags, HA affinity tags, His affinity tags, S affinity tags, methionine-His affinity tags, RGD-His affinity tags, FLAG octapeptides, strep tags or strep tags II, V5 tags, and / or VSV-G epitopes. Any epitope that can be linked to a polypeptide and has a corresponding affinity polypeptide that can be linked to another polypeptide can be used in the present invention as a peptide tag. In some embodiments, the peptide tag may comprise 1 or 2 or more copies of a peptide tag (e.g., repeating units, multimerization sites (e.g., tandem repeats)) (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25 or more repeating units). In some embodiments, the affinity polypeptide that interacts / binds with the peptide tag may be an antibody. In some embodiments, the antibody can be a scFv antibody. In some embodiments, the affinity polypeptide bound to the peptide tag can be synthetic (e.g., evolved for affinity interactions), including, but not limited to, an affibody, anticalin, monobody and / or DARPin (see, e.g., Sha et al., Protein Sci. 26(5):910-924(2017)); Gilbreth ( Curr Opin Struc Biol 22(4):413-420 (2013)), U.S. Patent No. 9,982,053, each of which is incorporated herein by reference in its entirety for its teachings regarding affibodies, anticalins, monobodies and / or DARPins. Exemplary peptide tag sequences and affinity polypeptides thereof include, but are not limited to, the amino acid sequences of SEQ ID NOs: 42-44.
[0297] In some embodiments, the guide nucleic acid can be linked to an RNA recruitment motif, and the polypeptide to be recruited (e.g., a deaminase) can be fused to an affinity polypeptide that binds to the RNA recruitment motif, wherein the guide binds to the target nucleic acid and the RNA recruitment motif binds to the affinity polypeptide, thereby recruiting the polypeptide to the guide and contacting the target nucleic acid with the polypeptide (e.g., a deaminase). In some embodiments, two or more polypeptides can be recruited to the guide nucleic acid, thereby contacting the target nucleic acid with two or more polypeptides (e.g., a deaminase). Exemplary RNA recruitment motifs and affinity polypeptides thereof include, but are not limited to, sequences of SEQ ID NOs: 45-55.
[0298] In some embodiments, the polypeptide fused to the affinity polypeptide can be a reverse transcriptase and the guide nucleic acid can be an extended guide nucleic acid connected to an RNA recruitment motif. In some embodiments, the RNA recruitment motif can be located at the 3' end of the extended portion of the extended guide nucleic acid (e.g., 5'-3', repeat sequence-spacer-extension portion (RT template-primer binding site)-RNA recruitment motif). In some embodiments, the RNA recruitment motif can be embedded in the extension portion.
[0299] In some embodiments of the invention, the extended guide RNA and / or guide RNA can be linked to one or two or more RNA recruitment motifs (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more motifs; e.g., at least 10 to about 25 motifs), optionally wherein the two or more RNA recruitment motifs can be the same RNA recruitment motif or different RNA recruitment motifs. In some embodiments, the RNA recruitment motif and the corresponding affinity polypeptide may include, but are not limited to, the telomerase Ku binding motif (e.g., Ku binding hairpin) and the corresponding affinity polypeptide Ku (e.g., Ku heterodimer), the telomerase Sm7 binding motif and the corresponding affinity polypeptide Sm7, the MS2 phage operator stem loop and the corresponding affinity polypeptide MS2 coat protein (MCP), the PP7 phage operator stem loop and the corresponding affinity polypeptide PP7 coat protein (PCP), the SfMu phage Com stem loop and the corresponding affinity polypeptide Com RNA binding protein, the PUF binding site (PBS) and the affinity polypeptide Pumilio / fem-3 mRNA binding factor (PUF), and / or a synthetic RNA aptamer and an aptamer ligand as the corresponding affinity polypeptide. In some embodiments, the RNA recruitment motif and the corresponding affinity polypeptide may be the MS2 phage operator stem loop and the affinity polypeptide MS2 coat protein (MCP). In some embodiments, the RNA recruitment motif and the corresponding affinity polypeptide can be a PUF binding site (PBS) and an affinity polypeptide Pumilio / fem-3m RNA binding factor (PUF).
[0300] In some embodiments, the components used to recruit polypeptides and nucleic acids can be those that function through chemical interactions, which can include, but are not limited to, rapamycin-induced FRB-FKBP dimerization; biotin-streptavidin; SNAP tag; Halo tag; CLIP tag; compound-induced DmrA-DmrC heterodimer; bifunctional ligand (e.g., a fusion of two proteins that bind to a chemical substance; such as dihydrofolate reductase (DHFR).
[0301] In some embodiments, a nucleic acid construct, expression cassette, or vector of the invention optimized for expression in a plant can be about 70% to 100% identical (e.g., about 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, or 100%) to a nucleic acid construct, expression cassette, or vector comprising the same polynucleotide but that has not been codon optimized for expression in a plant.
[0302] Also provided herein are cells comprising one or more polynucleotides, guide nucleic acids, nucleic acid constructs, expression cassettes or vectors of the invention.
[0303] The nucleic acid constructs of the present invention (e.g., constructs comprising a sequence-specific DNA binding domain, a CRISPR-Cas effector domain, a deaminase domain, a reverse transcriptase (RT), an RT template and / or a guide nucleic acid, etc.) and expression cassettes / vectors comprising them can be used as the editing system of the present invention for modifying a target nucleic acid and / or its expression.
[0304] The target nucleic acid of any plant or plant part (or plant grouping, such as a genus or higher classification) can be modified (e.g., mutated, such as base editing, cutting, incision, etc.) using the polypeptides, polynucleotides, ribonucleoproteins (RNPs), nucleic acid constructs, expression cassettes and / or vectors of the present invention, including angiosperms, gymnosperms, monocots, dicots, C3, C4, CAM plants, mosses, ferns and / or pseudoferns, microalgae and / or macroalgae. The plants and / or plant parts that can be modified as described herein can be plants and / or plant parts of any plant species / variety / cultivar. In some embodiments, the plants that can be modified as described herein are monocots. In some embodiments, the plants that can be modified as described herein are dicots.
[0305] As used herein, the term "plant part" includes, but is not limited to, reproductive tissues (e.g., petals, sepals, stamens, pistils, receptacles, anthers, pollen, flowers, fruits, buds, ovules, seeds, embryos, nuts, kernels, spikes, cobs, and shells); vegetative tissues (e.g., petioles, stems, roots, root hairs, root tips, pith, coleoptiles, stems, buds, branches, bark, apical meristems, axillary buds, cotyledons, hypocotyls, and leaves); vascular tissues (e.g., phloem and xylem); specialized cells, such as epidermal cells, parenchyma cells, collenchyma cells, stomata, guard cells, cuticles, mesophyll cells; callus; and cuttings. The term "plant part" also includes plant cells, including intact plant cells in plants and / or plant parts, plant protoplasts, plant tissues, plant organs, plant cell tissue cultures, plant callus, plant clumps, and the like. As used herein, "shoots" refer to aerial parts, including leaves and stems. As used herein, the term "tissue culture" includes cultures of tissues, cells, protoplasts and callus.
[0306] As used herein, "plant cell" refers to the structural and physiological unit of a plant, which generally includes a cell wall, but also includes a protoplast. The plant cell of the present invention can be in the form of an isolated unicellular cell, or can be a cultured cell, or can be a part of a higher organizational unit such as a plant tissue (including callus) or a plant organ. In some embodiments, the plant cell can be an algae cell. "Protoplast" is a plant cell that does not have a cell wall or only has a partial cell wall. Therefore, in some embodiments of the present invention, the transgenic cell comprising the nucleic acid molecule of the present invention and / or the nucleotide sequence is a cell of any plant or plant part, including but not limited to root cells, leaf cells, tissue culture cells, seed cells, flower cells, fruit cells, pollen cells, etc. In some aspects of the present invention, a plant part can be a plant germplasm. In some aspects, a plant cell can be a non-breeding plant cell that no longer generates a plant.
[0307] "Plant cell culture" refers to a culture of plant units such as protoplasts, cell culture cells, cells in plant tissue, pollen, pollen tubes, ovules, embryo sacs, zygotes, and embryos at various stages of development.
[0308] As used herein, a "plant organ" is a distinct and clearly structured and differentiated part of a plant, such as a root, stem, leaf, flower bud, or embryo.
[0309] As used herein, "plant tissue" refers to a group of plant cells organized into a structural and functional unit. in planta ) or any plant tissue in culture. The term includes, but is not limited to, whole plants, plant organs, plant seeds, tissue cultures, and any group of plant cells organized into structural and / or functional units. The term, when used with or without any specific type of plant tissue listed above or included in this definition, is not intended to exclude any other type of plant tissue.
[0310] In some embodiments of the invention, transgenic tissue cultures or transgenic plant cell cultures are provided, wherein the transgenic tissue or cell culture comprises the nucleic acid molecules / nucleotide sequences of the invention. In some embodiments, the transgenic can be eliminated from a plant developed from a transgenic tissue or cell by breeding the transgenic plant with a non-transgenic plant and selecting in the offspring a plant that comprises the desired gene edit but not the transgene used to generate the edit.
[0311] Any plant containing an endogenous brassinosteroid insensitive-1 (BRI1) gene can be modified as described herein to improve one or more yield traits. Non-limiting examples of plants that can be modified as described herein can include, but are not limited to, turfgrasses (e.g., bluegrass, bentgrass, ryegrass, fescue), feather grass, tufted hairgrass, miscanthus, reed, switchgrass, vegetable crops, including artichokes, kohlrabi, rocket, leeks, asparagus, lettuce (e.g., head cabbage, leafy greens, romaine lettuce), yellow taro, melons (e.g., musk melon, watermelon, Crenshaw melon, honeydew melon, cantaloupe), Brassica crops (e.g., Brussels sprouts, cabbage, cauliflower, broccoli, kale, collard greens, Chinese cabbage, bok choy), cardoon, carrot, napa cabbage, okra, onion, celery, parsley, chickpeas, parsnips, endive, peppers, potatoes, cucurbits (e.g., baby gourds, cucumbers, zucchini, pumpkin, honeydew melon, watermelon, cantaloupe), radishes, stem onions, rutabaga, eggplant, salsify, chicory, shallots , endive, garlic, spinach, green onions, pumpkin, leafy greens, beets (sugar beets and fodder beets), sweet potatoes, juncea, horseradish, tomatoes, carrots and spices; fruit crops such as apples, apricots, cherries, nectarines, peaches, pears, plums, prunes, cherries, quinces, figs, nuts (such as chestnuts, pecans, pistachios, hazelnuts, pistachios, peanuts, walnuts, macadamia nuts, almonds, etc.), citrus (such as clementines, golden oranges, tangerines, oranges, grapefruits, tangerines, mandarins, lemons, limes, etc.), blueberries, black raspberries, boysenberries, cranberries, currants, gooseberries, loganberries, raspberries, strawberries, blackberries, grapes (wine and table), avocados, bananas, kiwis, persimmons, pomegranates, pineapples, tropical fruits, pomeloes, cantaloupe, mangoes, papayas and lychees, field crops such as clover, alfalfa, timothy, evening primrose, meadowfoam (meadowfoam), foam), corn / maize (field corn, sweet corn, popcorn), hops, jojoba, buckwheat, safflower, quinoa, wheat, rice, barley, rye, millet, sorghum, oats, triticale, sorghum, tobacco, kapok, legumes (beans (e.g., green and dry), lentils, peas, soybeans), oil plants (rape, canola, mustard, poppy, olive, sunflower, coconut, castor oil plant, cocoa bean, peanut, oil palm), duckweed, Arabidopsis, fiber plants (cotton, flax, hemp, jute), Cannabis (e.g. Cannabis sativa , Cannabis indica and Cannabis ruderalis ), Lauraceae (cinnamon, camphor) or plants such as coffee, sugar cane, tea and natural rubber plants; and / or flower bed plants, such as flowering plants, cacti, succulent plants and / or ornamental plants (e.g., roses, tulips, violets), and trees, such as forest trees (broad-leaved and evergreen trees, such as conifers; for example, elm, ash, oak, maple, fir, spruce, cedar, pine, birch, cypress, eucalyptus, willow) and shrubs and other nursery stock. In some embodiments, the nucleic acid constructs of the invention and / or expression cassettes and / or vectors encoding the same can be used to modify corn, soybean, wheat, rapeseed, rice, tomato, pepper or sunflower.
[0312] In some embodiments, plants that can be modified as described herein can include, but are not limited to, soybean, canola, corn, wheat, rice, cotton, sugarcane, sugar beet, barley, oats, alfalfa, sunflower, safflower, oil palm, sesame, coconut, tobacco, potato, sweet potato, cassava, coffee, apple, plum, apricot, peach, cherry, pear, fig, banana, citrus, cocoa, avocado, olive, almond, walnut, strawberry, watermelon, pepper, grape, tomato, cucumber, or a Brassica species (e.g., Brassica napus ( B. napus )、Cabbage( B. oleracea ),turnip( B. rapa ),mustard( B. juncea ) and / or black mustard ( B. nigra )). In some embodiments, the plant that can be modified as described herein is a dicot. In some embodiments, the plant that can be modified as described herein is soybean (i.e., Glycine max ).
[0313] The present invention will now be described with reference to the following examples. It should be understood that these embodiments are not intended to limit the scope of the claims to the present invention, but are intended to be examples of certain embodiments. Any changes to the exemplary methods that occur to those skilled in the art are intended to fall within the scope of the present invention. Example Example 1. Editing strategy
[0314] A strategy was developed to generate edits in the 5' regulatory region of the soybean BRI1 gene of Glyma.06g147600 (SEQ ID NO: 72) and Glyma.04g218300 (SEQ ID NO: 83) to remove or modify the upstream open reading frames (uORF(s)) present in the transcripts of the BRI1 gene. To generate a series of alleles, CRISPR guide nucleic acids containing one or more spacers (SEQ ID NOs: 99-103) with complementarity to targets within the two BRI1 soybean genes were designed and placed into constructs for editing.
[0315] Lines carrying the edit in the BRI1 gene were screened, and those showing the edit in the targeted gene were advanced to the next generation.
[0316] Lines carrying an edit in the BRI1 gene fell into two categories: Genotype 1 contained lines with an edit in the uORF of the soybean gene Glyma.06g147600 (SEQ ID NO: 69), and genotype 2 contained lines with an edit in the uORF of the soybean gene Glyma.04g218300 (SEQ ID NO: 80). Genotype 1 lines included CE160306 (SEQ ID NO: 101, SEQ ID NO: 102), CE160313 (SEQ ID NO: 103, SEQ ID NO: 104), CE160326 (SEQ ID NO: 105), CE160327 (SEQ ID NO: 106, SEQ ID NO: 107), and genotype 2 lines included CE160331 (SEQ ID NO: 108, , SEQ ID NO: 109), CE160334 (SEQ ID NO: 110), CE160349 (SEQ ID NO: 111), CE160355 (SEQ ID NO: 112), CE160374 (SEQ ID NO: 113, SEQ ID NO: 114), CE160392 (SEQ ID NO: 115, SEQ ID NO: 116) and CE160403 (SEQ ID NO: 117). NO: 117). The edited alleles in each of genotype 1 and genotype 2 represent a series of deletions in the uORF region of the targeted gene, which are predicted to remove the "ATG" start site of at least one uORF in the BRI1 gene. Example 2. Phenotypic Assessment
[0317] The E0 plants described in Example 1 were allowed to produce E1 seeds. The E1 seeds were collected and planted, and the resulting E1 plants were evaluated at the R6 growth stage for plant architectural characteristics that may indicate an increase in yield as well as seed number (which is a direct indicator of plant yield). The plant phenotypes measured included plant height (measured in centimeters), the number of nodes on the main stem, the number of branches, the number of pods on the branches, the number of pods on the main stem, the number of pods per node on the main stem, the number of pods per plant, the number of seeds per pod, and the number of seeds per plant. The results are summarized in Tables 2 and 3, indicating that the edits obtained in the BRI1 gene are changing plant structure and may affect plant yield. Table 5 summarizes the results for the genotypes described in Table 4 for individual plant genotypes in which the "ATG" of at least one uORF associated with the target BRI1 gene has been altered.
[0318] Table 2
[0319] Table 3
[0320] Table 4: Genotypes
[0321] Table 5. Mean values of individual genotypes
[0322] The above content is an illustration of the present invention and should not be regarded as a limitation of the present invention. The present invention is defined by the appended claims, and equivalents of the claims are also included.
Claims
1. A plant or plant part thereof comprising at least one mutation in an endogenous brassinosteroid insensitive-1 (BRI1) gene encoding a BRI1 polypeptide (brassinosteroid receptor polypeptide).
2. The plant or part thereof according to claim 1, wherein the at least one mutation disrupts the upstream open reading frame (uORF) of the endogenous BRI1 gene (in a cis-regulatory element, such as in the promoter region).
3. The plant or part thereof of claim 1 or claim 2, wherein the at least one mutation is a base substitution, a base deletion and / or a base insertion.
4. The plant or part thereof according to any one of the preceding claims, wherein the at least one mutation comprises a base substitution to A, T, G or C.
5. The plant or part thereof according to any of the preceding claims, wherein the at least one mutation results in a hypomorphic mutation, a dominant mutation and / or a semi-dominant mutation.
6. The plant or part thereof according to any one of the preceding claims, wherein the at least one mutation is a deletion or insertion of at least one base.
7. The plant or part thereof of any one of the preceding claims, wherein the at least one mutation is a deletion of about 1 base pair to about 250 consecutive base pairs.
8. The plant or part thereof of any one of the preceding claims, wherein the endogenous BRI1 gene comprises a nucleotide sequence having at least 80% (e.g., 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100%) sequence identity to any one of SEQ ID NOs: 73-79 or 83-95.
9. The plant or part thereof of any preceding claim, wherein the endogenous BRI1 gene encodes a BRI1 polypeptide having at least 80% sequence identity to any one of SEQ ID NOs: 71, 72 or 82.
10. The plant or part thereof according to any one of the preceding claims, wherein the at least one mutation is in an upstream open reading frame (uORF) located 5' to the endogenous BRI1 gene.
11. The plant or part thereof of any of the preceding claims, wherein the at least one mutation is located in a region of the endogenous BRI1 gene that is located (a) at about nucleotides 2-213, 42-174, 62-154, 82-134 and / or 92-124, as numbered with reference to nucleotide positions of SEQ ID NO: 69 (e.g., SEQ ID NOs: 73-79), and / or (b) at about nucleotides 1-267, 40-227, 70-195 and / or 100-168, as numbered with reference to nucleotide positions of SEQ ID NO: 80 (e.g., SEQ ID NOs: 83-95).
12. The plant of any one of the preceding claims, or a part thereof, wherein the plant is corn, soybean, rapeseed, wheat, rice, cotton, sugarcane, sugar beet, barley, oat, alfalfa, sunflower, safflower, oil palm, sesame, coconut, tobacco, potato, sweet potato, cassava, coffee, apple, plum, apricot, peach, cherry, pear, fig, banana, citrus, cocoa, avocado, olive, almond, walnut, strawberry, watermelon, pepper, grape, tomato, cucumber, or a Brassica species.
13. The plant or part thereof according to any one of the preceding claims, wherein the plant is soybean.
14. The plant or part thereof of any of the preceding claims, wherein the plant comprising at least one mutation has a phenotype of one or more improved yield traits compared to a plant lacking the at least one mutation (e.g., an isogenic plant (e.g., a wild-type, unedited plant or a null segregant)).
15. The plant or part thereof of claim 14, wherein the one or more improved yield traits comprise higher yield (bushels per acre), increased biomass, increased plant height, increased stem diameter, increased leaf area, increased number of flowers, increased number of pods including increased number of pods per node and / or increased number of pods per plant, increased number of seeds per pod, increased number of seeds, increased seed size and / or increased seed weight (e.g., increase in 100 seed weight), optionally increased number of pods and / or increased number of seeds.
16. The plant or part thereof according to any one of the preceding claims, wherein the at least one mutation is a non-natural mutation.
17. The plant or part thereof according to any one of the preceding claims, wherein the at least one mutation results in a mutated BRI1 gene having at least 90% sequence identity to any one of SEQ ID NOs: 101-117.
18. A plant cell comprising an editing system, the editing system comprising: (a) CRISPR-Cas effector proteins; and (b) A guide nucleic acid comprising a spacer sequence having complementarity to an endogenous target gene encoding a BRI1 polypeptide.
19. The plant cell of claim 18, wherein the endogenous target gene: (a) comprises a nucleotide sequence having at least 80% sequence identity to any one of SEQ ID NOs: 69, 70, 80, or 81, (b) comprises a region having at least 80% sequence identity to any one of SEQ ID NOs: 73-79 or 83-95, or (c) encodes a sequence having at least 80% sequence identity to any one of SEQ ID NOs: 71, 72, or 82.
20. The plant cell of claim 18 or claim 19, wherein the guide nucleic acid comprises the sequence of any one of the nucleotide sequences of SEQ ID NOs: 96-100.
21. The plant cell of any one of claims 18-20, wherein the plant cell is a soybean cell.
22. A plant regenerated from the plant part of any one of claims 1 to 17 or the plant cell of any one of claims 18 to 21.
23. The plant of claim 22, wherein the one or more improved yield traits comprise higher yield (bushels per acre), increased biomass, increased plant height, increased stem diameter, increased leaf area, increased number of flowers, increased number of pods including increased number of pods per node and / or increased number of pods per plant, increased number of seeds per pod, increased number of seeds, increased seed size and / or increased seed weight (e.g., an increase in 100 seed weight).
24. A plant cell comprising at least one mutation within an endogenous brassinosteroid insensitive-1 (BRI1) gene, wherein the at least one mutation is a substitution, insertion, deletion or inversion introduced using an editing system comprising a nucleic acid binding domain that binds to a target site in the endogenous BRI1 gene.
25. The plant cell of claim 24, wherein the at least one mutation is a base deletion or a base substitution.
26. The plant cell of claim 24 or claim 25, wherein the target site in the endogenous BRI1 gene is located within a region located: (a) about nucleotides 2-213, 42-174, 62-154, 82-134 and / or 92-124, as numbered with reference to nucleotide positions of SEQ ID NO: 69 (e.g., SEQ ID NOs: 73-79), and / or (b) about nucleotides 1-267, 40-227, 70-195 and / or 100-168, as numbered with reference to nucleotide positions of SEQ ID NO: 80 (e.g., SEQ ID NOs: 83-95).
27. The plant cell of any one of claims 24-26, wherein the editing system further comprises a nuclease, wherein the nucleic acid binding domain binds to a target site within a nucleic acid sequence having at least 80% sequence identity to a nucleotide sequence of any one of SEQ ID NOs: 69, 70, 80, or 81, or a target site within a nucleic acid sequence having at least 80% sequence identity to a nucleotide sequence of any one of SEQ ID NOs: 73-79 or 83-95, and at least one mutation within the BRI1 gene is generated following cleavage by the nuclease.
28. The plant cell of claim 27, wherein the nuclease is a zinc finger nuclease, a transcription activator-like effector nuclease (TALEN), an endonuclease (e.g., Fok1), or a CRISPR-Cas effector protein.
29. The plant cell of any one of claims 24-28, wherein the nucleic acid binding domain is a zinc finger, a transcription activator-like DNA binding domain (TAL), an argonaute, or a CRISPR-Cas effector nucleic acid binding domain.
30. The plant cell of any one of claims 24-29, wherein the at least one mutation within the endogenous BRI1 gene is an insertion and / or a deletion, optionally wherein the mutation is a modification of an ATG site in the uORF of the endogenous BRI1 gene or a deletion of all or part of the uORF of the endogenous BRI1 gene.
31. The plant cell of any one of claims 24-30, wherein the mutation is a non-natural mutation.
32. The plant cell of any one of claims 24-31, wherein the at least one mutation results in a mutated BRI1 gene having at least 90% sequence identity to the nucleotide sequence of any one of SEQ ID NOs: 101-117.
33. A plant regenerated from the plant cell of any one of claims 24-32, comprising at least one mutation in an endogenous BRI1 gene.
34. The plant of claim 33, wherein the plant exhibits a phenotype of one or more improved yield traits compared to a plant lacking at least one mutation (e.g., an isogenic plant (e.g., a wild-type unedited plant or a null segregant)).
35. The plant of claim 34, wherein the one or more improved yield traits comprise higher yield (bushels per acre), increased biomass, increased plant height, increased stem diameter, increased leaf area, increased number of flowers, increased number of pods including increased number of pods per node and / or increased number of pods per plant, increased number of seeds per pod, increased number of seeds, increased seed size and / or increased seed weight (e.g., an increase in 100 seed weight).
36. A method of producing / growing a transgene-free edited plant, comprising: Crossing the plant of any one of claims 1-17, 22, 23 or 33-35 with a non-transgenic plant, thereby introducing at least one mutation into the non-transgenic plant; and Progeny plants that contain at least one mutation and are free of the transgene are selected, thereby producing transgene-free edited plants.
37. A method of providing a plurality of plants having one or more improved yield traits, the method comprising growing two or more plants of any one of claims 1-17, 22, 23 or 33-35 in a growing area, thereby providing a plurality of plants having one or more improved yield traits compared to a plurality of control plants not comprising at least one mutation.
38. A method of generating a variation in a region of a brassinosteroid insensitive-1 (BRI1) transcript (mRNA), comprising: introducing an editing system into a plant cell, wherein the editing system targets a region of the brassinosteroid insensitive-1 (BRI1) gene encoding a region of a BRI1 polypeptide, and A region of the BRI1 gene is exposed to the editing system, thereby introducing mutations into the BRI1 gene and generating variations in the BRI1 transcripts in plant cells.
39. The method of claim 38, wherein the BRI1 gene comprises a nucleotide sequence having at least 80% sequence identity to any one of SEQ ID NOs: 69, 70, 80, or 81 and / or encodes an amino acid sequence having at least 80% sequence identity to any one of SEQ ID NOs: 71, 72, or 82.
40. The method of claim 38 or claim 39, wherein the region of the BRI1 gene targeted comprises a sequence having at least 80% sequence identity to any one of SEQ ID NOs: 73-79 or 83-95 and / or is located (a) at about nucleotides 2-213, 42-174, 62-154, 82-134 and / or 92-124 numbered with reference to nucleotide positions of SEQ ID NO: 69 (e.g., SEQ ID NOs: 73-79), and / or (b) at about nucleotides 1-267, 40-227, 70-195 and / or 100-168 numbered with reference to nucleotide positions of SEQ ID NO: 80 (e.g., SEQ ID NOs: 83-95).
41. A method for editing a specific site in a plant cell genome, the method comprising: Cleaves a target site in an endogenous brassinosteroid insensitive-1 (BRI1) gene in plant cells in a site-specific manner, wherein the endogenous BRI1 gene: (a) comprising a sequence having at least 80% sequence identity to any one of the nucleotide sequences of SEQ ID NO: 69, 70, 80 or 81, (b) comprises a region having at least 80% sequence identity to any one of the nucleotide sequences of SEQ ID NOs: 73-79 or 83-95, and / or (c) encoding an amino acid sequence having at least 80% sequence identity to any one of SEQ ID NOs: 71, 72 or 82, thereby producing an edit in an endogenous BRI1 gene in a plant cell and producing a plant cell comprising an edit in an endogenous BRI1 gene.
42. The method of claim 41, further comprising regenerating a plant from the plant cell comprising the edit in the endogenous BRI1 gene to produce a plant comprising the edit in the endogenous BRI1 gene.
43. The method of claim 41 or claim 42, wherein the editing results in a non-natural mutation.
44. The method of any one of claims 41-43, wherein the editing results in a mutated BHI1 gene having at least 90% sequence identity to the nucleotide sequence of any one of SEQ ID NOs: 101-117.
45. The method of claims 41-44, wherein the plant comprising an edit in the endogenous BRI1 gene exhibits a phenotype of one or more improved yield traits compared to a plant lacking the at least one mutation (e.g., an isogenic plant (e.g., a wild-type unedited plant or a null isolate)), optionally wherein the one or more improved yield traits include higher yield (bushels per acre), increased biomass, increased plant height, increased stem diameter, increased leaf area, increased number of flowers, increased number of pods including increased number of pods per node and / or increased number of pods per plant, increased number of seeds per pod, increased number of seeds, increased seed size and / or increased seed weight (e.g., an increase in 100 seed weight) compared to a control plant lacking the at least one mutation.
46. A method for preparing a plant, comprising: (a) contacting a population of plant cells comprising an endogenous brassinosteroid insensitive-1 (BRI1) gene with a nuclease linked to a nucleic acid binding domain (e.g., an editing system) that binds a sequence that: (i) has at least 80% (e.g., 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100%) sequence identity to the nucleotide sequence of any one of SEQ ID NOs: 69, 70, 80, or 81, (ii) encodes an amino acid sequence that has at least 80% sequence identity to any one of SEQ ID NOs: 71, 72, or 82, and / or (iii) comprises a region that has at least 80% identity to the nucleotide sequence of any one of SEQ ID NOs: 73-79 or 83-95; (b) selecting plant cells from the population in which the endogenous BRI1 gene has been mutated, thereby producing plant cells comprising a mutation in the endogenous BRI1 gene; and (c) growing the selected plant cells into plants.
47. A method for improving one or more yield traits in a plant, comprising (a) contacting a plant cell comprising an endogenous brassinosteroid insensitive-1 (BRI1) gene with a nuclease targeted to the endogenous BRI1 gene, wherein the nuclease is linked to a nucleic acid binding domain (e.g., an editing system) that binds to a target site in the endogenous BRI1 gene, wherein the endogenous BRI1 gene: (i) comprising a nucleotide sequence having at least 80% sequence identity to any one of SEQ ID NO: 69, 70, 80 or 81; (ii) comprises a region that is at least 80% identical to any one of SEQ ID NOs: 73-79 or 83-95; and / or (iii) encoding an amino acid sequence having at least 80% sequence identity to any one of SEQ ID NO: 71, 72 or 82, to produce a plant cell comprising a mutation in an endogenous BRI1 gene; and (b) growing the plant cell into a plant comprising the mutation in the endogenous BRI1 gene, thereby producing a plant having the mutated endogenous BRI1 gene and one or more improved yield traits.
48. A method for producing a plant or part thereof comprising at least one cell having a mutated endogenous brassinosteroid insensitive-1 (BRI1) gene, the method comprising contacting a target site in an endogenous BRI1 gene in a plant or plant part with a nuclease comprising a cleavage domain and a nucleic acid binding domain, wherein the nucleic acid binding domain binds to the target site in the endogenous BRI1 gene, wherein the endogenous BRI1 gene (a) comprising a sequence having at least 80% sequence identity to any one of the nucleotide sequences of SEQ ID NO: 69, 70, 80 or 81; (b) comprises a region having at least 80% sequence identity to any one of the nucleotide sequences of SEQ ID NOs: 73-79 or 83-95; and / or (c) encoding an amino acid sequence having at least 80% sequence identity to any one of SEQ ID NOs: 71, 72 or 82, thereby producing a plant or part thereof comprising at least one cell having a mutation in an endogenous BRI1 gene.
49. A method for producing a plant or part thereof comprising a mutated endogenous brassinosteroid insensitive-1 (BRI1) gene and exhibiting one or more improved yield traits, the method comprising contacting a target site in an endogenous BRI1 gene in a plant or plant part with a nuclease comprising a cleavage domain and a nucleic acid binding domain, wherein the nucleic acid binding domain binds to the target site in the endogenous BRI1 gene, Wherein the endogenous BRI1 gene: (a) comprising a sequence having at least 80% sequence identity to any one of the nucleotide sequences of SEQ ID NO: 69, 70, 80 or 81; (b) comprises a region having at least 80% sequence identity to any one of the nucleotide sequences of SEQ ID NOs: 73-79 or 83-95; and / or (c) encoding an amino acid sequence having at least 80% sequence identity to any one of SEQ ID NOs: 71, 72 or 82, thereby producing a plant or part thereof comprising an endogenous BRI1 gene having a mutation and exhibiting one or more improved yield traits.
50. The method of claim 47 or claim 49, wherein the one or more improved yield traits comprise higher yield (bushels per acre), increased biomass, increased plant height, increased stem diameter, increased leaf area, increased number of flowers, increased number of pods including increased number of pods per node and / or increased number of pods per plant, increased number of seeds per pod, increased number of seeds, increased seed size and / or increased seed weight (e.g., an increase in 100 seed weight) compared to control plants without the mutation.
51. The method of any one of claims 46-50, wherein the nuclease cleaves the endogenous BRI1 gene, thereby introducing a mutation into the endogenous BRI1 gene.
52. The method of any one of claims 46-51, wherein the mutation is a non-natural mutation.
53. The method of any one of claims 46-52, wherein the mutation is a substitution, insertion and / or deletion.
54. The method of any one of claims 46-53, wherein the mutation is located in one or more upstream open reading frames (uORFs) of the endogenous BRI1 gene.
55. The method of claim 54, wherein the uORF of the endogenous BRI1 gene is located at approximately nucleotides 2-213, 42-174, 62-154, 82-134 and / or 92-124 numbered with reference to the nucleotide position of SEQ ID NO: 69 (e.g., SEQ ID NOs: 73-79), and / or (b) approximately nucleotides 1-267, 40-227, 70-195 and / or 100-168 numbered with reference to the nucleotide position of SEQ ID NO: 80 (e.g., SEQ ID NOs: 83-95).
56. The method of any one of claims 46-55, wherein the mutation is a deletion of one base pair to about 250 base pairs, wherein at least one ATG site in the uORF is deleted.
57. The method of any one of claims 46-56, wherein the nuclease is a zinc finger nuclease, a transcription activator-like effector nuclease (TALEN), an endonuclease, or a CRISPR-Cas effector protein.
58. The method of any one of claims 46-57, wherein the nucleic acid binding domain is a zinc finger, a transcription activator-like DNA binding domain (TAL), an argonaute, or a CRISPR-Cas effector DNA binding domain.
59. The method of any one of claims 46-58, wherein the mutation is a hypomorphic mutation, a dominant mutation, and / or a semi-dominant mutation.
60. The method of any one of claims 46-59, wherein the mutation results in a mutated BHI1 gene having at least 90% sequence identity to the nucleotide sequence of any one of SEQ ID NOs: 101-117.
61. A plant produced by the method of any one of claims 46-60.
62. A guide nucleic acid that binds to a target site in a brassinosteroid insensitive-1 (BRI1) gene, wherein the target site is located in a region of the BRI1 gene that is located (a) at about nucleotides 2-213, 42-174, 62-154, 82-134 and / or 92-124, numbered with reference to nucleotide positions of SEQ ID NO: 69 (e.g., SEQ ID NOs: 73-79), and / or (b) at about nucleotides 1-267, 40-227, 70-195 and / or 100-168, numbered with reference to nucleotide positions of SEQ ID NO: 80 (e.g., SEQ ID NOs: 83-95).
63. The guide nucleic acid of claim 62, wherein the guide nucleic acid comprises a spacer region comprising a nucleotide sequence of any one of SEQ ID NOs: 96-100.
64. A system comprising the guide nucleic acid of claim 62 or claim 63 and a CRISPR-Cas effector protein associated with the guide nucleic acid.
65. The system of claim 64, further comprising a tracr nucleic acid associated with the guide nucleic acid and the CRISPR-Cas effector protein, optionally wherein the tracr nucleic acid and the guide nucleic acid are covalently linked.
66. A gene editing system comprising a CRISPR-Cas effector protein associated with a guide nucleic acid, wherein the guide nucleic acid comprises a spacer sequence that binds to an endogenous brassinosteroid insensitive-1 (BRI1) gene.
67. The gene editing system of claim 66, wherein the BRI1 gene: (a) comprising a sequence having at least 80% sequence identity to the nucleotide sequence of any one of SEQ ID NOs: 69, 70, 80 or 81; (b) comprises a region having at least 80% identity to the nucleotide sequence of any one of SEQ ID NOs: 73-79 or 83-95; and / or (c) encodes an amino acid sequence having at least 80% sequence identity to any one of SEQ ID NOs: 71, 72 or 82.
68. The gene editing system of claim 66 or claim 67, wherein the guide nucleic acid comprises a spacer sequence, and the spacer sequence comprises any one of the nucleotide sequences of SEQ ID NOs: 96-100.
69. The gene editing system of any one of claims 66-68, further comprising a tracr nucleic acid associated with the guide nucleic acid and the CRISPR-Cas effector protein, optionally wherein the tracr nucleic acid and the guide nucleic acid are covalently linked.
70. A complex comprising a guide nucleic acid and a CRISPR-Cas effector protein comprising a cleavage domain, wherein the guide nucleic acid associates with a target site in an endogenous brassinosteroid insensitive-1 (BRI1) gene, wherein the endogenous BRI1 gene: (a) comprising a sequence having at least 80% sequence identity to the nucleotide sequence of any one of SEQ ID NOs: 69, 70, 80 or 81; (b) comprises a region having at least 80% identity to the nucleotide sequence of any one of SEQ ID NOs: 73-79 or 83-95; and / or (c) encoding an amino acid sequence having at least 80% sequence identity to any one of SEQ ID NOs: 71, 72 or 82, wherein the cleavage domain cleaves the target strand in the BRI1 gene.
71. An expression cassette comprising (a) a polynucleotide encoding a CRISPR-Cas effector protein comprising a cleavage domain and (b) a guide nucleic acid that binds to a target site in an endogenous brassinosteroid insensitive-1 (BRI1) gene, wherein the guide nucleic acid comprises a spacer sequence that is complementary to and binds to (i) a portion of a nucleic acid having at least 80% sequence identity to any one of the nucleotide sequences of SEQ ID NO: 69, 70, 80 or 81; (ii) a portion of a nucleic acid having at least 80% sequence identity to any one of SEQ ID NOs: 73-79 or 83-95; and / or (iii) a portion of a nucleic acid encoding an amino acid sequence having at least 80% sequence identity to any one of SEQ ID NOs: 71, 72 or 82.
72. A method for generating a mutation in an endogenous brassinosteroid insensitive-1 (BRI1) gene in a plant, comprising: (a) targeting a gene editing system to a portion of a BRI1 gene comprising a nucleotide sequence having at least 90% sequence identity to any one of SEQ ID NOs: 73-79 or 83-95; and (b) selecting a plant comprising a modification in a region of one or more BRI1 genes that is at least 90% identical to the nucleotide sequence of any one of SEQ ID NOs: 73-79 or 83-95.
73. A method of generating a variation in a brassinosteroid insensitive-1 (BRI1) gene, comprising: introducing an editing system into a plant cell, wherein the editing system targets a region of an endogenous BRI1 gene encoding a BRI1 polypeptide, and A region of the endogenous BRI1 gene is exposed to the editing system, thereby introducing a mutation into the endogenous BRI1 gene and generating a variation in the BRI1 gene in the plant cell.
74. The method of claim 73, wherein the endogenous BRI1 gene comprises a nucleotide sequence having at least 80% sequence identity to any one of SEQ ID NOs: 69, 70, 80, or 81 and / or encodes an amino acid sequence having at least 80% sequence identity to any one of SEQ ID NOs: 71, 72, or 82.
75. The method of claim 73 or claim 74, wherein the region of the endogenous BRI1 gene that is targeted comprises at least 80% sequence identity to the nucleotide sequence of any one of SEQ ID NOs: 73-79 or 83-95.
76. The method of any one of claims 73-75, wherein a region of an endogenous BRI1 gene in a plant cell is contacted with an editing system to produce a plant cell comprising an edited BRI1 gene in its genome, the method further comprising (a) regenerating a plant from the plant cell; (b) selfing the plant to produce an offspring plant (E1); (c) determining one or more improved yield traits of the offspring plant of (b); and (d) selecting offspring plants that exhibit a phenotype of one or more improved yield traits compared to control plants.
77. The method of claim 76, further comprising (e) selfing the selected offspring plant of (d) to produce an offspring plant (E2); (f) determining one or more improved yield traits of the offspring plant of (e); and (g) selecting offspring plants that exhibit one or more improved yield trait phenotypes compared to control plants, optionally repeating (e) to (g) one or more additional times.
78. A method for detecting a mutant BRI1 gene (mutation in an endogenous BRI1 gene) in a plant, comprising detecting a BR1 gene having at least one mutation in the genome of the plant, wherein the mutation is located within a region having at least 80% sequence identity with the nucleotide sequence of any one of SEQ ID NOs: 73-79 or 83-95.
79. The method of claim 78, wherein the detected mutant BRI1 gene comprises a nucleic acid sequence having at least 90% sequence identity to any one of SEQ ID NOs: 101-117.
80. A soybean plant or plant part thereof comprising at least one mutation in at least one endogenous brassinosteroid insensitive-1 (BRI1) gene having a gene identification number (Gene ID) of Glyma.06g147600) (SEQ ID NO: 69) and / or Glyma.04g218300 (SEQ ID NO: 80).
81. The soybean plant or plant part thereof of clause 80, wherein the mutation is a non-natural mutation.
82. The soybean plant, or plant part thereof, of any one of claims 80 or 81, wherein at least one mutation results in a mutated BRI1 gene having at least 90% sequence identity to any one of SEQ ID NOs: 101-117.
83. A guide nucleic acid that binds to a target nucleic acid in a brassinosteroid insensitive-1 (BRI1) gene having a gene identification number (gene ID) of Glyma.06g147600 (SEQ ID NO: 69) and / or Glyma.04g218300) (SEQ ID NO: 80).
84. A mutated endogenous BRI1 gene produced by contacting a target site in an endogenous BRI1 gene in a plant or plant part with a nuclease comprising a cleavage domain and a nucleic acid binding domain, wherein the nucleic acid binding domain binds to the target site in the endogenous BRI1 gene, wherein the endogenous BRI1 gene: (a) comprising a sequence having at least 80% sequence identity to the nucleotide sequence of any one of SEQ ID NOs: 69, 70, 80 or 81; (b) comprises a region at least 80% identical to any one of SEQ ID NOs: 73-79 or 83-95; and / or (c) encodes an amino acid sequence having at least 80% sequence identity to any one of SEQ ID NOs: 71, 72 or 82.
85. The mutated endogenous BRI1 gene of claim 84, wherein the mutated endogenous BRI1 gene is a non-naturally occurring mutated endogenous BRI1 gene.
86. The mutated endogenous BRI1 gene of claim 84 or claim 85, wherein the mutated endogenous BRI1 gene comprises a hypomorphic mutation, a dominant mutation, and / or a semi-dominant mutation.
87. The mutated endogenous BRI1 gene of any one of claims 84-86, wherein the mutated endogenous BRI1 gene has at least 90% sequence identity to any one of SEQ ID NOs: 101-117.
88. A BRI1 transcript produced by the mutated endogenous BRI1 gene of any one of claims 84-87.
89. A mutated endogenous BRI1 gene and / or BRI1 transcript having a mutation in one or more uORFs.
90. The mutated endogenous BRI1 gene and / or BRI1 transcript of claim 89, wherein the mutated endogenous BRI1 gene and / or BRI1 transcript is a non-naturally mutated endogenous BRI1 gene and / or BRI1 transcript, optionally wherein the mutated endogenous BRI1 gene and / or BRI1 transcript comprises a hypomorphic mutation, a dominant mutation and / or a semi-dominant mutation.
91. The mutated endogenous BRI1 gene and / or BRI1 transcript of any one of claims 86 or 87, wherein the mutated endogenous BRI1 gene and / or BRI1 transcript has at least 90% sequence identity to any one of SEQ ID NOs: 101-117.
92. A method of producing a plant comprising a mutation in an endogenous brassinosteroid insensitive-1 (BRI1) gene and at least one polynucleotide of interest, the method comprising hybridizing a first plant with a second plant comprising at least one polynucleotide of interest to produce a progeny plant, wherein the first plant is a plant of any one of claims 1-17, 22, 23 or 33-35, 61 or 80-82; and Progeny plants are selected that comprise the mutation in the BRI1 gene and the at least one polynucleotide of interest, thereby producing plants that comprise the mutation in the endogenous BRI1 gene and the at least one polynucleotide of interest.
93. A method of producing a plant comprising a mutation in an endogenous BRI1 gene and at least one polynucleotide of interest, the method comprising Introducing at least one polynucleotide of interest into the plant of any one of claims 1-17, 22, 23 or 33-35, 61 or 80-82, thereby producing a plant comprising the mutation in the BRI1 gene and the at least one polynucleotide of interest.
94. A method of producing a plant comprising a mutation in an endogenous BRI1 gene and exhibiting a phenotype of improved yield traits, improved plant architecture and / or improved defense traits, the method comprising Crossing a first BRI1 gene plant with a second plant that exhibits a phenotype of improved yield traits, improved plant architecture, and / or improved defense traits, wherein the first BRI1 gene plant is a plant of any one of claims 1-17, 22, 23 or 33-35, 61 or 80-82; and Progeny plants comprising a mutation in the BRI1 gene and a phenotype of improved yield traits, improved plant architecture and / or improved defense traits are selected, thereby producing plants comprising a mutation in the endogenous BRI1 gene and exhibiting a phenotype of improved yield traits, improved plant architecture and / or improved defense traits compared to control plants.
95. A method of controlling weeds in a container (e.g., a flower pot or seed tray, etc.), a growth chamber, a greenhouse, a field, a recreational area, a lawn or a roadside, comprising: The herbicide is applied to one or more plants of any one of claims 1-17, 22, 23 or 33-35, 61 or 80-82 growing in a container, growth chamber, greenhouse, field, recreational area, lawn or roadside, thereby controlling weeds in the container, growth chamber, greenhouse, field, recreational area, lawn or roadside in which the one or more plants are growing.
96. A method for reducing insect predation on plants, comprising: Applying the insecticide to one or more plants of any one of claims 1-17, 22, 23 or 33-35, 61 or 80-82 reduces insect predation on the one or more plants.
97. A method of reducing fungal diseases on plants, comprising: Applying a fungicide to one or more plants of any one of claims 1-17, 22, 23 or 33-35, 61 or 80-82 thereby reducing fungal diseases on the one or more plants.
98. The method of claim 96 or claim 97, wherein the one or more soybean plants are grown in a container, a growth chamber, a greenhouse, a field, a recreational area, a lawn, or a roadside.
99. The method of any one of claims 92-98, wherein the polynucleotide of interest is a polynucleotide that confers herbicide tolerance, insect resistance, disease resistance, increased yield, increased nutrient use efficiency, or abiotic stress resistance.
